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ABSTRACT 
 
This study seeks to better understand the “public face” of human gene therapy through an 
examination of coverage of the technology in mainstream U.S. newspapers, news 
magazines, and online news sites from 1989 to 2011. By conducting a qualitative content 
analysis that employs a constant comparative method and uses the computer-assisted 
qualitative data analysis software HyperRESEARCH, prevailing images and metaphors 
about human gene therapy are identified. These images and metaphors are analyzed 
through the lens of the sociology of technology, with particular attention given to 
technological determinism, geneticization, and the sociology of expectations. Further, 
their connection to issues of self and identity, embodiment, and illness meanings is 
explored. Four main types of images and metaphors emerge from this analysis: 
essentialist, fatalistic, expectant, and conflictive. While these types present an array of 
diverse (and sometimes conflicting) characterizations of human gene therapy, they all 
contribute to a positive, hopeful public face of the technology, despite its limited 
successes and sometimes tragic failures over the past three decades. The study considers 
the broader implications of these findings and addresses the role sociologists could play 
  
in helping the public to navigate the media discourse surrounding human gene therapy 
and other emerging medical technologies. 
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Chapter 1 
Introduction 
 
Background and Context 
The technology of human gene therapy, composed of a variety of techniques by 
which disease-causing genes are replaced, repaired or redirected, has been developing 
since the 1980s and was approved for clinical trial in 1990.  Ten years of gene therapy 
clinical trials (punctuated by several tragic failures) passed before any treatment success 
was achieved, and even that success was tempered by complications. In its second 
decade, human gene therapy continued to struggle, achieving only marginal successes. 
Yet despite its slow start, erratic results, and highly publicized missteps, human gene 
therapy continued to receive significant funding and support –  not only for diseases with 
clear genetic causes, but also for common diseases with multifaceted etiologies, such as 
cancer and heart disease. (Crofts and Krimksy, 2005)  Only in recent years has the 
trajectory of human gene therapy seemingly slowed, with fewer developments being 
reported in the press and at least one high profile gene therapy company facing 
bankruptcy. (Timmerman, 2009) 
Human gene therapy has also received considerable attention in the mainstream 
media over the past two decades.  Through this attention, a “public face” of human gene 
therapy, shaped by the ways in which the technology has been presented and represented, 
has been created.  Examining the ways and contexts in which human gene therapy has 
been presented to the public can provide an important roadmap to one aspect of the 
 2  
technology’s social significance and can elucidate issues that may affect public opinion, 
technical and financial support, and policy decisions. 
 
1. Why media discourse about human gene therapy matters 
To understand why it is useful to study media content when considering the 
construction of human gene therapy, it is important to consider how such media discourse 
relates to publicly relevant scientific/technological issues in general, as well as genetics 
issues in particular.  In their seminal investigation of the media and public opinion on 
nuclear power, Gamson and Modigliani (1989) suggest that media discourse can have a 
significant influence on how issues are perceived, and, by extension, how issues are 
constructed.  Although this discourse does not necessarily shape policy decisions, it can 
have a strong influence on public opinion and the public face of the issue: “media 
discourse dominates the larger issue culture, both reflecting it and contributing to its 
creation” (Gamson and Modigliani, 1989, p. 3).  The information made available about 
an issue in the media helps to determine what the public knows, thinks, and feels about 
that issue, and “it makes a considerable difference that some [pieces or types of 
information] are more readily available than others” (p. 10).          
 Others also suggest that because media discourse has such a strong influence on 
public understanding, it can affect the directions taken within the issue.  Media discourse 
has been identified as “a site on which various social groups, institutions, and ideologies 
struggle over the definition and construction of social reality” (Gurevitch and Levy, 1985, 
p. 19).  The media is a location of (and therefore a contributor to) the construction of 
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issues, as it provides a forum for the promotion and discussion of various viewpoints and 
positions.  As Bauer writes, “mass media content makes images and arguments widely 
available and thereby may set the agenda, what to think about” (2002, p. 155).  The types, 
amount, and tone of content that are emphasized in the media can affect an issue’s 
development; the information about an issue that is deemphasized or excluded from 
public discussion can be equally influential.   
 The importance of media discourse is well illustrated by the fact that many issues’ 
key stakeholders are very concerned with controlling or directing the messages that the 
media delivers about their issues.  Far from being just a report of the results of media 
members’ research, media information about technologies is often influenced greatly by 
scientists, investors, corporate interests, commercial developers, politicians, and other 
individuals with vested interests in a technology’s success (or failure).  Gamson and 
Modigliani maintain that such individuals and groups participate in issue “sponsorship,” 
which “is more than merely advocacy, involving such tangible activities as speech 
making, interviews with journalists, advertising, article and pamphlet writing, and the 
filing of legal briefs to promote a preferred package” of their issue (1989, p. 6).  In terms 
of biotechnologies in particular,  
much of the media coverage may be the result of professional public 
relations activities. Research laboratories, business corporations, and 
advocacy groups try to set the agenda for mass media to put pressure on 
governments and/or to attract venture capital. Equally, governments 
engage in public relations to cultivate their positions. The public 
regulation of biotechnology is subject to intense lobbying by actors in the 
biotechnology movement…For many government actors, the mass media 
are the window to public opinion for all intents and purposes. (Bauer, 
2002, pp. 155-6) 
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Many genetics research stakeholders believe that the images of and messages 
about their technologies as presented by the media may determine public opinion, affect 
their future funding, and influence relevant government policy-making and regulation.  
The management of public opinion seems especially important in regard to genetics 
research, since many genetics technologies can be connected to deeply-rooted public 
concerns about moral, ethical, and biological side effects and consequences.  Further, this 
public opinion is often sought after by government agencies and private funding sources 
when considering the value of genetic research programs.   
A recent study of public opinion about genetics research asserts that the public 
does have many concerns about genetics technologies and that technology proponents 
should take notice: “Genetic researchers should not disregard public concerns…The 
public often funds the research…The public is a stakeholder in the debate over what 
constitutes ‘improper’ genetic manipulation” (Bates, 2005, p. 333).  Because they do 
have an awareness of the many ways in which media discourse might affect their 
research, many involved in genetics research take an active role in trying to direct the 
content that is being circulated. (Bauer, 2002, Stockdale, 1999)  Ettorre (1999) suggests 
that they must take on the role of “storyteller,” fashioning an image of their research that 
legitimates their work and agenda:   
…these storytellers attempt to construct complex genetic narratives 
accessible for popular consumption in both the popular and professional 
media.  This is an important, if not the most important, part of “genetics 
work”, establishing their scientific and cultural authority by the stories 
scientists tell, the metaphors they use…and the global range of their 
influence. (p. 543) 
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2. Human gene therapy and the media 
 Human gene therapy has been the subject of media interest since well before its 
first clinical trials were approved. (Martin, 1999; Lyon and Gorner, 1995)  Many suggest 
that early media coverage of human gene therapy presented a largely positive portrait of 
the technology and its potential. In fact, some emphasize that human gene therapy was 
portrayed in the media as a viable and important approach to treating disease without any 
evidence that it could be applied successfully.  Nelkin, citing Nature-Medicine, argues 
that human gene therapy’s “conceptual advances [had] become widely accepted and 
firmly established as medical principle before even a simple clinical instance of clinical 
efficacy has been demonstrated” (1996, p. 36).  Stockdale maintains that human gene 
therapy continued to be touted as a revolutionary form of treatment throughout the 1990s, 
surrounded by a “miracle technology aura” that held the technology up as a super-cure 
for inherited and noninherited diseases alike (1999, p. 582). Several significant clinical 
setbacks were well-documented in the media (Stolberg, 1999; Weiss and Nelson, 1999; 
Herald Sun, 2000; Kolata, 2000), but their impact may have been mediated, some argue, 
by reports of corrected procedures and assurances of human gene therapy’s enduring 
promise (Meikle, 2003; Spector, 2003; Lasalandra, 2000).   
The message delivered about human gene therapy has repeatedly been described 
as “hype” or “overselling” of the technology’s potential. (Young and Mautner, 2001; 
Stockdale, 1999; Nelkin, 1996; Orkin and Motulsky, 1995)  That human gene therapy has 
been understood as having a generally positive media image indicates that a close 
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examination of the media discourse that surrounds the technology could be an important 
part of understanding how the technological field has been constructed. Additionally, it 
seems important to examine how this positive image was constructed within specific 
media content – and, indeed, whether the overall discourse actually demonstrates a clear 
positive image when examined closely and methodically. This type of focused study of 
media content and imagery has been applied to other emerging genetics technologies 
(Petersen, 2001; Priest, 2001; Henderson and Kitzinger, 1999; Kitzinger & Reilly, 1997), 
but it has been less commonly applied to human gene therapy. Given that human gene 
therapy is one of the genetics technologies actually being used quite extensively on 
human subjects, it seems all the more vital for its media context to be subjected to in-
depth study.    
Several studies of human gene therapy located within the sociology of technology 
further illustrate the necessity of careful examination of the technology’s media 
discourse.  Stockdale (1999) studies the dynamics of human gene therapy as a treatment 
for cystic fibrosis (CF).  Upon examining the interests and positions of various issue 
stakeholders, he concludes that the CF patients (and to a lesser extent CF clinicians) are 
poorly positioned to have a strong voice in the CF human gene therapy discussion, due to 
the dominance of CF gene therapy researchers and funders. Stockdale suggests that 
media coverage overselling the promises of human gene therapy proliferated through the 
1990s in part because of the sponsorship of these parties, who encouraged positive 
messages about the field to help raise research funds.  He indicated that overly optimistic 
media coverage about human gene therapy for CF could increase the suffering of patients 
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by diverting their attention from other treatment alternatives. Further, “the emotional 
impact of raised and dashed hopes” could also be damaging to patients and their families 
(Stockdale, 1999, p. 584).  Despite his acknowledgment of the relevance of media 
discourse to human gene therapy development and application, Stockdale admits that 
“[a]s little research has been done on these issues, it is difficult to evaluate the broad 
impact of gene therapy publicity in this regard” (p. 584). This suggests an enduring need 
for better understanding of the way human gene therapy is discussed in the media. 
Martin (1999) draws upon several insights from the sociology of technology in a 
study of the development of the human gene therapy field.  He examines the processes 
and stakeholders involved in this development, concluding that the creation of a strong 
network of relationships among various research entities, biotechnology and 
pharmaceutical industry interests, and the genetic redefinition of a number of diseases 
(such as cancer and heart disease) were all important factors in human gene therapy’s 
construction.  Martin also notes a reflexive relationship between the development of 
human gene therapy and images of the body, particularly an emerging “genetic body” 
image via which both causes and treatments of disease become genetics-based. The 
author focuses a great deal upon “visions” of human gene therapy technologies and 
“redefinition” and “reconstitution” of disease, but he only implies rather than examines 
the location where these new concepts were largely articulated and distributed – namely 
media discourse. A close, systematic examination of media content could help to clarify 
the contribution of visions and redefinitions to the construction of the human gene 
therapy field. 
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Henderson et al. (2006) employ quantitative techniques to study the causes and 
incidence of what they term “therapeutic misconception,” or a belief in the possibility of 
benefit from participation in an early phase clinical trial that is not supported by existing 
clinical evidence.  The authors found a relatively high rate of therapeutic misconception 
(TM) in their sample, and their data revealed a relationship between TM and level of 
education, subjects’ relationship to clinical trial investigators, and the content of informed 
consent forms.  They found no significant relationship between whether or not each 
subject was aware of media coverage of the clinical study in which each he or she was 
taking part.  While the authors’ data suggest that knowledge of media coverage specific 
to the subjects’ studies does not affect their expectations of receiving benefit from 
clinical trials, their data are not capable of revealing the many other possible effects of 
general human gene therapy media content on clinical trial participants.  This highlights 
another area in which more knowledge about human gene therapy’s media discourse 
could be valuable, as a clearer understanding the effects of media messages on potential 
and existing clinical trial participants might lead to better participant decision-making 
and improved treatment experiences.   
 Studies of public opinion about gene therapy are another important area of 
research.  A 2005 study of Australians’ opinions about germ-line gene therapy suggests 
that views are mixed regarding the appropriateness of using this technology.
1
 (Evans et 
al., 2005)  A slight majority of respondents were in favor of germ-line gene therapy in a 
                                                 
1
 Funding for germ-line gene therapy is currently prohibited in the U.S.  Unlike somatic cell gene therapy – 
the kind presently being used in clinical trials, which involves the manipulation of nonreproductive cells – 
germ-line gene therapy manipulates reproductive cells, meaning modifications made via the therapy would 
be passed on to future generations.   
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“life or death” situation, but a majority did not support its use for more minor conditions.   
Similarly, a UK study published in 2005 (Wellcome Trust) showed general support for 
somatic cell gene therapy and skepticism about germ-line therapy.  Overall, respondents 
had little knowledge of human gene therapy and what it entailed.  Nonetheless, “[m]ost 
participants were found to be optimistic about progress in gene therapy research. Seven 
out of ten believed that gene therapy could already treat some or many diseases and six in 
ten think that gene therapy treatments for heart disease will exist within five to ten years” 
(p. 4).  A 1995 study of international opinion about human gene therapy found that about 
75% of its respondents favored the use of gene therapy to treat disease, especially for 
children. (Macer et al., 1995)  Few respondents rejected the technology’s use or felt it 
was more appropriate for inherited rather than noninherited diseases.  There was less 
support for using it for behavior modification or cosmetic purposes. Results such as these 
are quite striking, given human gene therapy’s limited clinical success. Although it is 
impossible to know how the respondents’ knowledge and opinions about human gene 
therapy were generated, it seems likely that media portrayals of it (or at least of genetics 
technologies in general) may have played some role. Studying these portrayals could 
complement public opinion studies and improve understanding of the construction of 
human gene therapy as a technological and clinical field. 
 These studies illustrate a multifaceted need for a clearer and deeper understanding 
of media discourse about human gene therapy. In my own study, I respond to that need 
by creating an analysis of that discourse that is both firmly grounded in media content 
and substantively conversant with the sociology of technology.  
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Problem Statement 
Although human gene therapy has long been characterized as an oversold or 
hyped new medical technology, there has been little thorough, systematic observation and 
analysis of how the technology has been portrayed and discussed in the media.  
 
Purpose of the Study 
The purpose of this study is to explore how human gene therapy has been 
presented in the mainstream media over the past 20 years. The study aims to use the 
insights and approaches of the sociology of technology to better understand the “public 
face” of human gene therapy. Without attempting to ascertain the intentions of either the 
sources or disseminators (e.g., scientists, research institutions, biotechnology firms, 
journalists) of media coverage about gene therapy, my goal is to summarize and analyze 
the various human gene therapy narratives that have emerged. Based on a belief that 
information about human gene therapy may affect public understanding and opinion – 
which in turn may influence public policy, funding opportunities, and other factors 
important to the technology’s development – this project is also meant to serve as a 
foundation for other social scientific research about human gene therapy. Further, its 
findings may be useful in clarifying the importance of media representations to the 
development and application of other emerging technologies. 
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Research Questions 
1. What types of images and metaphors are used to represent human gene 
therapy? 
 
2. What sorts of narratives are formed through the use of these images and 
metaphors? 
 
3. How can the tone of the media discourse about human gene therapy be 
characterized? 
 
4. How, if at all, do the images/metaphors/narratives/tone change over time? 
 
5. How, if at all, do these elements change in relationship to publicized 
successes or failures in the application of human gene therapy? 
 
Research Approach 
 This study examines media coverage of human gene therapy from 1989 to 2011, 
focusing on mainstream U.S. newspapers, news magazines, and online news sites. By 
conducting a qualitative content analysis that employs a constant comparative method 
and uses the computer-assisted qualitative data analysis software HyperRESEARCH, 
images and metaphors about human gene therapy occurring in media accounts are coded 
and analyzed, with coding categories being continually defined and updated throughout 
the data collection and analysis process. Further, I examine whether these images and 
metaphors contribute to the construction of larger media narratives about the technology. 
Patterns and changes over time – especially in relationship to specific well-publicized 
developments in the field – are assessed.  
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Assumptions 
 After a decade of studying the sociology of genetics technologies, I acknowledge 
that I bring my many preconceived ideas, thoughts, questions and feelings about genetics 
technology in general and human gene therapy in particular into this project. As one who 
recognizes both the promises and pitfalls of the technologies and their applications 
(insofar as they can be understood at this point), I feel that I bring a balanced viewpoint 
to this work. Yet even that balanced view (as I discuss in greater detail later) influences 
the ways in which I approach the topic, conduct data collection and analysis, and present 
my findings.  
Although my research approach is structured to make the most of my own 
situated knowledge, I will clarify here several of my personal assumptions about human 
gene therapy and the media. First, I assume that it is important to study medical genetics 
technologies sociologically. Regardless of their effects to date, it seems likely that 
genetics-based explanations and treatments for human diseases and conditions will be 
sought continually well into the foreseeable future. Because these technologies and their 
applications will lead to many questions, hopes, fears, and opinions in the coming years, 
understanding their social contexts is vital. Second, I assume that each technology is 
socially constructed. Its development is not just a natural result of scientific progress, but 
rather it is shaped by a network of human actors, institutions, objects, information and 
ideas. Finally, I assume that the media is an important part of that network. It is worth 
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studying both because of its role in shaping new technologies and because it is largely 
responsible for presenting information about those technologies to the public. These 
assumptions help to frame my understanding of and approach to my topic.  
 
 
Significance  
 Achieving a better understanding of the media discourse surrounding human gene 
therapy is an important step toward clarifying the technology’s social context. The 
approach used in this project could be used to examine the media discourses of many 
other emerging medical technologies, bringing similar benefit to the social study of areas 
like stem cells, nanotechnology, and pharmacogenetics, to name just a few. Also, the 
types of images, metaphors, and narratives about human gene therapy discovered in this 
study could be useful analytical categories to apply to these and other subject areas. 
I also see my study as deeply rooted in the sociology of technology and envision 
it as a meaningful contribution to the area. I feel it is important that sociology of 
technology studies be clearly identified as such, because I believe the field would benefit 
from more clearly defined boundaries and disciplinary identity. While certainly much 
meaningful work is being done that would qualify as sociology of technology, such work 
can be difficult to locate, since it is often labeled as the sociology of science or scientific 
knowledge, science and technology studies, social studies of technology, or another field 
of inquiry. It is understandable that this is the case, since sociological studies of 
technology (in addition to being rooted in the ideas of Marx, Weber, Ogburn, and many 
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other classical and contemporary theorists) are typically informed by an array of 
interdisciplinary sources, both in terms of theory and methodology. The predominant 
research paradigms that examine the social aspects of technology and technology 
development (such as actor-network theory, the social construction of technology, and 
systems theory) were developed not only by sociologists, but also by scholars from 
philosophy, history, political science, anthropology, and other disciplines. While they 
have seemingly achieved a sense of cohesion via the institutionalization of science and 
technology studies (STS), this cohesion may come at some level of expense to subfields 
like the sociology of technology.  
While I certainly see the benefit of interdisciplinary dialogue (and structured my 
own graduate coursework to take advantage of that benefit), I also feel there may be 
value to an institutionally stronger sociology of technology. A subfield with a more 
clearly articulated sense of its identity (which should include thorough discussion of its 
theoretical foundations) might help to encourage future scholars to enter the field and 
produce work that strengthens and adds meaning to both technology studies and 
sociology. I also feel a stronger sociology of technology would enhance rather than 
detract from STS, since it would contribute a clearer sense of what is at stake from a 
sociological perspective in technology development. My hope is that my own study of 
human gene therapy – while certainly drawing from the relevant body of interdisciplinary 
scholarship – will contribute to the strengthening and boundary setting of the sociology 
of technology. To this end, I prioritize clear and thorough discussion of both the classical 
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and contemporary sociological theory and sociological methods that underpin my 
research. 
 
 
 
Explanation of Key Terminology 
 
 
Human gene therapy – “[A]ny procedures that alter, transfer, activate, or suppress genes 
for diagnosis, prognosis, prevention, or treatment of diseases” (Crofts and Krimsky, 
2005, p.169).   
Media discourse – The body of data and information put forward by the mass 
communication industry. In this study, I focused on news media rather than entertainment 
and other forms of media (as discussed further in the Research Sample section below). 
Media content – The specific pieces of data or information (such as articles, briefs, 
internet posts, etc.) that make up the media discourse.   
Image – A verbal representation of an entity. In the context of this study, an image can 
describe, explain, or exemplify an entity in literal or figurative terms. 
Metaphor – A figure of speech wherein the language used refers to an entity not in a 
literal sense, but rather in terms of some other entity. In other words, a metaphor occurs 
when something is referred to by a name that actually belongs to something else (e.g., 
“DNA is a blueprint”). Although the rules of grammar differentiate them, for the 
purposes of this study, similes, wherein entities are referred to as like something else 
(e.g., “DNA is like a blueprint”), will also be included in the category of metaphor. 
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Narrative – A story or series of representations about an entity composed of images, 
metaphors, and other descriptive or ascriptive language.  
Tone – A quality that suggests a set of prevailing attitudes toward an entity or 
phenomenon.  
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Chapter 2 
Review of the Literature 
 
The Sociology of Technology and Genetics  
In the first section of this review, I examine several key issue areas in the 
sociology of technology that will be useful in making sense of the media representations 
of human gene therapy: the current status of technological determinism within the 
subfield; the relevance of the geneticization concept to sociological studies of 
technology; and possible contributions of the emerging (sub-)subfield of the sociology of 
expectations.  
 
1. Technological determinism 
An enduring debate in the sociology of medical technology addresses the role of 
technological determinism in studies of technological change. While many would assert 
that technological determinism (or the idea that technological change happens on its own, 
without social influences) is an irrelevant and long-outdated construct indicative of a 
limited or uninformed view of technology, others maintain that its persistent popular 
application demands that it be acknowledged and taken seriously. Examining this debate 
helps to identify some of the current priorities and prevalent standpoints of those working 
in the social studies of medical technology. 
 The very term “technological determinism” is likely unappealing to most 
sociologists today, suggesting as it does that cold, decontextualized technologies move 
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forward unaffected by social forces. Certainly technological determinism is not 
frequently used by social scientists as an organizing concept or research paradigm. Yet 
however inappropriate it might seem for scholarly application, it can be argued that 
technological determinism is commonly used to make sense of everyday life. As Smith 
and Marx write, “By now, most people in modernized societies have become habituated 
to the seeming power of advancing technology (and its products) to change the way they 
live. For them, indeed, the steady growth of that power is just another self-evident feature 
of modern life, an obvious fact that calls for no more comment than the human penchant 
for breathing”  (1994, p. ix). This habituated perspective would seem readily supported 
by the prevalence of media accounts and informal cultural analyses ascribing technology 
with transformative powers (“the automobile created suburbia,” “the Pill started a sexual 
revolution,” etc.).  
In addition to being embedded in popular consciousness, technological 
determinism is also rooted in classical sociological theory. While Karl Marx was among 
the first to locate technology within the sociological conversation, his work has also 
frequently been tied to technological determinism. (Bimber, 1990; MacKenzie, 1984; 
Shaw, 1979) His words could be viewed as predecessors of the deterministic language 
used popularly today: “The handmill gives you society with the feudal lord; the steam-
mill, society with the industrial capitalist” (1973, p. 109). Although the attention paid to 
capitalist sponsorship of and influence upon technology in Marx’s works makes it 
difficult to argue that he was a technological determinist in any strict sense, 
decontextualized excerpts from his writings can be used to promote a “technology drives 
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society” perspective. Another classical theorist associated with technological 
determinism, William Fielding Ogburn, was interested in how inventors and inventions 
were less the result of the genius of the “heroic inventor” (a characterization that was 
widespread in his time, perhaps rooted in Weber’s charismatic authority) and more the 
result of broad cultural trends and the natural progression of scientific knowledge. 
(Ogburn, 1966) Given the assumed inevitability of technological evolution, Ogburn 
suggested that the role of sociology was to determine how society could best adjust to the 
changes that technology would bring. This notion of society adapting to technology 
(rather than shaping technology) is fundamental to the technological determinism 
construct. 
In the generations after Marx and Ogburn, sociological studies of technology 
became increasingly focused on the deeply contextualized nature of technology and the 
complex ways in which human and institutional actors influence technological change. 
(Bijker et al., 1987; Latour, 1987; Callon et al., 1986; Hughes, 1983) Because the 
embeddedness of technology within social systems and networks was so strongly 
emphasized in these new approaches, technological determinism (and anything 
suggestive of it) became emblematic of the old-fashioned, essentialist research from 
which so many sociologists were trying to move away. In addition to disagreeing with it 
conceptually, another strike against technological determinism for many is that it “is 
imbued with the notion that technological progress equals social progress” (Wyatt, 2007, 
p. 168). The idea that technological advancement is always a good thing for society 
suggests that it should not be questioned or challenged; this suggestion would be 
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untenable to most sociologists, especially in light of the profit-seeking and proprietary 
interests that underlie much of technology development today.  
Despite technological determinism’s seeming incommensurability with current 
trends in social science analysis of technology, some scholars are arguing that it should 
not be written off or ignored. Because it is so commonly employed in popular discourse 
(and still to some extent in scholarship), they argue that its roots, dynamics, applications, 
and possible effects should be acknowledged and examined. (Wajcman, 2010; Hassan, 
2010; Wyatt, 2007; Mackenzie and Wajcman, 1999; Smith and Marx, 1994; Bimber, 
1990) In the case of medical technologies, recognizing technological determinism’s 
presence in the background of media coverage, policy discussions, and public discourse 
seems especially important. Medical technologies are very often seen as the result of the 
inevitable progression of scientific knowledge and portrayed as having inherent 
transformative powers (presumably because they deal with such essential issues as life 
and death). (Timmermans and Berg, 2003) Media accounts of medical technologies 
frequently herald their potential to cure disease and disorder, improve or enhance quality 
of life, and solve social problems. Because technological determinism is so present in the 
discourse surrounding medical technologies, it seems crucial to not only acknowledge it 
but also to examine how it might influence technology development.  
In my own study of media discourse surrounding human gene therapy – a medical 
technology that has historically been ascribed much transformative power even though it 
has rarely been successfully applied – it is important that the relationship between 
technological determinism and popular discourse be examined. I search for instances of 
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technological determinism in public images of human gene therapy, consider the possible 
influence of determinism within the media packages
2
 that present human gene therapy to 
the public, and explore the intersection of determinism and the larger context of genetic 
medicine in which the technology is located. In doing so, I try both to better understand 
the foundation of current human gene therapy media discourse and also to contribute to 
the broader conversation about the role of technological determinism in the sociology of 
technology.  
 
2. Geneticization 
 The concept of geneticization has been widely used in the sociology of medical 
technology in recent years. Coined by Abby Lippman (1991), geneticization suggests a 
growing tendency to define individuals’ health and behaviors as functions of their genetic 
make-up and to seek genetic explanations for illness and disease. It can also refer to the 
popularization of narratives and images that imply that genetics function deterministically 
(i.e., that genetic propensities lead to outcomes, giving no attention to social and 
contextual factors, sometimes referred to as “genetic essentialism” [Nelkin and Lindee, 
1995]). Often considered an extension of medicalization (which is a focus upon medical 
causes or treatments for various human conditions [Conrad, 1992]), geneticization is 
commonly used as an interpretive framework to understand the development of medical 
treatments and technologies. (Stempsey, 2006; Hall, 2005; Hedgecoe, 2003; Sherwin and 
Simpson, 1999) The emphasis geneticization places upon genetic etiologies is frequently 
                                                 
2
 See Gamson and Modigliani, 1989. 
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viewed as a negative development, since it can obscure the importance of other causes of 
disease and consequently deemphasize other (non-genetic) types of research and 
treatment. (Conrad, 2000)   Geneticization is also linked to reductionist ways of 
discussing genetic research breakthroughs (such as “finding the gene for breast cancer” or 
discovering the “diabetes gene”).  Although such phrases do not accurately represent the 
scope or implications of the research to which they refer, they are commonly used in 
media accounts and can become part of the public discourse. (Hall, 2005; Kitcher, 1996)   
Conrad (1999) suggests that the concept of genetic medicine was readily adapted 
into popular health discourse because it shared many common attributes with the 
predominantly accepted theory of disease etiology, germ theory. According to Dubos 
(1959), germ theory was based on three assumptions: a) the doctrine of specific 
aetiology, or that “every disease has a specific and knowable causal agent”; b) a focus on 
the internal [bodily] rather than the external environment; and c) conceptualization of the 
body as a machine (Conrad, 1999, pp. 230-1). In other words, germ theory suggests that 
specific entities like microbes or viruses invade the body and cause body parts to 
malfunction and become diseased, and that if these malfunctioning parts are repaired, the 
disease is eradicated. Although this theory was important to the development of many 
crucial medical treatments, it downplayed the complex ways in which environmental and 
other external factors contributed to disease. Conrad maintains that these assumptions 
paved the way for genetic explanations for disease. Although the incidence of conditions 
caused primarily by a specific gene is low, representations of traits or diseases being 
caused by one gene (what Conrad refers to as the “OGOD [one gene, one disease] 
 23  
assumption”) became prevalent in the news media (“the obesity gene,” “the breast cancer 
gene,” etc.). (1999, p. 232) According to Conrad, this easy insertion of genetic 
approaches to medicine into the media discourse “has spawned a naive form of genetic 
determinism that assumes (in language at least) that there are specific genes for specific 
traits under all circumstances” (1999, p. 237). In fact, genetic predispositions in most 
cases do not inevitably lead to disease, but rather do so only through complex (and 
largely not yet understood) interactions with external and environmental factors.  
A concept akin to geneticization is Anker and Nelkin’s (2004) “molecular vision,” 
which similarly represents the shifted focus in biological and medical science from 
studying the whole person to studying the “molecules,” or genetic make-up, of the human 
body: 
Molecular vision…has displaced the visceral references that had once 
defined the authenticity of the body and the authority of traditional 
biology as a descriptive science.  Despite the complexity of life, this vision 
implies that we are but a sequence of nucleic acids, a “code script” of 
information. (Anker and Nelkin, 2004, p. 19)  
 
This redefinition of what constitutes the unit of study in science separates researchers and 
their work from bodily realities and lived experience and locates them in a world of 
cellular manipulation.  Anker and Nelkin maintain that the growing pervasiveness of 
molecular vision is manifested in art and other cultural representations, suggesting that 
the phenomenon is reaching the general public through more than just its relationship to 
biomedical science. (Anker and Nelkin, 2004) 
Although few would argue that genetic explanations for and approaches to human 
problems have not increased in recent decades, there is debate among sociologists and 
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other scholars as to whether this has changed public understanding or perceptions of 
health, disease, and medicine.  In other words, is geneticization really affecting public 
opinion? Some suggest that empirical studies have not indicated that increased reliance 
upon genetics-based technologies by clinicians or increased representation of genetic 
explanations in the media have resulted in an increasingly geneticized view of illness or 
disease among the public. (Hedgecoe, 2009) They believe that geneticization is a limiting 
and overly deterministic way of describing how genetics relates to public understanding 
and suggest that it may not be a worthwhile concept to apply to empirical investigations 
in the social sciences. (Kerr, 2004; Condit, 1999)  
For the purposes of my study of images of human gene therapy, I acknowledge 
that to assume (without gathered evidence) that geneticization is occurring within public 
consciousness is inappropriate (just as it is inappropriate to make any such untested 
assumptions in sociology); undoubtedly most people do not see genetics as the sole cause 
of illness or disease, nor do they absorb geneticized media representations without 
relating them to their collected knowledge. Further, to suggest that geneticization may 
affect public consciousness is not to say that it would necessarily cause the public to have 
an entirely geneticized view of health and illness; its effects would surely be more 
nuanced and should, I believe, continue to be considered when studying public opinion.  
Because geneticization is perhaps more easily observable in public discourse than 
in public opinion, it may be less controversial to study its possible presence and effects in 
the former arena. Beyond whatever influence it might have on general public opinion, 
geneticization in public discourse might have an effect upon sponsorship of certain 
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medical technologies, an important area of consideration within the sociology of 
technology.  
Also, geneticization as a theoretical concept (in that it addresses 
objectification/atomization of the body/health and promotion of expert/medical authority) 
is conversant with several sociological theories of medicine and social control (e.g., 
Parsons’ “sick role” [1951] and Foucault’s “medical gaze” [1973]). This could make 
geneticization helpful in understanding how and why certain medical technologies (and 
the health definitions and institutions they support) are privileged.  
Since my unit of analysis is the imagery/narrative context surrounding human 
gene therapy (and not public opinion), and because I appreciate the thoughtful and 
conceptually sound ways in which geneticization, genetic essentialism and other related 
ideas have been developed (Conrad, 2000; Nelkin and Lindee, 1995; Lippman, 1991), I 
feel that examining the role of geneticization is both appropriate and valuable in my 
study. Further, geneticization is particularly relevant for the study of human gene therapy, 
since the technology seems to directly respond to the notion that “genes cause disease.”  I 
hope that through my careful qualitative analysis of human gene therapy images, 
metaphors, and narratives, I can contribute to the conversation about the interpretive 
utility of geneticization.  
 
3. The sociology of expectations 
A question receiving increasing attention in the sociology of medical technology 
addresses the role that expectations play in shaping technological change. A nascent 
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subfield known as the sociology of expectations has emerged, largely as a response to the 
hopeful narratives that tend to surround new technological programs. Scholars of the 
sociology of expectations suggest that rather than dismiss hopeful expectations of 
technology as “hype,” sociologists should acknowledge and examine their possible 
impact upon technological development. As Hedgecoe and Martin state in their study of 
the emerging medical technology of pharmacogenetics, “Instead of seeing the speculative 
claims made about the future of pharmacogenetics as ephemeral and irrelevant, we argue 
that they are fundamental to the dynamic processes that create new socio-technical 
networks. Understanding the formation, mobilization and shape of these expectations or 
'visions' is therefore central to the analysis of an emerging biotechnology” (2003, p. 328). 
Other studies (which tend to employ sociology of technology perspectives such as 
actor-network theory [Latour, 1987; Callon et al., 1986] or the social construction of 
technology [Bijker et al., 1987]) have similarly suggested that expectations can affect 
technology development. They propose that expectations function as actors or elements 
of the larger network within which a developing technology is embedded, helping to 
define and shape the technology, not just describe it. (Selin, 2007; Brown and Kraft, 
2006; Kitzinger and Williams, 2005) Expectations can be “fundamentally ‘generative’, 
they guide activities, provide structure and legitimation, attract interest and foster 
investment” (Borup et al., 2006, pp. 285-6). The notion of expectations as “generative” or 
“performative” is common, alternatively expressed in ways such as expectation as 
“script” (whereby an expectation helps determine a plan of action for the development of 
a technology), “vision” (or a set of ideas about how a technology might be put into 
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practice), or as an element of “communities of promise” (or a group of agents, ideas and 
practices that focus on a particular hopeful outcome). (Brown and Kraft, 2006; Hedgecoe 
and Martin, 2003; Akrich and Latour, 1992) Conceived of in these ways, expectations 
become an important variable in the construction of emerging technologies and merit 
sociological attention.  
Themes and concepts which are foundational to the sociology of expectations can 
be found in the work of various classical and contemporary sociological theorists. 
Although not focused directly on expectations as a sociological concept, much of Max 
Weber’s work was deeply infused with a sense of the importance of expectations of 
future events to social life. His theories of economics stressed that in a capitalist system, 
all levels of economic action were informed by expectations about the future - that, for 
instance, “every form of rational calculation…is oriented to expectations of prices and 
their changes” (Weber, 1978, p. 92). His theory of rationality attended to the effects of 
uncertainty, asserting that agents’ decisions in general are based on expectations they 
form in response to the uncertainty of future outcomes. (Parsons, 2006) Analyses that 
identify an underlying focus on the future/futurity in Weber’s theories of progress, 
rationality, and vocation also affirm that Weber helped to lay a foundation for today’s 
sociology of expectations. (Adam, 2005)  
George Herbert Mead’s theory of the self, particularly in the “me,” or the 
reflexive self that develops in response to social expectations, also laid groundwork for 
the sociology of expectations. Although his analysis was at the behavioral level, it helped 
to legitimate expectation as a factor of social influence, presenting it as generative in 
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terms of the self as the sociology of expectations now presents it in terms of technology. 
(Mead, 1967)  
Robert K. Merton’s self-fulfilling prophecy provides another dimension of 
support for current theories of expectation. Merton contended that “[t]he self-fulfilling 
prophecy is, in the beginning, a false definition of the situation evoking a new behavior 
which makes the originally false conception come true” (1948, p. 195). The sociology of 
expectations could reasonably substitute “expectations” for “false definitions” (although 
the expectations would likely not be defined as false, but rather, perhaps, as not yet 
proven true). The basis of Merton’s concept (that definitions of social phenomena or 
situations, whether accurate or not, can influence actors in such a way as to further 
support those definitions) is highly corroborative with the main concept of the sociology 
of expectations (that expectations, whether they will come true or not, can influence 
technological development in such a way as to support the realization of those 
expectations).  
The sociology of expectations has already been applied to the study of a variety of 
emerging medical technologies, including stem cell therapies, nanotechnology, cord 
blood banking, pharmacogenetics, and membrane technology. (Kitzinger and Williams, 
2005; Selin, 2007; Brown and Kraft, 2006; Hedgecoe and Martin, 2003; van Lente and 
Rip, 1998) In fact, it is new and developing technology areas such as these for which the 
subfield is most valuable, since – in the absence of clinical results – expectations are in 
many cases one of more tangible sources of material for social scientists to study.  
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The sociology of expectations, therefore, seems useful for my own study of 
human gene therapy (and has, in fact, been used previously in studies of this emerging 
technology [Horst, 2007; Martin, 1999]). After its first U.S. clinical trial in 1990, human 
gene therapy for many years benefited from significant funding, public and regulatory 
support, and media coverage and promotion, despite few instances of clinical success 
(and several high-profile failures). (Crofts and Krimsky, 2005) Its oft-cited status as a 
presumed but unproven “miracle cure” seems to embody the hope/hype tension that 
studies of expectations seek to understand. Indeed, the possible negative effects of 
expectations surrounding the technology have been publicly identified. Per former 
National Institutes of Health director Harold Varmus,  
Expectations of current gene therapy protocols have been oversold. 
Overzealous representation of clinical gene therapy has obscured the 
exploratory nature of the initial studies, colored the manner in which 
findings are portrayed to the scientific press and public, and led to the 
widely held, but mistaken, perception that clinical gene therapy is already 
highly successful. Such misrepresentation threatens confidence in the field 
and will inevitably lead to disappointment in both medical and lay 
communities. (Orkin and Motulsky, 1995) 
 
Since my particular interest is in the media discourse surrounding human gene therapy, I 
drew upon the sociology of expectations to examine how the images, metaphors, and 
narratives within this discourse – as representations of expectations – may be helping to 
shape the development of the technology. 
 
Human Gene Therapy and Identity, Embodiment, and Illness Meanings 
 
1. Medical technology and self/identity 
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On a very basic level, the sociology of the self
3
 and the sociology of technology 
share an emphasis upon the reflexive relationship between their unit of study and 
society/social structure. Self and technology are both seen as creators and creations of the 
social contexts within which they are embedded. As George Herbert Mead - one of the 
founders of the sociology of the self and the symbolic interactionist approach with which 
it is closely connected - stated, “It is by means of reflexiveness - the turning-back of the 
experience of the individual upon himself - that the whole social process is thus brought 
into the experience of the individuals involved in it" (Mead, 1934, p. 134). Sociologists 
of technology recognize a similar reflexivity (although occurring not in individual 
consciousness so much as the within the networks that surround technology 
development).  From Marx’s assertion that technology was not neutral but rather affected 
by class interests through contemporary constructionist and network-focused approaches, 
the sociology of technology has long attempted to uncover the ways in which 
technologies and their social contexts shape one another.  
The sociologies of the self and technology are also both situated within larger 
academic communities of interest in their topics, in which other disciplines have longer 
traditions of studying that topic (e.g., psychology and philosophy in the case of self, and 
history and philosophy in the case of technology). While this has given these subfields a 
strong foundation of research upon which to build their studies, it also challenges the 
sociologies of self and technology to develop their own disciplinary identities. The 
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 Hereafter, the terms “the sociology of the self” and “self” will be used to represent sociological inquiry 
into the areas of self and identity. That “self” and “identity” are different is acknowledged (and emphasized 
in the work of scholars in the area [Owens, 2006; Stryker, Owens and White, 2000]); the use of the 
abbreviated term and a greater focus on the more basic concept of self are exercised here in the interest of 
concision. 
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sociology of self has struggled somewhat with tensions between pragmatism and 
postmodern theory. However, it has maintained a sense of disciplinary cohesion, in part 
because “[w]hether phenomenal or discursive, fragmentary or unitary, stable or 
transitory, emotional or rational, linguistic or embodied, the self is assumed to be a 
product of social interaction” (Callero, 2003, p. 121). Although much sociological study 
of technology occurs under the disciplinary umbrellas of a number of related fields 
(including science and technology studies [STS] and the sociology of scientific 
knowledge [SSK]), a similar shared understanding that technological change is shaped by 
social interaction does unite much of this work.  
With their common sociological orientation and location within broad 
interdisciplinary conversations, it is unsurprising that the sociologies of self and 
technology also converge within studies of the shaping and effects of many technologies. 
Medical technology, due to its immediacy to individuals and their life experiences, is an 
area of study where both the sociology of technology and the sociology of the self are 
particularly valuable. To understand a medical technology, sociologists of technology 
typically examine the context in which the technology has been developed, tested, and 
implemented. The various actors (humans, objects, institutions, etc.) that inhabit this 
context, often referred to as a network, are viewed as instrumental in shaping and 
reshaping the technology. (Bijker et al., 1987; Latour, 1987; Callon et al., 1986) Here, the 
sociology of self becomes relevant in that it helps to explain how human actors’ 
perceptions and understandings of their personhood influence their actions, which in turn 
influence technological development.  
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Mead’s foundational theory of the “I” and “me” components of the self suggests 
that each person has a “me,” or an objective self that is composed by the individual 
internalizing the attitudes and expectations of the social world, and an “I,” which is the 
agentic self. The “me” determines from social interaction how the individual should act, 
and the “I” acts accordingly. (Mead, 1934) The network surrounding a medical 
technology includes various human actors (scientists, researchers, funders, doctors, 
patients, families, etc.), each of whom has a “me” that has formed in response to his/her 
social world and an “I” who acts in response to the “me.” In many cases, theories of the 
self like Mead’s are used implicitly within sociology of technology research, in that they 
inform sociologists’ understanding of how human actors and social forces interrelate. 
Nonetheless, a more explicit inclusion of concepts from the sociology of the self within 
technology studies seems to present an opportunity for more sophisticated network 
analyses that feature closer examinations of the dynamics of human action and 
technology development.  
Some sociological studies of technology do clearly denote their use of symbolic 
interactionism (which emphasizes the generativity and contingency of human interaction 
and is closely tied to Mead’s sociology of the self). (Star, 1996; Fujimura, 1992; Clarke 
and Gerson, 1990) It has been argued that because “[s]ymbolic interactionism focuses on 
relationships rather than things,” these types of studies contribute to the sociology of 
technology by reminding scholars that as they examine the complex networks of actors 
that influence technological change, they should not neglect the relationships and 
interactive contexts within which such change actually occurs (Van House, 2003, p. 26). 
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 One criticism of technology studies that employ a symbolic interactionist 
perspective is that they underemphasize the effects of power upon technological 
development. (Van House, 2003) By contrast, the writings of Michel Foucault comprise 
one of the most power-conscious bodies of work that has occurred at the intersection of 
the sociologies of technology and self. Like Mead, Foucault saw the self as generated 
through social interaction, but he emphasized the power-ladenness of this interaction: 
“For Foucault, the self is the direct consequence of power and can only be apprehended 
in terms of historically specific systems of discourse. So-called regimes of power do not 
simply control a bounded, rational subject, but rather they bring the self into existence by 
imposing disciplinary practices on the body” (Callero, 2003, p. 118). Foucault did not 
believe in an essential or fixed self, but rather he felt that self and identity were entirely 
produced through discourse and social interaction, both of which were directed by ever-
changing power relations. With society functioning as a virtual Panopticon, wherein the 
individual’s behavior is subjected to constant surveillance and sanction, the formation of 
the self is less a personal process and more a function of disciplinary power. (Foucault, 
1977) This type of self – which could be likened to a Meadian “me” that exists without 
an acting “I” – is often referenced (albeit perhaps mostly implicitly) in sociology of 
technology studies.  
For Foucault and in general, sociological analyses of technology tend to focus 
more on the effects of technology upon the self than on the self’s effect upon 
technological change.  Many possible reasons for this trend exist, from a tradition of 
technological determinism within sociology (Smith and Marx, 1994; Marx, 1973; 
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Ogburn, 1966) to the practical reality that effects upon the self seem more measurable 
(via interviews, surveys, etc.) than effects upon complex technological systems. Further, 
the tendency of contemporary sociologists to be very mindful of power relations could 
make studying technology’s effects upon the self more appealing than the reverse.  
Foucault’s strong emphasis on power elicited criticism that his theories rob the 
individual of agency, resistive ability, and participation in the development of his/her 
self: “Foucault’s work often implies a one-way movement of power over and above the 
individual, one consequence of which is that the psychic dimensions of human 
experience are firmly denied and the self is seen as simply a by-product of discourse” 
(Elliott, pp. 99-100). Although in his later work Foucault did attempt to examine possible 
ways in which the individual could affect the formation of his/her self (Foucault, 1988), 
whether he allowed the individual any true measure of personal freedom is often still 
questioned. (Elliott, 2008; McNay, 1994) Despite these criticisms, Foucault’s work adds 
much to the body of sociological knowledge about the development of the self as a 
structurally bound (and power-laden) process. As discussed further below, his analysis of 
the self as it relates to the body has contributed significantly to sociology in general and 
the sociology of the body in particular. 
 Much valuable sociological research has been done that examines the effects of 
medical technologies upon the self, especially in regard to genetics-based medical 
technologies. Nelkin and Lindee (1995) suggested that DNA and genetics knowledge 
have taken on a sacred quality, and that this in turn has changed the way our culture 
thinks about the self: “The gene has become a way to talk about the boundaries of 
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personhood… [j]ust as the Christian soul has provided an archetypal concept through 
which to understand the person and the continuity of self, so DNA appears in popular 
culture as a soul-like entity...[DNA] is the essential entity – the location of the true self” 
(pp. 41-2). This redefinition of the essential self as being written in the individual’s 
genetic code could affect the individual’s perceptions of his/her ability to participate in 
self-development – if self is predetermined by genetics, one might conclude that little 
room for individual agency remains.  
The genetic version of self could also affect individuals’ attitudes toward and 
relationships with medical technologies, both genetics-based and traditional. Genetic 
medicine gains legitimacy as the essential solution to health problems, whereas other 
explanations for illness and disease seem outdated and less promising. Further, 
individuals’ relative power within their relationship with medical technology is decreased 
when genes define the self, as they become dependent upon complex technologies and 
the experts that develop and administer them. To have any power of self-determination or 
input into the shaping of medical technology seems out of reach when the self is located 
within an entity that cannot be perceived or understood without specialized equipment 
and expertise.  
The genetic self, in cases where an individual is found to be genetically 
predisposed to some disease or condition, could also lead to the individual taking on an 
identity of “potentially ill” (Conrad, 2005). Such an identity could affect not only the 
individual’s relationship to medical technology but also his/her social interactions and 
life status. (Rapp, 1999)  
 36  
At the same time, an idea of a self that could be changed or improved through 
genetic means could give the individual a sense of hope or limitless potential. New 
advances in genetic medical technology could be perceived as an “important change that 
also expands the physical limits of one’s self. By opening the previously closed door we 
enter a new expanded area of functioning” (Liakopoulos, 2002, p. 11).  
Further, although genetic medical technologies may themselves be young and 
emerging, rationales that support a genetics-based definition of the self are not: “The 
notion that genetics defines one’s identity and one’s destiny is deeply rooted in the 
dominant western cultures, in discourses of individuality and individual responsibility 
(liberalism and humanism), biological differences in human types and diseases ‘running 
through families’” (Petersen, 2006, p. 485). This cultural resonance of a genetic 
explanation of self, along with the continuing stream of financial and cultural support for 
genetic medical technologies (Crofts and Krimsky, 2005), suggest that future sociological 
research of the self should certainly take the relationship of self and emerging medical 
technologies into account. 
 
2. Medical technology and the body/embodiment 
The relationship between new technologies and the body – especially in terms of 
how the body and its social meaning are affected by technology, often in ways that 
involve some exertion of power or control – has long been an object of concern for 
sociological theorists. In fact, “the body as a physical component of social control had a 
habit of appearing in some of their most important writings on methodology, the 
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constitution of social systems, and modernity” (Shilling, 2004, p. 21). Examining 
classical and contemporary sociological theories of the body reveals many valuable ways 
of thinking about the reflexive relationship between body and technology. 
 Karl Marx was very interested in the ways in which the human body was 
impacted by technology. He contended that the laborer’s use of tools and machinery 
affected his embodiment and distinguished the human body from that of the animal: 
“Thus Nature becomes one of the organs of his activity, one that he annexes to his own 
bodily organs…the use and fabrication of instruments of labour, although existing in 
germ among certain species of animals, is specifically characteristic of the human labour 
process” (Marx, 1912, 199-200). Because the use of technology so defined human 
embodiment, Marx viewed the body as a powerful means by which capitalist control 
could be exerted over the individual. By binding laborers to productive technologies, the 
capitalist could effectively shape their experiences of their bodies, defining them by their 
value to the production process. (Wendling, 2009) 
Max Weber contended that rationalization and bureaucratization trapped the 
individual in an “iron cage,” restricting his/her life activities to a compulsory 
maintenance of the capitalist system. Because technology was such an integral part of the 
system, it follows that technological development contributed to this restriction: “Tied to 
the technical and economic conditions at the foundation of mechanical and machine 
production, this cosmos today determines the style of life of all individuals born into it, 
not only those directly engaged in earning a living” (Weber, 2001, p. 123). Therefore, 
Weber clearly shared Marx’s belief that technology had significant effect upon 
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individuals’ lives and social experiences. Weber also shared Marx’s concern with the 
effects of the capitalist system upon the body. He contended that along with 
rationalization came individuals’ psychological compulsion toward discipline and 
asceticism, which in turn promoted austerity and deprivation in regard to bodily matters 
and practices. As Shilling writes, “Hard work and effort in the sphere of production was 
coupled with frugality and denial of the sensuous in the sphere of consumption” (2004, p. 
25).  
The body in relationship to technology (and medical technology in particular) was 
also examined closely by Foucault. Like Marx, he viewed the body largely as site of 
social control. Echoes of Marx can be detected in Foucault’s discussion of his own 
concept of “bio-power,” which he saw as a “subjugation of bodies” that accompanied the 
rise of disciplinary institutions such as the military, medicine, and education: “This bio-
power was, without question, an indispensable element in the development of capitalism; 
the latter would not have been possible without the controlled insertion of bodies into the 
machinery of production” (Foucault, 1978, pp. 262-3).  
Foucault saw the body as both an input into economic and technological 
development and a means by which power is exerted through technology, an “object of 
knowledge” (1977, p. 176). In either case, the body is subjected to control, manipulation 
and the mechanisms of power and is a “docile body,” able to act only insofar as its 
actions serve the interests of the powerful.  
Foucault also contended that the organization and orientation of hospitals and the 
medical technologies they contained were designed “to permit an internal, articulated and 
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detailed control – to render visible those who are inside it…to carry the effects of power 
right to them, to make it possible to know them, alter them” (1977, p. 190). No 
technology, however seemingly neutral or benevolent, could be used without an assertion 
of power. Per Callero, “[P]ractices that are normatively represented as humane 
interventions in support of community health, safety and education actually serve as 
mechanisms of domination” (2003, p. 117).  
 Feminist sociologists also have written widely about technology and the body and 
their relationship to power structures. Since the underlying premise of much feminist 
scholarship is that women and the feminine have long been objectified within patriarchal 
societies, feminist scholars are well positioned to address the effects of technology on the 
body. Donna Haraway has examined how medical technologies and the discourses 
surrounding them have promoted an objectified notion of the body. In studying the 
immune system as a medical construct, she describes it as “a plan for meaningful action 
to construct and maintain the boundaries for what may count as self and other in the 
crucial realms of the normal and the pathological” (Haraway, 1999, p. 204). Haraway 
suggests that these boundaries affect both technological development and individuals’ 
own body attitudes and practices.  
Although technology and power interact in ways that objectify the body, Haraway 
suggests that individuals can use the interwovenness of 
technology/power/bodies/representations to their resistive advantage. To identify the 
body as a “cyborg” challenges the notion of separation between individual and machine 
and “counters the dualisms of self and other, mind and body, male and female, culture 
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and nature, and maker and made that, [Haraway] says, translate into mechanisms of 
domination” (Van House, 2004). The cyborg body can no longer be totally objectified by 
technology, because it is technology. In Haraway’s words, “The machine is not an it to be 
animated, worshipped, and dominated. The machine is us, our processes, an aspect of our 
embodiment. We can be responsible for machines; they do not dominate or threaten us’’ 
(1991, p. 180). Other feminist scholars have argued that in order to counter the 
undeniable objectifying effects of technology on the body, individuals must cultivate an 
“embodied self” or “experienced body” through taking control of their own health and 
medical care, actively resisting or challenging negative impacts of technologies, or 
participating in practices such as performance, art, and the creation of counter-narratives. 
(Davis, 1997) 
 
3. Medical technology and illness/illness meanings 
 While “illness” may be commonly conceived of as an individual biological reality 
untouched by social influence, contemporary social scientists have sought to demonstrate 
the socially constructed nature of illness. (Bird et al., 2000; Zborowski, 1953) What 
constitutes illness varies broadly across cultures and is produced and reproduced through 
social interactions. (Zola, 1966) Similarly, models of treating illness vary culturally and 
across racial and ethnic groups (e.g., the Western biomedical model versus holistic or 
traditional approaches). (Robinson, 2002) Because illness is so affected by social forces 
and contexts, it is important to examine its relationship to the development and utilization 
of medical technologies 
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Some of the more valuable work examining illness as a social construction has 
been written by the social scientist and physician Arthur Kleinman. In The Illness 
Narratives (1988), he presents a rich description of illness as a culturally-bound 
experience and explores the effects of social factors – including medical technology – on 
illness. Kleinman also differentiates between “illness” and “disease,” with disease 
representing the biological condition and illness representing the wider range of 
interpretations, symbols, and narratives of disease as it is experienced. He develops the 
concept of “illness meanings” to give voice to this more refined understanding of illness. 
Kleinman asserts that   
[t]he study of illness meanings is not only about one particular 
individual’s experience; it is also very much about social networks, social 
situations, and different forms of social reality. Illness meanings are 
shared and negotiated. They are an integral dimension of lives lived 
together. Illness is deeply embedded in the social world, and consequently 
it is inseparable from the structures and processes that constitute that 
world. (1988, p. 186) 
 
By grounding illness within its social context, Kleinman’s work encourages consideration 
of the relationship between illness and technology. He notes the imperative of medical 
technology to “keep the patient alive at any cost,” suggesting that medical technology 
tends to address disease alone while ignoring the multifaceted nature of illness (1988, p. 
153). Kleinman also addresses the potential of medical technology to discourage people 
with illness from participating in their own care. When complex technologies are seen as 
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the solution to health problems, the input of the clinician-expert becomes privileged and 
the input of the patient
4
 loses value.  
This possible effect of technology seems highly relevant to studies of genetics-
based medical technologies. When the source of illness (most likely already reduced 
conceptually to disease) is identified within ever-smaller biological entities (i.e., 
genes/genetic code/DNA), the patient becomes increasingly removed from the treatment 
process. The ability to interpret, make sense of, or express one’s own illness meanings 
may also be challenged when the source of illness seems so intangible and the 
understanding of treatment technologies so dependent upon expertise. (Frank, 1997)  
Indeed, in the age of genetics-based diagnostic technologies (which in some cases 
reveal propensity toward illness in asymptomatic individuals), the individual may need an 
expert to even determine whether he/she is ill or well. (Nelkin and Lindee, 1995; 
Lippman, 1991) Although genetic treatments for disease are not yet commonplace, 
significant financial and ideological support for genetic medical technologies persists, 
even though – as in the case of human gene therapy – clinical trials have been underway 
for decades with no real successes and several high-profile failures. (Crofts and Krimsky, 
2005)  Public discourse abounds with suggestions of genetic medicine as a “holy grail” or 
“miracle cure.” (Horst, 2007; Liakopoulos, 2002; Martin, 1999)  
Even as the use of genetic medical technologies seems likely to expand, 
possibilities exist for mitigating the alienating effects of such technology upon patient 
experience. Kleinman asserts that “the purpose of medicine is both control of disease 
                                                 
4
 Even the use of the term “patient” suggests a conception of health concerns as disease rather than illness; I 
use it here because of its conventional ubiquity, but with an acknowledgment of its bias. 
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processes and care for the illness experience” (1988, p. 253). He suggests that from 
medical school to physician and clinic practices, a rethinking of what it means to care for 
the patient must occur. As asserted by Kleinman and others (e.g., Bell, 2002; Hyden, 
1997), patient narratives about their illness experience must be sought and recognized as 
valuable medical information. While this is relatively rare within the context of Western 
managed care, such an approach has been associated with an improved care experience 
for both patients and physicians.
5
 These findings imply that if medical professionals 
provide care that gives voice and responds to patient experience and illness meanings, 
even seemingly alienating medical technologies could be used for treatment that is both 
biologically effective and in the best interest of the whole person. Certainly, it seems 
important that sociological analyses of emerging medical technologies acknowledge the 
challenges these innovations may present to patients’ meaning-making processes and to 
clinicians’ attempts to provide care that responds to the complexity of patient experience. 
 
Summary   
This review outlines some of the important debates and areas of interest within 
the sociology of technology that are relevant to my inquiry into the media discourse about 
human gene therapy. Key findings include the strong historical presence of technological 
determinism in sociology and popular discourse; the interpretive value of the concept of 
geneticization; and the utility of the sociology of expectations for analyzing and 
                                                 
5
 Various studies indicate that despite physician concerns that soliciting patient narratives would be much 
more time consuming, such types of visits are barely longer than regular visits. Both physicians and 
patients are more satisfied with visits wherein doctors ask about psychosocial issues and patients are treated 
as partners in their own care. (Ong et al., 1995; Mazur, 1993; Roter and Hall, 1992) 
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understanding media images, metaphors, and narratives about human gene therapy. 
Further, the many intersections between the sociological study of medical technologies 
and studies of self/identity, body/embodiment, and illness/illness meanings provide 
numerous opportunities to strengthen and more deeply contextualize my analysis of 
human gene therapy media discourse.  
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Chapter 3 
Methodology 
 
 This chapter describes the research methodology used in my study, with emphasis 
upon the following areas: the rationale for my research approach, the research sample, 
data collection and analysis processes, a brief discussion of ethical issues, and several 
criteria for evaluating the trustworthiness of the research.  
  
Rationale for Research Approach 
 In the following sections, I explain my rationale for electing to work within the 
qualitative research tradition and to use a qualitative content analysis method. I then 
discuss my decision to use media content as my source of data about human gene 
therapy. Finally, I consider why it is useful to examine the metaphors present in media 
discourse about human gene therapy.  
 
1. Why qualitative research? 
Scientific research as it has traditionally been viewed and practiced (that is, within 
the positivist tradition that has dominated science throughout most of its history) relies 
heavily on a belief in its ability to uncover objective truth, independent of researcher 
perspective.  Scientific researchers are commanded to remain outside of or separated 
from their research, to be careful that their perspectives, preconceptions and values do not 
“contaminate” their findings.  Only by doing so can they approach discovery of the 
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“objective,” “essential” truths about their topic of inquiry.  As Weber maintained in his 
call for “value-free” research and Durkheim (1938) insisted in his theory of objective 
“social facts,” social science researchers have long been cautioned to isolate their own 
sensibilities, opinions, and worldviews from their scientific pursuits.  According to this 
view of knowledge-building, the researcher’s viewpoint should be that of an observer 
looking in from the outside (or “etic,” per Guba and Lincoln’s characterization), not an 
active participant in the research context (or “emic”). (Guba and Lincoln, 1998)  Any 
knowledge derived when the researcher fails to bracket his/her perspective is not 
“scientific,” but rather is speculative and tainted.  This connects to a conviction that there 
is an important difference between “scientific” and other types of knowledge, and that 
only “scientific” knowledge, arrived at through this detached approach, actually gets at 
the “Truth” about how the world works.   
The idea that the self is something that “gets in the way” of legitimate knowledge-
building is not limited to scientific research as it is practiced, but rather is grounded in a 
basic belief of many prominent Western philosophies (such as those of Descartes, Kant, 
Husserl, and many others) - namely a separation of body and mind, of knower and 
known, of subjective perspective and objective truth. (Shand, 2002) This belief forces 
researchers to perform their work as automatons, not allowing any of the qualities that 
make them human interfere with the task of extracting objective truth from the “objects” 
of study.   
Within the qualitative research paradigm, the objective, detached, value-free 
researcher is both an unrealistic and undesirable characterization.  Instead, the humanity 
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and perspective of the researcher are recognized as inescapable parts of the research 
experience and embraced as such.  Researchers are not able to separate completely from 
the research process, because their idea of what can be known about their topic 
(ontology), how they feel they can get at what can be known (epistemology), and the way 
in which they do so (methodology) are all shaped and influenced by their own 
viewpoints.  This challenges not only the conventional belief that the researcher should 
be removed from the object of study, but also the positivist view of science and reality 
that is based in a conviction that there is a singular, objective truth that can be arrived at 
through properly controlled scientific research. 
I readily admit that it can initially feel rather anomic to think that perspective 
influences and colors all research; I have journeyed through the stages of confusion and 
uncertainty that seem inevitably to accompany the realization that all knowledge has been 
affected by its creators.  The idea that the scientific method is not a surefire way to 
discover essential, objective “Truth” (and the accompanying uncertainty as to whether 
there even is such a “Truth”) challenges what most of us are taught to believe from our 
earliest days as learners and could make the process of discovery seem frustrating and 
pointless.   
However, I choose to focus on how the idea creates an opportunity for social 
science to play a more meaningful and activist role in society.  It shows that sociological 
inquiry is less an opportunity to discover the one “true” reality than it is a means by 
which researchers can connect what they observe in the world to what they know about it. 
Research can involve a type of knowledge-building that does not try to privilege one 
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understanding of reality over another, but instead acknowledges that all knowledge 
relates to a context.  By drawing attention away from how accurate knowledge is, it 
creates space for considering what practical purpose knowledge can serve.  Thus, the 
acknowledgment that the humanity of the researcher is unavoidably present in the 
research process reminds me that, whether I believe that there is one “Truth” or many, 
“multivalent” realities, my goal as a researcher should not be to reveal truth, but rather it 
should be to relate what I observe to what I know in a way that is both meaningful and 
potentially life-changing for others. 
The approach I selected to study human gene therapy reflects my commitment to 
the values of qualitative research. Rather than simply counting and quantifying the 
images and metaphors I have found within the media content, I recognize them as part of 
a broad and dynamic context and describe them in terms of their positions in that context. 
Doing so inevitably means my perspective comes into play, since the process of relating 
content to context necessitates decision-making and interpretation that is affected by my 
own knowledge and beliefs. In addition to generating rich descriptions of images, 
metaphors, and narratives, the value of studying human gene therapy media qualitatively 
lies in connecting it to the larger context of the field. If the media is a vital actor in the 
construction of a technology (as is argued by STS scholars such as Bijker et al. [1987], 
Latour [1987], and Callon et al. [1986]), then a deep, situated understanding of media 
content could actually contribute to responsible development within human gene therapy 
technology in the future.   
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Qualitative content analysis (also referred to as ethnographic content analysis or 
qualitative document analysis [Altheide, 1996]) extends the approach of the qualitative 
paradigm to the analysis of textual materials, which historically had been analyzed 
through quantitative counting and measuring in social science research. Qualitative 
content analysis also allows a more flexible and thorough analysis of the data, one that is 
not limited by preordained categories: “If one uses only structured protocols in content 
analysis research, critical questions, issues and shortcomings that may become apparent 
at a later time may have to be forsaken due to lack of data. If, however, ethnographic 
materials are also included, then it is usually possible to return to the data when other 
questions and inquiries arise” (Altheide, 1996, p. 23). Because, as Prior argues, 
“[d]ocuments need to be considered as situated products, rather than as fixed and stable 
things in the world,” it is important to approach them in a way that acknowledges their 
contextualized nature. (2003, p. 26) My approach to collecting and analyzing human gene 
therapy media content (discussed further below) is based on these research principles. 
 
 
2. Analyzing media content 
In order for media content to have relevance as a source of sociological data, it 
must be demonstrated to affect individual or collective understanding, perception, or 
experience in some way. One of the earliest approaches to characterizing this influence 
was developed by Erving Goffman. (1986) His frame analysis suggests that when 
humans interact with the world around them, they (unconsciously) draw upon a collection 
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of “organizational premises” (based on thought and experience) which can be called a 
frame. This frame shapes their understanding of new ideas and experiences.  
For Goffman, the media was both an example of a frame in action (via journalists’ 
understandings of the world influencing the topics they choose and how they report about 
them) and a contributor to the development, boundary-setting, and maintenance of 
frames. Frame analysis, typically in a reformulated fashion, has been applied to many 
studies across disciplines since Goffman’s origination of the concept. My study of human 
gene therapy in public discourse references the concepts of frame analysis to remain 
grounded in the basic premise that all media coverage of technology is both shaping and 
shaped by standpoints.  
 Gamson and Modigliani’s (1989) approach to applying frame analysis to the 
study of the media has also served as a foundation for much future work. They suggested 
that media coverage of an issue is guided by an organizing frame, which determines what 
is at stake and what matters about the issue. Within that frame, various interpretive 
packages emerge that can further refine the way the issue is presented to the public. 
These packages help to construct meaning about the issue at hand and can in turn have an 
effect upon public understandings and opinions about the issue. How influential each 
package becomes depends, according to Gamson and Modigliani, on cultural resonance 
(how well the package fits into existing cultural themes), sponsor activities (how much 
individuals or organizations directly or indirectly promote the package), and media 
practices (how journalists negotiate with the package). 
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Gamson and Modigliani’s approach has much relevance to studies of the media 
narratives surrounding emerging medical technologies. Especially because it is so 
naturally conversant with many of the most widely used methods of the sociologies of 
science and technology, the approach could be applied effectively to an analysis of how 
media images and narratives about new technologies might relate to the technologies’ 
development. For the purpose of my study, their concepts of frame and package are used 
to organize and make sense of the overriding themes that emerge from the data. Their 
concept of cultural resonance may also be useful for relating human gene therapy images, 
metaphors, and narratives to larger cultural and sociotechnical contexts.  
 
 
3. Studying metaphors 
 An additional area of interest in the study of media representation of science and 
technology is the use of metaphor. According to Lakoff and Johnson (1980), metaphors 
influence the way people think about issues, especially because the way we think and talk 
is (unless we are dealing directly with pure physical reality) essentially metaphorical. 
Because metaphors are so ingrained in modern thought processes, people often do not 
even recognize metaphors when they encounter them but instead interpret them as 
statements of reality.  
Since metaphors are so tightly (and unconsciously) interwoven with human 
thought and language, they have considerable power. Metaphors can be instrumental in 
fostering social intimacy, creating knowledge, and categorizing new information. 
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(Liakopoulos, 2002) Their generative qualities make them an important area of attention 
when studying public discourse; as van Dijck writes, “Metaphors are crucial narrative 
tools in the popularisation of knowledge; they provide prototypes for imaginary 
creations” (1998, p. 22).  
Metaphors are very common in media accounts about science and technology, 
particularly genetics technologies (perhaps, to some extent, because a clear common 
vocabulary about the new and complex area of genetics has not yet been realized).  
Various scholars maintain that such metaphors are more than just representational and in 
fact can influence not only public understanding/opinion and media discourse about 
technologies, but also the construction of the technologies. Stahl asserts that 
“[p]articularly potent images or metaphors, once part of a media frame, can go on 
reciprocally shaping the social world and the media accounts of that world for a long 
time” (1995, p. 238). Wilson suggests that “[m]etaphors in science have the power to 
shape research paradigms” (Wilson, 2003, p. 197). Further, as Nelkin writes,  
metaphors are more than an aid to explanation: repeated metaphors affect 
the ways we perceive, think and act, for they shape our understanding of 
events. They also structure our attitudes about public – and scientific – 
issues…Although people interpret scientific information and ascribe 
meaning to metaphors according to their personal experience and previous 
knowledge, metaphors are powerfully persuasive tools. (2001b, p. 556) 
 
Nelkin also argues that metaphors are not simply reflections of the perspectives or 
intentions of those who invoke them, but rather they are “social products” that are shaped 
by the complex cultural contexts within which they develop. (1995, p. 13)  
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 Regarding genetic metaphors in particular, Nelkin directs attention back to the 
eugenics narratives of the 1920s, when images of heredity such as “germplasm” and 
“blood” were judged to be determinants of behavior and character. She suggests that the 
next major wave of genetic metaphors surfaced in the 1970s, when the public became 
aware of the emergence of molecular genetics research. Metaphors such as 
“Frankenstein’s monster” and “tinkering with life” exemplified a narrative of a 
frightening technology that could change or harm humanity in a fundamental way. 
(Nelkin, 2001b) By the 1980s, more positive imagery emerged, with new findings in 
DNA and genetics being heralded as miraculous discoveries for the improvement of 
human health.  
As genetic science became a prominent part of public health discourse, Nelkin 
asserts that metaphors describing it began to fall into four thematic categories: “first, 
essentialist metaphors: genes are the essence of personal identity; second, religious 
metaphors: the gene is a sacred entity; third, fatalistic metaphors: genes are destiny; and 
last, commercial metaphors: genes are commodities” (2001b, p. 557, emphasis added). 
These categories are an important aid to thinking about how genetics has been 
characterized in popular discourse in the past 30 years.  
 Essentialist metaphors: Metaphors within this frame imply that individuals’ 
genetic makeup determines their health, personality, behaviors, or other personal 
characteristics. Borrowing from information technology, genetics since the 1980s have 
frequently been characterized as holding the “code” or “instructions” for human life. 
Comparing DNA to a “blueprint” or “script” suggests even more strongly that an 
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individual’s fate is determined by his/her genetics. This type of imagery downplays the 
complex interaction between genes and environment and “reduces the self to a molecular 
entity, equating human beings, in all their social, historical, and moral complexity, with 
their genes” (Nelkin, 1995, p. 2). Popular discourse has further endowed genes with 
deterministic power by “naming” genes in relationship to conditions or characteristics to 
which they might contribute (“the obesity gene,” “the alcoholism gene,” etc.). Such 
naming implies that if one has the gene, one will inevitably face the condition.  
 Religious metaphors: This theme can be viewed as an extension of the essentialist 
theme. Asserting that genetics determine the essence of an individual’s identity propels 
genetics into the realm that has most traditionally been responsible for negotiating issues 
of human essence, namely religion. DNA (and efforts to understand it, such as the 
Human Genome Project) has been referred to as “the Holy Grail” and “the Bible,” strong 
religious imagery that imbues DNA with defining power over human life. DNA becomes 
a “sacred text” that reveals not only physical structure but metaphysical essence. (Nelkin, 
2001b) Insofar as it is portrayed as capturing the essence of an individual, DNA can be 
likened to the Christian soul. Like the soul, “DNA is relatively independent of the body, 
gives the body life and power, and is the point at which true identity [and self] can be 
determined” (Nelkin, 1995, p. 40). Manipulation of human genetics has frequently been 
referred to in popular discourse as “playing God,” reinforcing the sacredness of the gene.  
 Fatalistic metaphors: If genetics are the essence of identity, suffused with sacred 
power, it then follows that they can predetermine an individual’s fate. Metaphors such as 
“oracle” and “crystal ball” are intensified versions of the ubiquitous essentialist 
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“blueprint” image of DNA. These images, in addition to ascribing even more power to 
genetics and further minimizing the influence of environmental factors, imply “a certain 
inevitability in the structure of existing social categories” (Nelkin, 2001b, p. 558). If 
genes control human destiny, then external efforts to improve the human condition seem 
doomed to futility. Fatalistic metaphors, therefore, promote an image of genetics that 
could have dangerous effects on public attitudes toward personal responsibility, social 
research and activism, and public policy. 
 Commercial metaphors: As the science of genetics has been appropriated by 
profit-seeking biotechnology firms, metaphors that commodify genes and genetic 
information have emerged. Calling sources of genetic information “gold mines” or 
“treasure troves” objectify DNA and depersonalize its meaning and value. Nelkin admits 
that this category of metaphors conflicts with the previous three themes and could have 
the effect of “placing the human body in an ambiguous space” (2001b, p. 558).  
 This discussion illustrates the importance of metaphor as unit of analysis in the 
study of human gene therapy media discourse. Both the generative qualities of metaphor 
and the long history of metaphors used to describe genetics technologies suggest that 
looking at metaphors helps to clarify the shape and impact of media discourse about 
human gene therapy. 
 
Research Sample 
The sample consists of human gene therapy-related news articles, summaries, 
briefs, and posts from major U.S. newspapers, popular news magazines, and online news 
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sites.
6
 Which mass communication sources to be used was determined by consulting 
common circulation/traffic rankings for each of the source categories and selecting the 
five highest ranked sources from each list.
7
 The sources selected were searched for pieces 
containing the following search terms: “human gene therapy,” “gene therapy,” “gene 
therapeutics,” or “gene transfer”; any piece containing one or more of these terms was 
included in the sample.
8
 In case of the selected newspapers and magazines, they were 
searched via an online database; the online news sites were searched via their respective 
homepages and online archives.   
Only media pieces published or released in or after 1989 were included.  Because 
the U.S.’s first human gene transfer experiment began in 1989, this date provides a 
                                                 
6
 My sample was limited to text-based data in the interest of ease and accuracy of coding and comparative 
analysis. My choice of limiting my sample to news media rather than the broader realm of popular media 
that would include film, entertainment television, music, books, etc. was also made to promote 
manageability of the sample. While popular works referencing human gene therapy may also play a role in 
constructing public opinion and technological development, I elected to restrict my study to news media so 
that the comparability of my data sources might allow me to develop a more in-depth analysis of their 
contexts and meanings. 
7
 Newspapers – 1. The Wall Street Journal 2. USA Today 3. The New York Times 4. Los Angeles Times 5. 
The Washington Post. (Audit Bureau of Circulations, September 30, 2010.) 
Magazines – 1. Time 2. Newsweek 3. US News and World Report 4. The New Yorker 5. The Economist. 
(Audit Bureau of Circulations, August 9, 2010.) 
Online news sites – 2. CNN 6. The Huffington Post 8. Fox News 11. Reuters 12. ABC News (Omitted – 1. 
Yahoo News 4. Google News and 7. digg [because these sites aggregate news stories from many other 
sources rather than generate their own stories]; 5. The New York Times 9. The Washington Post and 10. Los 
Angeles Times [to avoid duplication with their print versions]; and 3. MSNBC [because it lacks a searchable 
archive].) (eBizMBA Rank, which is an average of each website's Alexa Global Traffic Rank, and U.S. 
Traffic Rank from both Compete and Quantcast, February 2011.) 
Also, although it is certainly true that the chosen sources of media content – let alone the media types 
selected – are by no means the only ways in which individuals may encounter information about human 
gene therapy, they were chosen as both a logistically feasible and a reasonably representative sample of 
American mass media portrayals of the technology. 
8
 Although it is likely that many media pieces that do not expressly mention gene therapy may be pertinent 
to this research topic, it was necessary to create some boundaries regarding what information should be 
included, for practical and analytical reasons.  Such sources yielded insights that were used to inform 
analysis, but they were not considered as data sources. 
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sensible starting point for examining the technology and field.
9
 The selected media 
sources were searched from 1989 to 2011 in an effort to discern whether any patterns or 
changes in the images/metaphors/narrative/tone occurred over time. I also paid special 
attention to certain dates that marked events important to the development of human gene 
therapy, examining whether any changes or trends in the way the media discussed human 
gene therapy emerged after those dates. These dates (which have been identified in 
multiple sources as landmark moments in the history of human gene therapy 
[Timmerman, 2009; Crofts and Krimsky, 2005; Martin, 1999]) are as follows: 
 September 14, 1990 – the first instance of a clinical trial participant in the 
United States being treated for a genetic disease by human gene therapy. 
 September 17, 1999 – the death of clinical trial participant Jesse Gelsinger. 
 April 27, 2000 – the announcement of success in treating SCID 
 January 15, 2003 – the announcement that two pediatric clinical trial 
participants developed a leukemia-like condition as a gene therapy side 
effect. 
 July 24, 2007 – the death of clinical trial participant Jolee Mohr.  
 May 7, 2009 – Targeted Genetics, one of the leading human gene therapy 
companies, reveals it is near bankruptcy. 
  
 
                                                 
9
 Pertinent information from earlier dates was used for background information and to support analysis but 
was not included in the dataset. 
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Data Collection and Analysis 
My data were collected from the set of human gene therapy-related media pieces 
selected to form my sample (assembled by the criteria described above). The process I 
used to gather these data is based on a type of qualitative content analysis informed by 
grounded theory. (Glaser and Strauss, 1967) In this process, I sought the elements 
described in my first research questions – namely, images and metaphors about human 
gene therapy. As I read through my cases, I endeavored to identify any language that was 
metaphorical or that described, explained, or exemplified human gene therapy in some 
way. Where I found such language, I assigned a code to the relevant text segment to 
precisely reflect the specific image or metaphor identified. These images and metaphors 
became my primary data. Throughout my data collection and analysis process, these 
images and metaphors were organized into types and subtypes that reflected 
commonalities between the many discrete images and metaphors coded (See Appendix 
B). Relationships between the subtypes were then analyzed by examining subtype co-
occurrences.
10
 By filtering cases using Boolean searches, I determined how frequently 
each subtype co-occurred with every other subtype within the cases sampled.
11
 For 
frequently co-occurring subtype pairs, I examined their co-occurrences in detail and 
identified emergent themes and concepts. From these findings (the images/metaphors, 
                                                 
10
 According to Namey et al. (2008), examining the co-occurrence of pairs of data codes creates valuable 
information that can be used as “a guide for reviewing and reorganizing the text data for interpretation” (p. 
145). 
11
 In other words, I would create a case filter that sought only cases where Subtype A AND Subtype B were 
both present and then noted how many cases remained after generating that filter. I did this for every 
possible combination of subtypes. I then identified which subtypes co-occurred most frequently (in terms of 
both raw numbers and percentages of total subtype occurrences). 
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their types/subtypes, and subtype co-occurrences), larger narratives emerged and became 
another level of data to be examined and re-examined. 
My data collection process, then, was to some extent contemporaneous with my 
data analysis, which is consistent with the principles of grounded theory. I subscribe to 
the belief that qualitative data should be analyzed inductively, meaning that analytic 
concepts and categories should emerge from the data and should not be deduced 
according to prior hypotheses.  (This is especially important here because there has been 
little previous research into media images of human gene therapy and therefore little 
basis for directly relevant pre-established hypotheses.) This can be achieved through use 
of the constant comparative method, whereby concepts are continuously revised, refined 
and reapplied throughout the process of data collection and analysis. (Strauss and Corbin, 
1994)  This involves an active process of memoing, journaling and analysis that begins as 
soon as the first data are gathered. Such a process not only ensures that analytic 
categories are grounded in the data, but it also guides the process of data collection, 
leading the researcher to areas that might benefit from further investigation. Although my 
approach is informed by grounded theory, it is closer to Altheide’s (1996) ethnographic 
content analysis (ECA), because I am less interested in theory building (a cornerstone of 
grounded theory) and more interested in rich description and analysis of the data (which 
are featured in ECA).  
To support and systematize this effort, I used HyperRESEARCH, one of several 
increasingly popular
12
 computer-assisted qualitative data analysis software packages.  
                                                 
12
 See MacMillan and Koenig, 2004; Bourdon, 2002. 
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HyperRESEARCH allows the researcher to assign codes to any chunk of text (including 
audio/visual materials), to organize, categorize, filter, and map codes and their 
relationships, and to (if desired) use hypothesis testing and theory-building tools to 
analyze data.  Codes are linked to source materials, and changes are automatically 
applied across all linked entities.  Retrieval of coded information can also be performed 
with an automated command.  (Hesse-Biber et al., 1991)  In addition to increasing 
transparency, the use of HyperRESEARCH helps to automate some mundane tasks.  It 
does not perform any analysis; rather, it is a tool through which the analysis process can 
become better organized and less time-consuming. 
  
Ethical Issues 
 It is also necessary to address the ethical concerns of studying genetics-related 
issues.  On a basic level, probing the images and meanings of genetics technologies 
brings up many controversial ideas about life and death, health and embodiment, self and 
identity, and more.  Although this project is based on the belief that the benefit of 
examining these issues far outweighs the risks, it is important to acknowledge that this 
type of research can be challenging and difficult for some readers.  Human gene therapy 
requires another level of sensitivity, since gene therapy research (and its success or 
failure) has very serious relevance to people suffering from various diseases and to those 
who care about and for them.  My hope is that clarifying the media discourse surrounding 
human gene therapy will contribute to more thoughtful and purposive discussions of the 
technology and field.  A thorough analysis of human gene therapy media images and 
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narratives may also present opportunities for further inquiry into the construction of the 
field, which in turn may lead future developments in the field in directions that are more 
sensitive to the public good and more responsive to patient needs. 
 
 
 
Trustworthiness 
The standard for validity measurement in this project is based on the principle of 
analytic realism forwarded by Altheide and Johnson (1994), which emphasizes careful 
attention to process in research, with particular focus on issues of research contexts, 
perspective, and the power of text.  In order to achieve “validity”, the researcher must be 
continually aware of the (often complex and changing) contexts of his/her observations, 
must repeatedly acknowledge the role of his/her perspective (and that of research 
subjects), and must exercise awareness of how his/her writing style and approach may 
privilege certain interpretations.   
Further, researchers “should faithfully report…multivocality (or cacophony) and, 
if possible, show where the author’s voice is located in relation to these.  Central to this 
ethic is the renewed realization that all knowledge is perspectival, so the ethical practice 
of ethnography demands that the author’s perspective be specified” (Altheide and 
Johnson, 1994, p. 490). This type of validity – validity-as-reflexive-accounting – “places 
the researcher, the topic, and the sense-making process in interaction” (p. 489). With 
these ideas in mind, I tried to be continuously aware of my own perspective and 
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presuppositions about human gene therapy. Because I am well-acquainted with a large 
body of sociological thinking about genetics that tends to emphasize the potential 
negative consequences of genetic manipulation, it was important for me to acknowledge 
my own possible bias against human gene therapy.  
Similarly, because many scholars have suggested that media coverage of human 
gene therapy is rife with overselling and hype, I needed to be aware of how my own 
preconceived notions might color my perception of the data, and, by extension, affect my 
efforts to allow my coding categories to emerge from the data. I engaged in memoing and 
journaling throughout the data collection and analysis process. Not only did this help to 
organize my thoughts and discoveries, but it also contributed to the confirmability of my 
findings. By conducting clearly documented, transparent research, I helped to ensure that 
my results correspond to the data in a reasonable and consistent manner. 
Another measure of the trustworthiness of qualitative research is transferability. I 
tried to create a study that would be (both methodologically and substantively) highly 
transferable to other research into media discourses of new medical technologies in 
general and genetic medical technologies in particular. Many new technological fields 
share characteristics similar to those of human gene therapy (such as generating high 
expectations, reliance on public support for research funding, presenting a challenge to 
traditional ways of thinking about health, medicine, identity and the body, etc.). The same 
deep, systematic analysis conducted could be useful in increasing understanding of the 
media contexts surrounding these types of emerging technologies. Indeed, since each new 
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discovery in medical technology is likely to generate significant media attention, it seems 
very important that ways of studying media discourse be developed and refined.  
 
 
 
Summary 
 
 As discussed above, this study responds to the acknowledgment in much research 
into genetics and human gene therapy that representations of genetics technologies in the 
media matter, and that they may have an effect on the development and use of 
technologies.  Although there have been studies of the relationship between media 
coverage and other genetics fields and technologies, human gene therapy has not received 
the same level of research attention.  Other sociological studies of gene therapy recognize 
that media imagery is an important area to consider, but such studies do not perform an 
in-depth examination of that imagery or collect or analyze media-based data. Therefore, a 
study of the media images, metaphors, and narratives about human gene therapy seems to 
fill an identified research gap.  I responded to this gap by conducting a qualitative study 
grounded in the data and informed by the theories of the sociology of technology. I hope 
for my research to serve as a foundation for many other studies into the construction of 
human gene therapy as a technology/research field/clinical treatment; it is possible that 
the findings made in this project will provide a basis for observational, interview and 
other types of studies that will examine how media discourse contributes to the 
development of genetic medical technologies.     
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Chapter 4 
 
Findings – Image and Metaphor Types and Subtypes 
 
 
 As stated previously, the purpose of this study is to explore how human gene 
therapy has been presented in the mainstream media over the past 20 years. To that end, I 
examined five research questions (see Page 11), using a sample of articles about human 
gene therapy from selected major U.S. mass communication sources since 1989. In doing 
so, I compiled a list of hundreds of metaphors and images used to describe gene therapy. 
I then subjected this list to a careful process of study and analysis (which included 
assessment of both the frequency with which images and metaphors occurred within the 
sample and their relative salience and relevance to the development and application of the 
gene therapy field). Through this process, I identified several categories (or types) of 
images and metaphors based on shared orientation and meaning. These types also 
correspond to larger narratives about gene therapy that emerged from the data. Through 
this process of study and classification (and through a deep immersion in the data), I also 
determined the primary tones taken within the sampled media coverage. Finally, I 
considered how the images, metaphors, narratives and tones changed over time and in 
relationship to major events within gene therapy’s developmental history. Chapters 4, 5, 
and 6 outline the results arrived at through these processes.
13
 (For a roadmap to the 
findings presented in these chapters, please see Appendix A.) 
                                                 
13
 Consistent with my research methods, the emphasis of my findings is on thick description and data 
immersion, as opposed to frequency counts and quantitative measurement. That being said, the interpretive 
types and narratives I discovered through my analysis process were still informed by how often certain 
images and metaphors appeared within the sample (although mediated by the intensity, salience and 
interconnectedness of the images).  
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 The following sections provide a summary of the discoveries made through my 
analysis process. In addition to descriptions of the various types which I identified, many 
images and metaphors (as well as their immediate context), quoted directly from my 
sample, are included. Within this quoted material, multiple examples of similar imagery 
are often presented. The purpose for this is twofold. First, I hope to honor the tradition of 
“thick description” (Geertz, 1973) by providing a detailed representation of the imagery 
found, as well as a deep contextualization within my setting (which of course was the 
text-based realm of media discourse about human gene therapy). I also intend for the 
reader to experience a sense of immersion in the data, since to understand the 
significance of media images/metaphors/narratives about human gene therapy, it is 
helpful to observe their similarities and unique applications across multiple sources. The 
definitions and brief interpretations of my types, subtypes, and discoveries that are 
presented here are expanded upon in Chapter 7.  
 
Finding 1 
 
(Research Question 1: What types of images and metaphors are used to represent human 
gene therapy?) 
 
Four primary types of images and metaphors occur within human gene therapy-
related U.S. mass media articles since 1989 – essentialist, fatalistic, expectant, and 
conflictive.  
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  In the following section, each of these types, as well as many subtypes that more 
specifically illustrate the images and metaphors identified, are defined, briefly discussed, 
and then examined in detail. As mentioned, the intention is to immerse the reader in the 
data, so many excerpts from the sample illustrating each type and subtype are included.
14
 
 
 
 
Essentialist images and metaphors 
 The essentialist type consists of imagery and metaphors that suggest that human 
gene therapy relates to or has the potential to affect or alter the essence of human life. 
This type is closely related to the essentialist and religious metaphor themes developed 
by Nelkin (2001b) in reference to media portrayals of genetics in general (See Chapter 2).  
Like her themes, the essentialist type includes imagery that characterizes the gene as “the 
essence of personal identity” and “a sacred entity” (2001, p. 557). When applied to gene 
therapy, the characterization can be extended to the gene as “the essence of health,” since 
gene therapy research is primarily focused on the treatment of disease at the level of the 
gene.  In the essentialist type, genes are presented as having inherent qualities, which 
then affect human health (either positively or negatively). Gene therapy technology is 
represented as a way to either bolster or inhibit those qualities. In addition to emphasizing 
the meaning and value of the gene, essentialist images and metaphors invest human gene 
therapy with sacred power, suggesting that the technology (via its influence upon genes) 
                                                 
14
 In the data excerpts, italics have been added to emphasize the images/metaphors being discussed.  
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interacts with humanity on a fundamental level and may redefine what it means to be 
human.  The essentialist type moves human gene therapy away from the objective realm 
of science and technology and into subjective realms like self and religion. Through the 
use of familiar objects and concepts, it associates gene therapy with the component parts 
of the human body, identity, and experience, suggesting that by affecting the parts, the 
technology may transform the whole. Essentialist imagery occurs within five main 
subtypes – numinous, mechanical, good gene vs. bad gene, computer-related, and 
text/language-related.  
  
 
 
1. Numinous subtype 
 A particularly strong subtype of essentialist imagery about gene therapy is the 
numinous subtype. Numinous, defined as “spiritual or supernatural; surpassing 
comprehension or understanding; mysterious,” represents the range of images and 
metaphors about gene therapy that evoke religion, spirituality, deities, souls, magic, and 
the otherworldly (Random House, 2011). In general, this imagery subtype connects gene 
therapy to the human inner being by suggesting that the technology affects and interacts 
with humanity in way that transcends the corporeal level on which it is applied. 
The most commonly used type of numinous imagery is that of “hailing,” 
“praising,” or “heralding” the findings, applications and potential of human gene therapy. 
These terms are strongly associated with religious tradition, text, and ritual and present 
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gene therapy in a highly favorable light. They suggest that gene therapy is “good” to an 
extent worthy of dramatic exclamations or trumpeting angels. They also lift gene therapy 
up out of earthbound reality and replace it in an elevated, sacred position.  These types of 
terms are often presented in the passive voice with no clear subject doing the “hailing” or 
“praising.” Even in those cases where a subject is named, it is typically a vague, 
generalized subject, like “scientists,” “many,” or “experts.” Passages such as the 
following well represent the use of the terms within the sample: 
o “The therapy worked in only two of 17 patients who were treated. But 
many researchers are hailing the study…as groundbreaking because it 
provides compelling evidence in human patients that gene therapy can 
be effective against one of the toughest challenges in medicine: 
terminal cancer.” (Wall Street Journal, 09/01/2006) 
o “Stokes was one of a handful of people in a preliminary study by 
Jeffrey Isner and his colleagues at St. Elizabeth's Medical Center in 
Boston. It is among a flurry of studies heralding what enthusiasts hope 
will be a new era in the treatment of artery disease.” (USA Today, 
12/08/1998) 
 
As is the case in these excerpts, terms like “hailing” and “praising” usually occur in the 
context of approval of or support for gene therapy.  However, such approval is not always 
present-tense; some of this imagery appears in discussions of gene therapy’s past. Used in 
this way, the terms suggest that confidence in the great promise of gene therapy has been 
shaken and seemingly question its hallowed status. 
o “Remember gene therapy? Hailed a quarter-century ago as the 
salvation of medicine, it has achieved no real success.” (New York 
Times, 01/01/2006) 
o  “For years, gene therapy was heralded as a technology that would 
soon yield blockbuster drug innovations.”  (New York Times, 
03/03/2005) 
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o “Fifteen years ago, scientists heralded gene therapy as a medical 
revolution that would quickly bring cures for crippling and deadly 
diseases. After more than 900 clinical trials, however, gene scientists 
can claim few real successes, and even the technology's longtime 
supporters say gene therapy has developed far more slowly than they 
had expected.” (USA Today, 04/05/2005) 
 
Other uses of the terms acknowledge the many struggles the field has experienced but 
suggest that its promise is finally being realized. This use of “heralding” and “hailing” 
creates additional dramatic effect; the technology’s triumph over challenges could bolster 
its sacred status. 
o “Gene therapy, heralded in the early 1990s, then stalled by one 
setback after another, is finally starting to live up to its promise.” 
(Time, 01/11/1999) 
o “The experiments are being hailed as a watershed in a nearly decade-
long effort to conquer the most-common lethal inherited disease in the 
U.S.” (Wall Street Journal, 09/21/1990) 
 
The word “miracle” is also commonly employed to describe the potential power 
of gene therapy. Journalists and gene therapy patients (not scientists or other actors) most 
typically use the term. When used by journalists, it is more often expressed in a negative 
way (as in gene therapy technology not being a miracle), whereas patients seem the most 
likely to use it in a positive way when discussing gene therapy as a treatment for their 
disease. The use of the term “miracle” – even when used to describe what gene therapy is 
not – elicits the supernatural and associates gene therapy with an ability to treat or cure 
disease that lies outside the bounds of science and technology. 
o “Gene Therapy: Expect Progress, Not Miracles” (Wall Street Journal, 
05/02/2000) 
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o “DON'T WORRY. This is not another story about all the miracles that 
medical technology can -- or will be able to -- perform. It is instead 
about all those miracles-to-come that never came.” (Wall Street 
Journal , 11/13/1989) 
o “Hooper hasn't needed nitroglycerin since the procedure, and he has 
even taken up golf. ‘To me,’ he says, ‘this is nothing short of a 
miracle.’” (Los Angeles Times , 11/19/2001) 
o “I am superstitious about calling it a miracle: I don't want to invite 
further attention from the evil eye. But let me whisper that as far as I 
am concerned, the news about gene therapy is very good.” (Time, 
11/22/1999) 
 
 
Another common numinous image is that of “faith” in gene therapy.  This term is 
used to represent the confidence (or lack thereof) that the technology will be able to treat 
or cure disease. Phrases like “leap of faith” or “losing faith” are used, acknowledging the 
uncertainties surrounding gene therapy’s applicability or reacting to the field’s long 
history of failure or marginal success. The use of the term “faith” is another instance of 
language moving gene therapy out of the province of science and into the otherworldly 
realm, since faith is so strongly associated with the supernatural. Further, it also implies a 
complete or unquestioning trust or loyalty, which is less compatible with the objective, 
test-oriented nature of the scientific method and more in line with religious belief and 
devotion. 
o  “Researchers Push Limits of Humanity; Cyborgs: 'Wearable' 
Computers, Digital Implants and DNA Engineering could Change 
Forever what it Means to be Mortal. Enthusiasts Put their Faith in 
Technology, Not Religion, to Find Eternal Life.” (Los Angeles Times, 
06/28/1998) 
o [The patients’ relatives] are Catholic and they pray, but it is clear from 
the way they defer to the gene therapist whenever he enters the room 
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that they are also putting their faith in Wilson himself.” (Washington 
Post, 02/15/1994) 
o “With gene therapy, as with no other branch of biomedical research, 
scientists and subjects alike take visionary leaps of faith.” (USA Today, 
02/02/2000) 
o “Federal health officials released plans today for closer monitoring of 
clinical trials involving gene therapy, saying they hoped the new 
procedures would restore faith in a field battered by scandal.” (New 
York Times, 03/08/2000) 
o “Other investors lost faith in gene therapy in 1999 when teenager Jesse 
Gelsinger died after he was injected with a modified virus carrying a 
gene in an experiment at the University of Philadelphia.” (USA Today, 
04/05/2005) 
 
Invoking sacred objects is another way of talking about gene therapy that can be 
found in the sample. Most commonly, gene therapy technologies or results are 
represented by the metaphor of the Holy Grail. This metaphor not only likens gene 
therapy to a sacred entity, but it also suggests that the effort of working toward the 
realization of effective gene therapy treatments (like a quest to find and/or prove oneself 
worthy of a Holy Grail, which is a common literary and popular reference) is itself sacred 
or infused with divine power or meaning.  
o "’Gene therapy is the Holy Grail that could eventually cure this 
disorder,’ says Sharon Hesterlee, a neuroscientist and director of 
research development for the Muscular Dystrophy Assn. in Tucson.” 
(Los Angeles Times, 04/24/2006) 
o “After 10 years of research on more than 4,000 subjects, gene therapy 
researchers may finally have reached their Holy Grail-- curing a 
patient with a genetic disease.” (Los Angeles Times, 04/28/2000) 
 
The grail metaphor is also used in reference to the profane or unholy when discussing the 
possible misuses of gene therapy technologies. 
 72  
o “What is clear…is just how impatient some coaches and athletes are to 
find new and ingenious ways to cheat. First it was steroids, then EPO, 
then human growth hormone - and now the illicit grail seems to be 
gene therapy.” (New York Times, 06/03/2007) 
 
Images of various religious practices like “prayer,” “blessing,” and “sacrifice” 
also portray gene therapy as having divine significance and further elevate it to the realm 
of the numinous.  
o “When it first made headlines about a decade ago, gene therapy 
seemed the answer to the prayers of thousands of people affected by 
hereditary diseases” (New York Times, 08/04/1998) 
o “[The Recombinant DNA Advisory Committee] began by drafting a 
list of questions scientists would have to answer to receive the 
subcommittee's blessing.” (Washington Post, 01/20/1991) 
o "’They'll sacrifice Penn, they'll sacrifice Jim Wilson,’ Mr. Gelsinger 
said. ‘These guys screwed up, yes. But they should not be put out of 
business.’ (New York Times, 01/27/2000) 
 
Similarly, comparing actors in the gene therapy field to “saints” and other 
religious figures suggests that the work of gene therapy is not simply sterile science; 
rather, it a divine endeavor worthy of extreme devotion.  
o “Miller, whose agency must join the National Institutes of Health in 
approving all federally funded human gene therapy procedures, uses 
words like ‘saintly’ and ‘fanatical’ in describing [gene therapy 
scientist French] Anderson.” (New York Times, 03/31/1991) 
o “Physicians argue that [gene therapy] scientists are like cloistered 
monks and nuns, divorced from the needs of patients.” (New York 
Times, 04/24/1990) 
 
Comparing gene therapy to “monsters,” “dragons,” or other mythic, magical, or 
extraterrestrial characters or creatures also evokes the numinous, suggesting that the 
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technology derives its power from – or has the potential to turn its recipients into – 
something other than human. Further, these types of metaphors suggest that gene therapy 
might somehow slip out of the control of science and take on an otherworldly life of its 
own. 
o  “Frightening images of Dr. Frankenstein and his monster…haunt 
those who are concerned about this remarkable new ability to 
manipulate genes.” (New York Times, 09/01/1993) 
o All too often, talk about altering genes raises science fiction images of 
giant ants, Andromeda strains and Frankenstein's monster. Such 
images have lingered. (Washington Post, 09/25/1990) 
o (Referring to the gene therapy/biotech sector in China): “We liken it to 
a baby dragon, which is hard to ignore, and, as it grows, becomes 
increasingly hard to ignore.” (Reuters, 01/07/2008) 
o “’I don't think there is any way to hold back knowledge.’ He said he 
thought it was best to understand early on what was coming, "so we 
can decide how to handle it," but that, essentially, the genie was out of 
the bottle.” (New York Times, 11/22/1994) 
 
References to “magic” are also common, typically suggesting that gene therapy 
may possess capabilities for treating or curing disease that go beyond the scope of 
standard scientific discovery. This imagery often presents gene therapy as the answer 
scientists have been seeking for a long period of time and as the definitive approach to 
treating a particular disease.  
o “Scientists are excited because these genetically derived treatments 
hold the promise of being the long-sought ‘magic bullet.’” (Los 
Angeles Times, 10/20/1991) 
o “Doctors have long dreamed of a magic bullet that could travel 
harmlessly through the body to diseased cells, enter those cells and 
switch off the wayward genes that cause the suffering. Now, new 
research holds out hope for just such a treatment,” (Newsweek, 
06/10/2005) 
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o “Once scientists know which genes are involved in particular types of 
brain cancer, they can work molecular magic, adding genes to beef up 
the defensive team or deleting them to undermine the offense.” (USA 
Today, 05/17/1999) 
 
 
Magical imagery is also referenced when discussing the hopes and motivations of those 
who invest in gene therapy technologies and companies. 
o  “Biotech stocks have been growing faster than mutating mold as Wall 
Street again embraces the dream of finding magic cures for maladies 
persistently plaguing humanity.” (USA Today, 02/17/2000) 
o “The [biotech] industry was supposed to be awash by now in magical 
biological bullets curing everything from baldness to cancer.” (Wall 
Street Journal, 05/20/1994) 
 
Despite its prevalence in these types of hopeful narratives, the term “magic” (more so 
than other numinous imagery) is often used in a negative context, focusing on 
unreasonable expectations of gene therapy or the dangers of relying upon the technology 
as a magical cure. In this sense, the presumed “magic” of gene therapy is implicitly or 
explicitly identified as an impediment to finding other accessible, effective treatments for 
disease. 
o “He thinks that the public is holding gene therapy research to an 
unrealistically high standard. ‘This field was supposed to be magic. 
And people think that, if you don't reach a high level of expectation, 
you are a failure,’ he said.” (Los Angeles Times, 04/17/2000) 
o “After the rise of genetic engineering in the late '70s, gene therapy had 
been touted as a magic bullet that would quickly fix an array of 
debilitating and often fatal inherited ills. It was nowhere near that 
simple.” (Los Angeles Times, 08/28/2006) 
o “There is no such thing as a magic bullet to cause all cancers to go 
away.” (Wall Street Journal, 05/04/2000) 
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Gene therapy and reliance upon it as a treatment option are also sometimes 
characterized as “temptations” in the sample. This once again moves gene therapy into 
the realm of the numinous, likening it to something dangerous on a spiritual, moral, or 
religious level, and suggesting that (rather than being a soulless technology) the 
technology arouses essential human longings and desires. Insofar as “temptation” is used 
to describe implied unethical uses of gene therapy, it also characterizes it as a technology 
with both sacred and profane possible uses, which further secures a place for gene 
therapy within the numinous realm.  Temptation imagery is also used to describe 
scientists’ commercial opportunities. Although it is exceedingly common for clinical and 
academic gene therapy researchers to also have positions at and interests in gene therapy 
companies, the use of this type of imagery suggests that for scientists to share in the 
profits of their research is wrong or “sinful.” It suggests that profiting from gene therapy 
research – even if it is allowed under current policy – is problematic on a level beyond 
that of regulations and scientific practice. 
o New gene-sleuthing technology, when combined with high-speed, 
computerized chemistry, is producing countless tempting leads for 
treating illnesses ranging from AIDS to cancer, from heart disease to 
depression. (Wall Street Journal, 02/02/ 1998) 
o  “Our duty is to go into the era of human genetic engineering as 
respectfully as possible. That means that we should not use human 
genetic engineering for any other purpose than the treatment of serious 
disease, no matter how tempting it might be.” (Newsweek,  
01/01/2000) 
o  “With billions of dollars in product sales potentially at stake for 
industry, and untold fortunes riding on biomedical stock prices, 
commercial temptations abound.”(Los Angeles Times, 12/07/2003). 
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Other images and metaphors that appear less often but further illustrate the variety 
of numinous imagery used to discuss gene therapy include salvation/damnation, 
evangelism, and the soul. The metaphor of “salvation” or “savior” is occasionally 
applied. It presents another example of assigning gene therapy significance beyond the 
earthly, suggesting that the technology would not only be capable of treating disease, but 
would also provide the patient with some level of redemptive value or meaning. This 
metaphor is typically used when discussing patients’ hopes for or public perception of 
gene therapy as a potential cure: 
o “As of August, the government had reviewed 331 gene-therapy 
protocols involving more than 4,000 patients. Just 41 were for the 
"monogenic," or single-gene, defect diseases whose patients so 
desperately hoped gene therapy would be their salvation.” (New York 
Times, 11/28/1999) 
o “Hailed a quarter-century ago as the salvation of medicine, it has 
achieved no real success. ‘Gene therapy still isn't a therapy last time I 
checked,’ said Mildred Cho, an ethicist at Stanford University.” (New 
York Times, 01/01/2006) 
 
Similarly, when gene therapy is judged to have overpromised its developmental pace or 
curative power, images of “damning” or “condemning” are used to convey that its failure 
goes beyond just a display of the limitations medical technology, but rather represents a 
serious moral failing: 
o “More damningly, the report concluded that the technology had been 
tainted by hype, leading to ‘the mistaken and widespread perception 
that gene therapy is further developed and more successful than it 
actually is.’” (Los Angeles Times, 08/28/2006) 
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o “And in December, a panel of experts appointed by Varmus issued a 
report that condemned most gene therapy efforts as ‘pure hype,’ 
concluding that Wall Street and the public have been misled into 
believing that gene therapy was right around the corner. Not so, they 
said.” (Los Angeles Times, 03/03/1996) 
 
Proponents of gene therapy are sometimes characterized as “proselytizers” or 
“evangelists” – numinous imagery that suggests that gene therapy is not just a medical 
technology, but rather a sacred pursuit to which some are fervently devoted. 
o “Dr. Anderson, who like Dr. Rosenberg is hard-driving and ambitious, 
had long been a proselytizer for gene therapy, sometimes suggesting 
that he was God's instrument in making it a reality.” (New York Times, 
03/26/1995) 
o “[H]e flashes the passionate certitude of a scientific evangelist: 
‘There's no doubt that gene therapy will revolutionize medicine over 
the next quarter century.’” (Los Angeles Times, 07/25/1999) 
  
Another metaphor commonly used in media representations of genetics is that of 
the “soul.” While perhaps not as frequently employed as in discussions of other genetics 
topics such as DNA or the human genome, discussions of genetic manipulation’s 
potential impact on the human “soul” or “essence” do occur in media coverage of gene 
therapy.  
o “When scientists announced they had the technology to insert new 
genes into a cell to try to fix a genetic defect responsible for a disease, 
Frankenstein maniacs had a field day. Manipulate a person's genes? 
Re-engineer the soul?” (Washington Post, 03/11/1997) 
o “Gene therapy has always been a controversial area of science, 
because it has the potential to change the essence of the human race.” 
(Washington Post, 01/30/2000) 
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This letter to the editor seems to illustrate a reader’s skepticism over gene therapy, 
while also demonstrating either the reader’s high expectations of – or possibly a satirical 
critique of others’ perceived expectations of – the technology. Whatever the writer’s 
intent, the suggestion that gene therapy could be used to “improve the human soul” 
associates the technology with essential human qualities that typically lie outside of the 
province of science: 
“I agree with Nicholas D. Kristof's statement that ‘genetic tinkering 
gives me the willies.’ Gene therapy should be used to improve the 
human soul, not the physical body. Why not try to manipulate the gene 
that causes hatred and killing? (I wouldn't mind eliminating my sweet 
tooth as well.)” (New York Times, 08/27/2004) 
 
“Soul” imagery is also invoked in reference to the feelings of actors engaged with gene 
therapy technology, as can be seen in several examples related to the 1999 death of 
clinical trial participant Jesse Gelsinger. Such usage suggests that gene therapy 
technology has a power beyond its earthly one, that it touches humans on a level deeper 
than the surface.  
o “After the hearing, Gelsinger's father, Paul, said that he does not blame 
Wilson for his son's death. ‘I touched souls with this man,’ Gelsinger 
said. ‘There is nothing wrong with Wilson.’” (Los Angeles Times, 
12/09/1999) 
o “The concerns are reminiscent of the regulatory scrutiny and soul-
searching that followed the death of 18-year-old Jesse Gelsinger in a 
1999 gene-therapy trial at the University of Pennsylvania.” (Wall 
Street Journal, 10/11/2002) 
 
As demonstrated, the numinous subtype includes many images and metaphors 
that relate gene therapy to the divine, the supernatural, and the human inner being. This 
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imagery contributes to the characterization of gene therapy as not just another medical 
technology, but rather as a unique and far-reaching phenomenon that may affect the 
innermost parts of human existence.  
 
2. Good gene vs. bad gene subtype 
Also prevalent in the sample are images that suggest that genes, as the essence of 
health, have inherent qualities.  Such imagery usually implies that genes are “good” or 
“bad,” “healthy” or “diseased,” “working” or “defective,” or “normal” or “abnormal.” To 
propose that genes can be “good” or “bad” not only imbues them with essential power 
and significance, but it also suggests that bad genes can (and should) be manipulated, 
improved upon, or fixed, lest the health and identities of their owners be negatively 
affected. Such a notion lays the groundwork for many other images and narratives 
(including many that follow herein). If genes can be good or bad, the good ones should be 
preserved and the bad ones should be repaired. Gene therapy emerges as the most natural 
and logical method of doing so. Addressed implicitly in perhaps the majority of media 
accounts about gene therapy, good gene vs. bad gene imagery is also explicitly discussed 
in many cases. This imagery typically focuses on how gene therapy can help fix bad 
genes or replace them with good ones and is often used to explain to the reader (in clear 
and simple terms) how gene therapy works or why it should be pursued as a medical 
treatment. 
o “The new findings…suggest it may be possible within a few years to 
cure [cystic fibrosis] either by replacing the defective gene with a 
healthy one through gene therapy. (Los Angeles Times, 09/21/1990) 
 80  
o “Gene therapy is a medical procedure to treat a disorder or disease by 
restoring or replacing a faulty or missing gene in a person's body.” 
(Los Angeles Times, 09/29/1992) 
o “James Wilson: The man who throws good genes after bad ones” 
(U.S. News & World Report, 12/31/1990-01/07/1991) 
o “The idea behind gene therapy is disarmingly simple: to treat or cure 
disease by giving healthy genes to patients with defective ones.” (New 
York Times, 06/06/2000) 
o “In principle, the treatment uses healthy genes to counteract the effects 
of diseased ones,” (New York Times, 02/08/2000) 
o “Gene therapy involves inserting a working gene to replace a faulty 
one.” (Reuters, 11/05/2009) 
o “The goal is to transplant new genes into humans to do the work of 
defective ones -- or to give patients extra genes useful in fighting 
diseases.” (Time, 12/13/1993) 
o “In gene therapy, doctors aim to replace defective genes with normal 
ones, using harmless viruses as delivery vehicles,” (USA Today, 
04/28/2008) 
o “Ever since scientists learned over a decade ago that cancer is the 
result of defective genes, they have dreamed of shutting down tumor 
growth simply by replacing the bad genes with good ones.” (Wall 
Street Journal, 05/06/1998) 
o “Inherited diseases that are due to an absent or aberrant gene would 
seem to be to best remedied by supplying the healthy, functioning 
gene.”  (Wall Street Journal, 05/02/2000) 
 
3. Mechanical subtype 
Another group of images and metaphors that connects gene therapy to the human 
essence is the mechanical subtype. In this group, imagery tends to portray gene therapy 
technology as a method for designing, controlling, altering, or improving the essential 
components of the human person. The comparison of the gene and other biological 
entities to various mechanical parts and functions is fundamental to the subtype. Because 
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these parts and functions are implied to be integral to the essence of the human whole, 
gene therapy becomes, by extension, a way of reaching and potentially modifying that 
essence. The frequent use of mechanical imagery (and its strong focus on the component 
parts of the human body) contributes a reductionist quality to the gene therapy discourse.  
One mechanical image featured prominently in the sample is that of gene therapy 
as a method of “fixing” or “repairing” broken or defective genes. This image is 
predicated on the assumption that “broken,” faulty, or imperfect genes cause disease, and 
it suggests that if gene therapy technology can repair these broken genes, it possesses the 
power to protect, improve, or save humanity.  
o  “And by the 22nd century, doing the best for your kid may include gene 
therapy – or ‘fixing’ the imperfect eggs by replacing bad genes with good 
ones.” (New York Times, 06/11/2000) 
o “Fixing the Genes” (Time, 01/11/1999) 
o “And more generally, gene therapy - the notion of fixing or replacing 
defective genes - has been studied in people for more than 15 years 
without much success.” (Huffington Post, 11/21/2007) 
o “Gene therapy is the scientific community's hottest new scheme for 
treating disease. The basic idea is to insert a specific gene into a cell to 
repair a problem and restore function.” (USA Today, 11/25/1994) 
o “A year after scientists found the gene that causes cystic fibrosis, two 
research teams have used the gene to repair cells taken from CF patients.” 
(Wall Street Journal , 09/21/1990) 
 
Another very common mechanical metaphor used in the sample is that of gene 
therapy functioning as a “switch” that “turns on and off” genes or cells. In other words, 
gene therapy is portrayed as having the ability to activate or deactivate genes within the 
body, controlling health outcomes by deactivating disease-causing genes or activating 
disease-fighting genes. 
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o “A biologist and a chemist may have found a way to install a biological 
‘switch’ in human cells that could turn genes on and off as needed. The 
discovery may open a new way to treat human ills with gene therapy.” 
(Wall Street Journal, 01/26/1994) 
o “Researchers in Pennsylvania said Thursday that they have taken a vital 
step toward real gene therapy by designing a special gene that can be 
turned on and off as needed,” (Los Angeles Times, 01/01/1999) 
o “[One researcher] has spent her career trying to find the genetic switches 
that govern hair growth.” (New Yorker, 01/09/2006) 
o “RNAi burst on the scene a decade ago when U.S. scientists Andrew Fire 
and Craig Mello showed certain types of RNA could switch off genes that 
trigger disease,” (Reuters, 09/26/2007) 
o “An even bigger obstacle, however, is that gene therapy, a technology that 
is still unproven, would be needed to slip light-switch genes into a 
patient's nerve cells.” (New York Times, 08/14/2007) 
 
Relatedly, the term “tinker” is often used when discussing gene therapy (and other 
genetic) technologies. While many times it used in a similar way in the sample as “fix” or 
“repair,” “tinker” also tends to occur within the context of accounts that carry a 
cautionary tone (which will be discussed in more detail later in this chapter). Whereas 
“fixing” or “repairing” are typically presented as at least acceptable and often laudable, 
“tinkering” often is used when gene therapy is portrayed as dangerous or threatening to 
the “natural order” or essence of humanity.  
o “At the moment, gene therapy researchers are aiming their fledging 
attempts at living patients with established diseases. They are not ready to 
address the ethical question of whether it is right to tinker around, 
inadvertently or otherwise, with the genes of people to come.” (New York 
Times, 04/14/1992) 
o “Many people seem to feel that tinkering with genes is somehow different. 
New technology, especially unfamiliar technology that seems to disturb 
the natural order of things, tends to elicit what George Orwell called 
‘vague fears and horrible imaginings.’” (Wall Street Journal , 09/08/1999) 
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o “A generation ago, scientists worried that tinkering with the genes of even 
the simplest organisms was too dangerous--so much so that they convened 
an unprecedented conference at the Asilomar Conference Center in 
Monterey, Calif., to establish universal ground rules for gene research.” 
(Los Angeles Times, 04/27/1997) 
 
Another commonly used metaphor that references the design stage of mechanical 
endeavors is “blueprint.” In discussions of gene therapy, this metaphor typically refers to 
the function of genes, suggesting that they determine biological entities or processes. The 
“blueprint” metaphor is a strong representation of the essentialist type in that it suggests 
that genes are the determinants of health, disease, and the function of the human body. 
This image of genes within gene therapy discourse creates a foundation for imagery that 
portrays gene therapy as a technology that affects the most elemental aspects of human 
life. 
o “Genes that serve as the blueprint for various nerve growth factors, which 
stimulate development of brain cells, might be used for the treatment of 
Parkinson's, Huntington's and other diseases.”(Los Angeles Times, 
07/02/1998) 
o “The gene at the center of all this concern "codes," or provides the 
blueprint for, adenosine deaminase (ADA), an enzyme that breaks down 
toxic biological products.” (Time, 09/24/1990) 
o “Genes represent the molecular blueprint used by cells to produce proteins 
such as enzymes and hormones that carry out the second-by-second 
chemical functions of life.” (Wall Street Journal, 01/18/1994) 
 
Comparisons of the body, cells, or genes to machines and their parts are 
sometimes used to clarify or illustrate how gene therapy technologies and treatments 
work (or are perceived to work). By telling a story of “genes as component parts,” these 
metaphors illustrate an atomized or reductionist view of health and disease – human 
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health is dependent on the function of small units, and disease is treated by employing 
technological expertise to fix problems with those units. 
o “In their experiments, Dr. Chien and his colleagues focused on a gene for 
a protein called phospholamban, which acts as a brake on a pump that 
delivers calcium to heart-muscle cells.” (Wall Street Journal, 07/22/2002) 
o “They are called retroviral vectors, from the Latin "to carry." They are 
little more than stripped-down conveyor belts for genes.” (New York 
Times, 03/31/1991) 
o “But the ideal solution is to perfectly fix a genetic error without 
introducing any extra DNA, like the deft replacement of a spent battery in 
a car.” (Los Angeles Times, 11/12/2002) 
o “We think of the body as if it were a machine with replaceable parts: 
defects can be identified, removed and replaced through treatments like 
organ transplants, drugs and gene therapy.” (New York Times, 06/12/1994) 
 
4. Computer-related subtype 
 
Another type of imagery common within the sample is the comparison of various 
aspects of genetics to components and functions of computers. As is true of the numinous 
and mechanical subtypes, the images and metaphors of this subtype emphasize the 
inherent qualities of genes and how those qualities determine health outcomes.  
In the sample, the term “code” is frequently used when discussing genes. “Code” 
is a metaphor that is very common in public discourse about genetics in general (and is 
used in scientific discourse as well). Despite its common use, it is still useful to consider 
the particular way in which the “code” metaphor tends to be used in the context of gene 
therapy media accounts, which is to emphasize the genetic origins of – and possibilities 
for genetic treatments or cures for – disease. “Code” strongly suggests that genes have 
inherent, essential characteristics and that those characteristics control health outcomes. 
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o “Replacing one or more genes in the genetic code of an organism alters 
that life form's function.” (CNN.com, 04/10/2006) 
o “Alan Marcus, a professor of history at Iowa State University in Ames, 
echoes the view of genes as small units of ‘code,’ computer jargon for 
computer commands. Our genes program us to react in certain ways, as if 
they were small computer programs. And if so, why not plug new genes 
into an organism in a different order and get something entirely new? Why 
not program life like a computer?” (Los Angeles Times, 06/28/1998) 
o “If you have a faulty code that is preventing your computer from working 
properly, a computer technician can insert a segment of corrected code to 
make things right. When that's done with genetic material instead of 
computer code and in a living organism instead of a computer, that's gene 
therapy.” (USA Today, 04/15/2004) 
o “At its root, HIV is a genetic disease; the virus integrates itself into the 
genetic code of the infected cell. This makes us hopeful that there may be 
an effective treatment for HIV at the genetic level.” (Wall Street Journal, 
09/13/1993) 
 
A similar message is conveyed through the use of other computer-related 
terminology, such as “bugs,” “programming,” “operating system,” “software,” and 
“upgrade.” These images locate disease within the genes, emphasize the fundamental 
importance of those genes, and assign to gene therapy the unique ability to treat disease. 
o “The more harmful genetic variants are discovered, the more compelling 
the logic may seem of fixing the bugs in the genomic programming 
directly instead of treating the symptoms in each generation, a procedure 
called germ-line gene therapy.” (New York Times, 06/27/2000) 
o "’Here, we can replace a defective gene," he said, "and it's like 
reprogramming a computer in the cancer cells.’" (New York Times, 
08/29/1996) 
o “And in the long term, scientists hope to find ways to alter medical fate, 
directly changing faulty genes or adding genes that will help would-be 
patients resist the deleterious impact of their inherited programming.” 
(Los Angeles Times, 03/03/1996) 
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o “We are beginning to understand our own operating system -- genes -- and 
we're gaining the ability to try to ‘improve’ our genetic endowment.” 
(New York Times, 08/25/2004) 
o “Gene transfer is similar to making changes to the software in your 
personal computer.” (USA Today, 12/05/2006) 
 
 
5. Text/language subtype 
 
Metaphors and images that refer to various elements of gene therapy as features 
of text or language are also relatively common within the sample. “Writing,” “spelling,” 
“book,” “word processing,” “typo,” “alphabet,” and other similar terms and phrases are 
typically used to describe genes/DNA and gene therapy’s possible effects upon them. The 
text/language subtype is very similar to computer-related imagery in its emphasis upon 
genes as the essence of health and gene therapy’s resultant critical role in disease 
treatment.  
o “None of the substances with which dopers will likely experiment 
would completely rewrite a person's DNA.” (New York Times, 
06/03/2007) 
o “The signals tell the cell to start reading the ‘message’ written in a 
particular gene” (Wall Street Journal, 01/26/1994)  
o “Once the error is located, the chimeraplast tells the cell ‘to proof read 
and fix that misspelling,’ he said, adding, ‘The cell's own DNA repair 
system then removes that incorrect letter and puts in the correct 
letter.’” (New York Times, 09/06/1996) 
o As part of ordinary cell division, the DNA segment begins to make an 
exact copy of itself. At this time, ‘spelling errors’ in the genetics code 
can occur.” (USA Today,  12/14/1993) 
o “In February, scientists announced with great fanfare that they had 
produced a nearly complete sequencing of the entire 3.2 billion genetic 
letters that make up the human genome. The publication of the so-
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called "Book of Life" was widely hailed as the first step to curing 
scores of human ailments.” (Wall Street Journal, 06/11/2001) 
o “More powerfully, the zinc fingers can be deployed as a word 
processing system for cutting and pasting genetic text.” (New York 
Times, 12/29/2009) 
o “Rather than inject entire genes, the company's technology will just 
‘correct the typos’ in the patient's own genes.” (New York Times, 
08/04/1998)  
o  “Patent lawyers, however, say the Clinton-Blair proposal does nothing 
to diminish the value of gene patents. ‘Making the alphabet publicly 
available has not reduced the value of novels,’” (New York Times, 
05/14/2000) 
 
Fatalistic images and metaphors 
 
 The fatalistic type (based loosely on Nelkin’s category of fatalistic metaphors 
[2001b]), features images and metaphors suggestive of inevitability or forward motion 
toward a given end within the world of gene therapy. The function of genes, the 
realization of genetic propensities, and the path toward the success and acceptance of 
gene therapy as a medical treatment are among the subjects of this sort of imagery. The 
fatalistic type can be seen as a logically following the essentialist type. If genes – with 
which each human being is endowed at birth, beyond his/her control – are the essence of 
life and health, life and health outcomes must be (to a considerable extent)  inevitable. 
Gene therapy can be seen, therefore, as a way of controlling the effects of genetics. It also 
is frequently portrayed as having the same sort of preordained, autonomous, or 
irrepressible trajectory as genes.  Just as, per Nelkin, “genes are destiny” (2001b, p. 557), 
so too is gene therapy often depicted as the natural or inevitable result of scientific and 
technological progress in treating disease. Many of these fatalistic images and metaphors 
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are present within the sample and fall into three main subtypes – transportation-related, 
pioneering, and natural world-related metaphors.  
 
1. Transportation subtype 
 
The transportation subtype includes images and metaphors relating gene therapy 
to the movement of people or goods. It is similar to the mechanical subtype in its use of 
familiar objects and their functions to illustrate the way gene therapy works within the 
body, although the focus is on delivery as opposed to repair. Metaphors that suggest 
unrestrained or inevitable forward movement for the field of gene therapy also appear 
frequently. Transportation images and metaphors contribute to a narrative of determinism 
in that they tend to suggest that gene therapy will naturally advance and often portray this 
advancement as “meant-to-be.”  
Gene therapy technologies – and particularly the agents (commonly referred to as 
“vectors”) by which modified genetic material are delivered into a patient’s cells – are 
often compared to a variety of transport vehicles. Metaphors featuring vehicles that 
deliver passengers or cargo predominate. Such metaphors emphasize movement as a key 
aspect of gene therapy (thereby establishing that it is not a static form of medical 
treatment).  
o “In it, the researchers remove about 15 percent of the liver, separate 
and grow the cells in plastic dishes and supply the cells with copies of 
the gene they need, using a harmless virus as a delivery shuttle.”  (New 
York Times, 04/01/1994) 
o “A retrovirus (the same type of virus as the AIDS virus) is used as a 
taxi to transport the gene.” (Time, 09/24/90) 
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o “They hope to use the virus to ferry disease-fighting genes into regions 
of the human body generally inaccessible to modern medicines.” (Wall 
Street Journal, 01/18/1994) 
o “Gene therapy researchers have built a custom delivery van that ships 
genes only to selected cells - moving science a step closer to making 
gene therapy a reality.” (USA Today, 11/25/1994) 
o “However, the dystrophin gene -- which is the largest gene in the 
human genome -- doesn't fit inside these viral freighters.” (Los 
Angeles Times, 04/24/2006) 
 
Metaphors that compare the progression of gene therapy to a “road,” “avenue,” 
“route,” or similar term are frequently used. These metaphors typically imply presumed 
forward motion for the field, that a path has already been laid that gene therapy must 
simply follow.  
o “Humanity will gain much from taking the new therapeutic avenues 
opening up through genetic therapy. Some rewards are down the path, 
just after the fork.” (Los Angeles Times, 02/18/2003) 
o “Dr. Lenfant also said he believed the research held greater hope for 
heart disease than gene therapy, which many experts consider a highly 
promising route to new therapies.” (New York Times,  06/07/2001) 
o “Researchers show for the first time that healthy genes can safely be 
delivered to the lungs of people with cystic fibrosis, a key step on the 
road to successful gene therapy.” (USA Today,  09/01/1994) 
 
 New research discoveries are often said to “pave the way” for future successes in 
the field. This again suggests an assumption that gene therapy will move forward, which 
contributes to a fatalistic image of the field.  
o ''This is meant to pave the way to introducing genes that can improve 
the survival of cancer patients.'' (New York Times, 05/2306/03/1990) 
o If Dr. Bordignon's experiments succeed, they may pave the way for 
treatments of much more widespread illnesses, such as sickle-cell 
anaemia and thalassaemia. (The Economist, 09/05/1992) 
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o “The National Institutes of Health has approved two gene therapy 
trials for treating cancer and an AIDS study that it says could pave the 
way for future gene therapies.” (Wall Street Journal, 10/07/1992) 
 
Also common are characterizations of gene therapy findings, activities, and 
policies as “steps” along a path toward future discoveries, successes, or applications of 
the technology. Use of the “step” metaphor is typically associated with positive or 
hopeful stories about gene therapy’s potential. This metaphor is another instance of 
fatalistic imagery, since it implies that gene therapy events are not discrete occurrences 
but rather are part of a presumed forward-moving trajectory.  
o “IN what could be a big step forward for gene therapy, a small 
company in California has patented a way to produce large quantities 
of a virus that can be used to "infect" patients with the genes they need 
to fight illnesses like cystic fibrosis.” (New York Times, 01/11/1993) 
o “Scientists have taken a new step in the quest for gene therapy for 
muscular dystrophy.” (Wall Street Journal , 08/16/2005) 
o “A federal scientific panel Wednesday took a potentially major new 
step in gene therapy as it for the first time approved a plan to treat an 
illness by inserting new genes in patients.” (Los Angeles Times, 
03/08/1990) 
 
Notably, the “step” metaphor – particularly as “first step” – is frequently used in 
statements made by gene therapy scientists and researchers describing the significance of 
the findings being presented within the media account. (The quoted scientists include 
both those responsible for the discussed findings and “experts” within the field who are 
commenting on others’ findings.) The use of “first step” quite explicitly suggests that 
more “steps” are expected, indicating gene therapy is presumed to have a future.  
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o  “Dr. William Mobley, the chairman of the neurology department at 
Stanford University, who is familiar with the research, called the 
procedure ‘a very important first step’ toward finding a novel way to 
treat Alzheimer's disease. (New York Times, 04/11/2001) 
o “’This is the first step for what will almost certainly be a revolution in 
medical treatment,’ says Dr. W. French Anderson of the National 
Heart, Lung and Blood Institute, a co-developer of the technique.” 
(USA Today, 08/01/1990) 
 
Metaphorical language referring to “landmarks,” “milestones,” and other points of 
note along a stated or implied “road” or “path” to successful and/or routine use of gene 
therapy to treat disease also appears frequently within the sample. Such language is used 
commonly by both article authors and the gene therapy clinicians and researchers they 
quote. Like “first step,” these metaphors suggest continuing development for the field of 
gene therapy by referring to current events as moments in a larger journey.  
o “’This is the most dramatic improvement in a patient's condition that 
has been achieved using gene therapy to date--a real milestone,’ said 
Dr. Jennifer Puck of the National Human Genome Research Institute 
in Bethesda, Md.” (Los Angeles Times, 04/28/2000) 
o “The altered cells were injected into Andrew's body four days later in 
what could become part of a remarkable medical milestone: the first 
attempts to cure a disease by gene therapy.” (Time,  05/31/1993) 
o “’These exciting results need to be validated in a larger trial, but we 
believe this is a milestone -- not only for the treatment of Parkinson's 
disease, but for the use of gene-based therapies against neurological 
conditions generally,’ Kaplitt said in a statement.” (Reuters, 
06/22/2007) 
o “The landmark study ‘represents the first time that foreign genes have 
been introduced into people, and it shows that the technique is feasible 
and safe,’ said Dr. Steven A. Rosenberg, chief of surgery at the 
National Cancer Institute.” (Los Angeles Times, 08/30/1990) 
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o “Three years after receiving the landmark gene-therapy treatments (for 
a form of SCID, the so-called bubble-boy disease), Cynthia Cutshall, 
left, and Ashanthi DeSilva appear to be thriving” (Time, 01/17/1994) 
o “In what's being called a landmark study, researchers used gene 
therapy to successfully treat six patients with severe hemophilia, a 
blood-clotting disorder.” (Huffington Post, 12/10/2011) 
 
Nearly as common was the use of metaphors such as “roadblock,” “detour,” and 
“pitfall” to describe instances of gene therapy challenges or setbacks. While these terms 
clearly refer to negative moments within the implied gene therapy journey, they 
nonetheless reinforce the notion that the journey is ongoing and that the field is 
anticipated to continue moving forward. 
o “…several teams of researchers launched independent and 
collaborative efforts to show that cells…could be corrected by giving 
them healthy versions of the gene. But the scientists hit several 
unexpected roadblocks,” (Wall Street Journal,  09/21/1990) 
o “If no further roadblocks are encountered, Anderson said, he expects 
to start transferring genes into human patients by late fall.” (Los 
Angeles Times,  07/31/1990) 
o  “’Maybe the quickest route to solving cystic fibrosis is to take a 
detour,’ said Dr. Alan E. Smith, chief scientific officer at Genzyme 
Corporation, a biotechnology company that conducted eight 
unsuccessful gene therapy trials for cystic fibrosis. Now the company 
is concentrating on cancer and cardiovascular disease...” (New York 
Times, 08/04/1998) 
o “Ethical pitfalls await world of gene therapy” (USA Today, 
05/22/1991) 
 
“On the verge” and other like phrases that invoke the idea of a geographical edge 
or boundary are also sometimes used to represent the anticipation of successful 
applications of gene therapy technology. These images suggest momentum within the 
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field and imply that gene therapy has been moving forward and is about to reach an 
important point in its journey. 
o “This development comes amid other signs suggesting that gene 
therapy may be on the verge of delivering on at least some of its 
unfulfilled promise.” (Time, 02/14/2000) 
o “What began as a highly scrutinized and controversial procedure is on 
the verge of becoming an almost familiar, if still experimental, 
therapy.” (Washington Post, 01/21/1992) 
o “Scientists stand on the brink of performing gene therapy” (Time,  
08/13/1990) 
o “…the first attempts at gene therapy remind the public that scientists 
are on the threshold of manipulating humanity.” (New York Times, 
10/17/1993) 
 
Similarly, the phrase “around the corner” is commonly used in reference to gene 
therapy successes that are expected to happen in the near future. However, it is equally 
likely to be used when discussing dashed or as yet unrealized hopes about the technology. 
Despite the fact that the “around the corner” image is sometimes used negatively, it does 
not deny that gene therapy is on a forward-moving journey, suggesting only that it is not 
as close to realization as some have claimed. The use of the metaphor, even negatively, 
evokes images of movement and progress. 
o “These new therapies and others are just around the corner,” (Los 
Angeles Times, 04/30/1997) 
o  “Surveying the public for approval of the use of gene therapy fosters 
the dangerous misconception that the wholesale cure of genetic 
diseases using this technique is just around the corner.” (New York 
Times, 10/16/1992) 
o “… Wall Street and the public have been misled into believing that 
gene therapy was right around the corner. Not so, they said.” (Los 
Angeles Times, 03/03/1996) 
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o “… gene therapy was marketed to the public as a near panacea just 
around the corner.” (Wall Street Journal, 05/02/2000) 
 
The metaphor “green light” is often used to discuss opportunities within the gene 
therapy field, especially in terms of government oversight and regulation. This is another 
example of imagery that invests the gene therapy field with unrestrained forward 
progress, lending a fatalistic quality to the depiction of the technology. The “green light” 
metaphor also could be interpreted as asserting not only that gene therapy is moving 
forward, but also that it should be. This calls forth an additional aspect of determinism by 
assigning a “meant-to-be” quality to gene therapy’s advancement. 
o “The government has given the green light to researchers to find a cure 
for cystic fibrosis using experimental gene-therapy procedures,” (Los 
Angeles Times, 12/05/1992) 
o “Researchers at the University of California at San Diego got a green 
light from the federal Recombinant DNA Advisory Committee to 
conduct a safety test of a new gene therapy against human 
immunodeficiency virus, or HIV.” (Wall Street Journal, 09/13/1993) 
o “Scientists got the green light to try gene therapy on two diseases: 
melanoma and an immune-system impairment.” (USA Today,  
08/01/1990) 
 
2. Pioneering subtype 
 
Related to but distinct from transportation imagery is the pioneering subtype. 
Gene therapy researchers and clinicians, the projects and technologies with which they 
work, and the patients they treat are frequently referred to as “pioneers” or “pioneering.” 
This imagery is consistent with the fatalistic notion of forward motion toward a given 
end. In that a pioneer is one who will “open up and explore a new area” (Random House, 
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2011), “pioneering” operates under the assumption that the new area (in this case, gene 
therapy as a treatment for disease) exists. By calling gene therapy actors pioneers, the 
assumption that gene therapy will continue to exist as a technological field and area of 
medical treatment is implied.  
o  “One of the pioneers of human genetic engineering predicts that 
within 30 years, there will be a gene-based therapy for most diseases.” 
(Newsweek, 01/01/2000) 
o “Wilson, a gene therapy pioneer, has licensed patents related to gene 
therapy to a number of biopharmaceutical companies.” (Reuters, 
09/22/2008) 
o “Dr. Crystal, a former investigator at the National Institutes of Health, 
is a pioneer in gene therapy and knows first hand the difficulty of 
making it work in people.” (Wall Street Journal, 01/06/1998) 
o “The delivery system for genes used in the two pioneering trials is a 
virus – the same general type that gives people colds.” (USA Today, 
10/30/1990) 
o “As one Los Angeles newborn recovered from pioneering gene 
therapy to combat an immune system disease, another afflicted infant 
Monday underwent the same treatment-one that doctors hope can be 
used to fight other, more common genetic disorders.” (Los Angeles 
Times, 05/18/1993) 
o "’I've told the patients exactly how I feel,’ Dr. Rosenberg said, ‘and 
they realize they're pioneers. This is a very experimental approach, but 
it represents an attempt to open a new door to treating cancer.’" (New 
York Times, 01/30/1991) 
o “The verdict on the pioneering children of gene therapy: so far, so 
good” (Time, 01/11/1999) 
 
The related metaphor of frontier is also very commonly used, typically in 
reference to the gene therapy field. As is true of “pioneering,” the use of “frontier” 
suggests that gene therapy is presumed to have a future as a medical treatment.  
 96  
o “Gene therapy, a procedure in which defective copies of a gene are 
replaced with new working copies, is the most promising frontier in 
medicine, offering hope of a cure for diseases like cancer and AIDS.” 
(Los Angeles Times, 02/05/2000) 
o “’We believe very strongly that [gene therapy] is going to be one of 
the most exciting new frontiers in drug development” (New York 
Times, 08/16/1995) 
o “’For the first time, we're altering an individual's genes,’ says W. 
(‘Dusty’) Miller, a gene-therapy researcher at the Fred Hutchinson 
Cancer Research Center in Seattle. ‘That's a new frontier, and you had 
better make sure you're doing the right thing.’” (Time, 09/24/1990) 
o “A National Institutes of Health panel opened a new frontier in 
medicine by approving the first human tests of gene therapy to fight 
disease.” (Wall Street Journal, 08/01/1990) 
 
 
Metaphors comparing gene therapy research or practitioners to inventions and 
innovators from various other fields also support a pioneering narrative. The fatalistic 
aspect of this narrative (which implies that gene therapy as a medical treatment will 
endure) is reinforced by using early developments in other fields with long-ranging 
success (such as manned flight and space exploration) as examples.  
o "This is a landmark experiment. It's the Kitty Hawk of gene therapy." 
(New York Times, 04/01/1994) 
o “…the accomplishment "is tantamount to the first satellite that was 
launched that showed we could escape gravity…That opened up the 
whole space program. This is going to open up a whole new era of 
gene transplant for therapeutic purposes." (Wall Street Journal, 
08/30/1990) 
o “Dr. Steven Rosenberg… likened [the gene therapy treatment] to the 
first flight of the Wright brothers.” (New York Times, 10/09/1991) 
o "’It's exciting…It is definitely the wave of the future.’ But, he added: 
‘It's a little bit like the first car or the first airplane.’” (New York 
Times, 08/09/1994) 
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3. Natural world-related subtype 
Images and metaphors that reference the natural world are quite common within 
the sample.  Their references to gene therapy generally fall into one of three categories – 
forces or elements of nature that are dramatic or difficult to control; plants/agriculture; 
and evolution. Imagery that relates to forces or elements of nature focuses on motion, 
change, and control. Metaphors that compare gene therapy to plants and agriculture 
evoke inevitability and natural growth processes.  Evolutionary images share the qualities 
of plant metaphors and add a sense of continual improvement of the gene therapy field. 
These metaphors contribute to a fatalistic portrayal of gene therapy in their emphasis on 
the inevitability and power of the field’s forward motion.  
Three of the four classical elements – water, earth, and fire – are present in the 
metaphorical language of the gene therapy discourse studied. Water metaphors most 
often appear in the form of “waves,” “cascades,” or similar representations of sweeping 
motion. These metaphors tended to refer to moments of advancement within the gene 
therapy field.  
o “…the Nasdaq biotech index remains up almost 30 percent this year, 
thanks to investors' belief that a new wave of drug discovery and gene 
therapy is imminent.” (New York Times, 03/15/2000) 
o “The discovery of the gene set off a wave of euphoria, with many 
people convinced that cystic fibrosis would soon be cured.” (New 
Yorker, 05/04/2009) 
o “The new experiment is the most recent in a cascade of recent 
developments suggesting that scientists may someday create a range of 
therapies based on implanting healthy genes to replace defective, 
disease-causing ones.” (Wall Street Journal, 04/19/1991) 
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o “…more than 280 drugs are in middle- or late-stage clinical trials. And 
the unraveling of the genetic code presents a cascade of 
opportunities.” (New York Times, 12/16/1998) 
 
In the sample, a commonly used earth-related image is that of gene therapy 
technologies or research as “groundbreaking.” This term (despite being so common in 
general discourse) refers to a violent disturbance of land surface and therefore is 
suggestive of dramatic, forceful change. In this way, the earth element – which would 
seem more likely to be represented with static imagery – is, like water, a way of relating 
gene therapy to the natural world via images of motion.  
o “Now a team of scientists has won a patent for a gene therapy 
technique based on groundbreaking work done at the University of 
Michigan in the 1980's.” (New York Times, 10/06/1997) 
o “[S]he has raised $4 million to fight his genetic disease and was able 
to get him ground-breaking gene-therapy treatment” (New York Times, 
05/11/2008) 
o “But many researchers are hailing the study, which was published 
yesterday in the online edition of Science, as groundbreaking because 
it provides compelling evidence in human patients that gene therapy 
can be effective against one of the toughest challenges in medicine: 
terminal cancer.” (Wall Street Journal, 09/01/2006) 
 
Fire-related metaphors appear occasionally in the data, mostly in the form of 
“burning,” “igniting,” or “rekindling” and in reference to levels of interest in gene 
therapy technologies and research. These metaphors are, again, change-oriented – fire 
inherently represents instability, since it alters matter from the moment it is lit and 
continues to change in size and intensity (often somewhat unpredictably) as it burns. 
Because of its extreme heat and the ease with which it can get out of control, fire is also 
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another example of dramatic natural imagery and lends excitement to the discussion of 
gene therapy. 
o “…the fires under [gene therapy] efforts burned brighter after last 
year's announcement at the White House that the human genome--all 3 
billion letters of human DNA--had been figured out.” (Los Angeles 
Times, 02/12/2001) 
o “Those findings were published in 1990, the same year that the 
National Institutes of Health, a federal research agency based in 
Bethesda, Md., successfully used gene therapy to treat a child 
suffering from immune disorders. This ignited the gene therapy 
stampede.” (Wall Street Journal , 01/03/1994) 
o “But recent findings from several studies are rekindling excitement for 
[gene therapy].” (Wall Street Journal, 07/07/2010) 
o “’ …the results of the [gene therapy] research contract with Vical, 
begun in January, 1989, have rekindled his enthusiasm…” (Los 
Angeles Times, 03/23/1990) 
 
Another natural entity commonly referenced in the sample is light (or darkness). 
Light-related metaphors are typically used to highlight positive or hopeful attitudes 
toward gene therapy, and “dark” or “shadow” metaphors portray concerns about the field. 
Light metaphors evoke images of inception/creation and clarity and often suggest an 
overriding sense of “good”; darkness relates to images of the hidden or sinister. Because 
their occurrence in nature is so basic and unavoidable, these metaphors also represent 
gene therapy as having inherent qualities (such as good or bad, brilliant or dangerous), 
and that these qualities will propel it forward in one inevitable direction or another.  
o “In those days, the idea that diseases could be treated, or even cured, 
by infusing patients with healthy DNA was the bright light of 
medicine, offering hope to patients and the promise of profits to 
investors. But the light has dimmed considerably.” (New York Times, 
12/12/1999) 
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o “Dr. Wilson wrote that the [gene therapy] work was ‘a shining 
example of the use of the fundamental concepts of biology to attack 
what may appear to be insurmountable problems.’” (New York Times, 
09/03/1996) 
o “But these two final-stage [cancer gene therapy] trials represent a ray 
of hope.” (Wall Street Journal, 05/04/2000) 
o “…for now it is important that the public understands what it is all 
about as well as its extraordinary potential for good, and not just its 
possible dark side.” (New York Times, 09/01/1993) 
o “This is an important step in gene manipulation, perhaps leading 
eventually to gene-replacement disease cures--or, on a darker path, 
insertion of desirable traits into human embryos” (Los Angeles Times, 
12/26/1999) 
o “[Jesse Gelsinger’s] death stunned the gene-therapy scientific 
community and cast a shadow over the entire field.”(Wall Street 
Journal, 01/24/2000) 
 
Various terms borrowed from the animal world are used to describe gene therapy 
technologies and research. Vectors are often referred to as “defanged” viruses. Gene 
therapy work is occasionally said to involve “taming” or “shepherding.” Like the 
previous natural metaphors, these images tend to focus on the primal and uncontrollable 
aspects of the natural world. In this case, however, gene therapy is associated with 
controlling these natural forces, as opposed to being likened to one. 
o  “In trying to cure cystic fibrosis, researchers inserted a healthy copy 
of the defective gene that causes the respiratory illness into a defanged 
common cold virus.” (Wall Street Journal, 05/30/2002) 
o “But the findings also imply to some that the public is extremely 
optimistic about the progress of gene therapy and other experimental 
approaches to taming inherited diseases,” (New York Times, 
09/29/1992) 
o “These first three studies are to see if gene therapy is safe to try, not to 
prove if it works. Yet studies in monkeys suggest at least one of the 
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approaches has the potential to finally target the underlying disease, 
not merely tame its symptoms.” (Wall Street Journal, 12/13/2005) 
o “Two weeks ago, Dr. James Wilson of the University of Pennsylvania 
in Philadelphia also began a gene therapy trial using the adenovirus to 
shepherd in copies of the cystic fibrosis gene, treating a 32-year-old 
woman from New Jersey.” (New York Times, 09/22/1993) 
 
Another kind of metaphor found in the sample that compares gene therapy to 
dramatic, dynamic natural forces is the weather-related. “Cloud,” “flood,” “storm,” 
“flurry,” and “heat” are all used to describe what are portrayed as highly impactful 
current or potential developments (both positive and negative) within the gene therapy 
field. The “cloud” metaphor is somewhat unique in its more passive quality; in referring 
to moments of negative feeling toward gene therapy, it portrays the field as weakened or 
stalled. However, the cloud metaphor implies a sense of the temporary – clouds 
eventually give way to sun (as indicated by use of the “clouds lifting” image). The other 
weather-related metaphors again represent gene therapy technologies as being or 
triggering irrepressible, forward-moving forces that bring about dramatic change.   
o “Gene-therapy research has been under a cloud since the 1999 death 
of an Arizona teenager in a gene-therapy experiment and subsequent 
revelations that researchers weren't properly reporting safety 
information to the NIH.” (Wall Street Journal, 03/09/2001) 
o  “Though the virus itself is considered pretty harmless, its use in gene 
therapy has fallen under a cloud after the death of Jesse Gelsinger, a 
patient being treated for a rare metabolic disease at the University of 
Pennsylvania.” (New York Times, 02/18/2000) 
o “Study lifts cloud over promising genetic therapy” (Reuters, 
09/26/2007) 
o “…a government advisory committee ruled Wednesday that the 
director of the National Institutes of Health could issue ‘compassionate 
approvals’ for the use of unproven gene therapies in medical 
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emergencies. The decision is expected to result in a flood of hundreds, 
perhaps thousands, of requests for such waivers for terminally ill 
patients.” (Los Angeles Times, 01/15/1993) 
o “Meanwhile, genetic discoveries will trigger a flood of new 
pharmaceuticals--drugs aimed at the causes of disease rather than the 
symptoms” (Newsweek,  04/10/2000) 
o “Despite the media storm of excitement surrounding the NIH's 
approval of clinical trials for human gene therapy, few organizations 
are coming to grips with the economic questions.” (Los Angeles Times, 
11/08/1990) 
o “First greeted with largely uncritical publicity, Dr. Rosenberg's [gene 
therapy] research later weathered a storm of criticism by medical 
skeptics like Charles Moertel, a professor at the Mayo Clinic, and 
litigation by watchdog groups like Jeremy Rifkin's Foundation on 
Economic Trends.” (Wall Street Journal, 01/30/1991) 
o “It is among a flurry of studies heralding what enthusiasts hope will be 
a new era in the treatment of artery disease.” (USA Today, 12/08/1998) 
o “But expectation that coronary-artery disease may turn out to be a 
particularly promising target for gene therapy, a highly experimental 
field of research, is prompting a flurry of interest from scientists, 
pharmaceuticals companies and investors.” (Wall Street Journal, 
01/06/1998) 
o  “More than 40 trials are under way around the world, making gene 
therapy the hottest new area of medical research.” (Time, 01/17/1994) 
o “Gene therapy is the scientific community's hottest new scheme for 
treating disease.” (USA Today, 11/25/1994) 
 
 
Plants and agriculture represent yet another segment of the natural world from 
which gene therapy metaphors are drawn. Such metaphors occur in discussions of gene 
therapy aims, techniques, results, and potential impacts. Images of “harvest” and 
“fruition” are common, as are (to a somewhat lesser extent) “roots,” “ripening,” and 
“weeding.” The comparison to the plant world suggests that the development of gene 
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therapy is an organic, dynamic growth process with relatively predictable or inevitable 
stages (from “seed” to “fruit” to “harvest”).  
o “These results and others still in the laboratory stage suggest that 
intensive efforts over the last decade to understand genetic diseases are 
beginning to bear rich fruit in therapeutic applications.” (Los Angeles 
Times, 09/21/1990) 
o ''This paper is the first fruit of a long and involved process… hopes 
there will be a large harvest to come.” (New York Times, 08/30/1990) 
o “We have come such a long way since 1990…We will begin to see the 
fruits of that effort in about five years.”(USA Today, 02/24/2003) 
o “’We believe the long-term future of gene therapy is ‘in vivo,’ he said, 
referring to gene-therapy treatments performed in the body, without 
the need to harvest cells.’” (New York Times, 07/11/1995) 
o   “Odds are that even after doctors learn to read the genetic roots of 
these disorders, and tell us that we are at risk, it will be a long while 
before they can tell us exactly how to fix things.” (New York Times, 
11/06/2005) 
o “…scientists have been able to get the gene to take root in only a small 
percentage of cells.”(Wall Street Journal, 07/22/2002) 
o “The immune deficiency tackled by the French -- known as severe 
combined immunodeficiency, type X1, or SCID-X1 -- was deemed a 
particularly ripe target for gene therapy.” (New York Times, 
04/30/2000) 
o “Gene therapy, for instance, is ripe for cosmetic-enhancement 
applications.” (Wall Street Journal, 12/31/1999) 
o “In fact, if gene therapy lives up to its promise, parents may someday 
be able to go beyond weeding out undesirable traits and start actually 
inserting the genes they want--perhaps even genes that have been 
crafted in a lab.” (Time, 01/11/1999) 
 
A final natural world metaphor that appears occasionally in the sample is 
“evolving” or “evolution,” used in reference to the development of the gene therapy field. 
Like the plant metaphor, this implies a developmental inevitability, that gene therapy will 
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go through predictable stages as it grows. “Evolution” also conveys a sense of 
improvement – that as gene therapy progresses, it will become increasingly improved or 
more advanced.  
o “The marketplace matters, and it's not at all clear how basic economics 
will shape the evolution of human gene therapies.” (Los Angeles 
Times, 11/08/1990) 
o “Dr. Kohn, the principal researcher in one of the three trials now 
suspended, suggested that gene therapy could follow the same path as 
monoclonal antibodies, which took nearly 30 years to evolve from 
discovery to marketed therapies.” (New York Times, 03/03/2005) 
o "This really is a historic week in the evolution of [gene therapy]” (USA 
Today, 05/18/1993) 
 
Expectant images and metaphors 
 The expectant type follows from both the essentialist and fatalistic types. If genes 
are the essence of life and health and therefore position gene therapy as an inevitably 
necessary area of treatment that is destined to move forward in its development, then 
expectations for gene therapy should naturally be high. Images referencing these high 
expectations abound within the sample, appearing commonly in reference to gene therapy 
as a potential treatment or cure for inherited and noninherited disease alike. Doubts and 
disappointment about the minimal realization of these expectations that has occurred in 
the decades that have followed the first clinical trial are also included. The two primary 
subtypes of expectant imagery – promise-related and hopeful – represent attitudes toward 
gene therapy (both positive and negative) that are based on the (past or current) 
assumption that the field will continue to develop and continue to be regarded as a 
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potentially effective approach to remedying disease. The imagery is present within a wide 
variety of media accounts, regardless of whether the accounts promote the notion that 
gene therapy should be a primary focus for medical researchers.
15
 
 
1. Promise-related subtype 
 The promise-related imagery occurring within the sample addresses the notion of 
gene therapy’s presumed eventual effectiveness as a treatment for disease. It includes 
both positive expectations of the gene therapy field and its potential and also 
uncertainties about whether its potential will ever be realized.  
Imagery suggesting that gene therapy holds great promise appears very frequently 
throughout the entire sample.  
o “Scientists using a defused common cold virus as a weapon have 
developed a new form of gene therapy that shows great promise for 
treating such lung disorders as cystic fibrosis” (Los Angeles Times, 
04/19/1991) 
o “Gene therapy, a procedure in which defective copies of a gene are 
replaced with new working copies, is the most promising frontier in 
medicine, offering hope of a cure for diseases like cancer and AIDS.” 
(Los Angeles Times,  02/05/2000) 
o “A gene therapy treatment helped people with advanced heart failure 
pump blood more efficiently without causing serious side effects a 
year after treatment, researchers said on Monday, showing yet more 
promise for this treatment approach.” (Reuters, 11/15/2010) 
o “…both procedures hold immense promise and that so far the worst of 
the feared side effects have not materialized.” (Time; 11/23/98) 
                                                 
15
 While certainly many of the images and metaphors mentioned in the previous (and following) types are 
colored by or relate to expectations, the images and metaphors that will be included in the expectant type 
are those that refer most directly to expectations while also not fitting into one of the other three types.) 
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o “Gene therapy is seen as one of the most promising fields of research 
in which scientists try to replace defective or missing genes that cause 
disease with healthy ones that treat or cure the disease.” (USA Today, 
03/08/2000) 
o “We continue to see gene therapy as a promising therapy for all those 
who have not benefited from current technologies.” (Washington Post, 
01/15/2003)  
o “Researchers reported the most promising evidence yet that gene 
therapy can help patients grow new blood vessels and restore blood 
flow to damaged heart muscle.” (Wall Street Journal, 11/14/2001) 
o “While gene therapy is still waiting for its first miracle drug, many 
promising avenues are in development” (Wall Street Journal, 
03/14/2001) 
o “’This work is quite high-tech and futuristic, but it's also 
extraordinarily promising.’" (New York Times, 08/09/1994) 
o “[Gene Therapy is a] New Promise For Treating A Crippler” (New 
York Times, 08/13/2002) 
 
Images regarding the timing of gene therapy realizing its promise also appear in 
the sample, generally suggesting that it is only a “matter of time” until the field 
experiences major or enduring success or offering (usually vague) predicted time periods 
for when the promise will be realized.   
o “…no gene-therapy drug exists today. But that could change. ‘The 
consensus is that it's simply a matter of time,’” (Wall Street Journal, 
10/14/2002) 
o “…gene therapy applied to treat ordinary body cells has so far been a 
failure. But in time the technique will doubtless work” (New York 
Times, 06/27/2000) 
o “It may take years before the promises [of gene therapy for 
cardiovascular disease] are fulfilled.” (New York Times, 09/14/1994) 
o “No one denies that gene therapy holds extraordinary promise or that it 
will eventually yield results.” (Time, 10/09/1995) 
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Expressions of disappointment in “broken promises” are also common 
(particularly in cases from later years). These images reinforce the image of gene therapy 
as a promising new technology, but they also suggest that faith in that promise may not 
be able to withstand continued failure or minimal evidence of success.  
o “No one, perhaps, is more acutely aware of gene therapy's broken 
promise than Mark Batshaw, the pediatrician who proposed the 
experiment that cost Jesse Gelsinger his life.” (New York Times, 
11/28/1999) 
o “If the treatment itself should prove to be the cause of [Gelsinger’s] 
death it would likely be the first by someone undergoing gene therapy 
and could be a severe setback for the experimental technique, whose 
fulfillment has long fallen short of its high promise.” (New York 
Times, 09/29/1999) 
o “Gene therapy, Dr. Verma said, had the same sort of promise attached 
to it two decades ago. In that field, too, scientists predicted too much 
too soon” (New York Times,  12/18/2001) 
o "’Gene therapy has been `five years away' for 20 years,’" (Wall Street 
Journal, 02/18/2005) 
o “Gene therapy, a technique long on promise and so far very short on 
fulfillment, may be achieving a glimmering of success in a treatment 
for hemophilia B” (New York Times, 03/02/2000) 
o “If angiogenesis gene therapy works, it may rejuvenate a field whose 
promise was trumpeted a decade ago but has proved almost uniformly 
disappointing.” (Washington Post, 07/24/2001) 
o “While gene therapy once had great promise, it has failed to live up to 
expectations.” (Wall Street Journal, 01/15/2003) 
o “Researchers said the once-promising drug has been dropped like a hot 
potato.” (CNN.com, 11/18/2005) 
o “…gene therapy, ‘more than any other field of medicine, had the aura 
of the future about it, the ring of impossible promise.’ But gene 
therapy is also one of those stories in modern biomedicine that has 
never progressed beyond sounding too good to being true.” (New York 
Times, 04/18/2004) 
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Relating to the perception of promises being broken or insufficiently realized, 
“hype” and similar terms also commonly appear in the sample. These images suggest 
exaggerated or oversold promises. They appear in the contexts of both (usually negative) 
discussions of failed gene therapy attempts and (usually positive) discussions of the 
possibility of new triumphs. Therefore, although hype is frequently noted, it is not always 
portrayed as an appropriate way of characterizing gene therapy (or suggesting that high 
expectations should necessarily be abandoned). 
o “…a panel of experts appointed by Varmus issued a report that 
condemned most gene therapy efforts as ‘pure hype,’” (Los Angeles 
Times, 03/03/1996) 
o  “Almost a decade ago, the promise of gene therapy was blown full of 
hype by scientists who were certain they would be curing the world of 
disease by now.” (USA Today,  06/10/1999) 
o "’This has been an overhyped area that has failed to reach its promise 
for very obvious technical reasons,’" (Wall Street Journal, 
10/27/1999) 
o “Gene therapy has been much hyped over the years as a treatment for 
cancer and other diseases where DNA is known to play a central role 
but scientists have run into a series of technical and safety problems.” 
(Reuters, 04/17/2008) 
o “Yet after all the tests and all the hype, there is still no unambiguous 
proof that gene therapy has cured--or even helped--a single patient.” 
(Time, 10/09/1995) 
o “[F]amilies and even some doctors have become deluded by 
unrealistic hopes - and by hype from gene therapy's growing cadre of 
scientist-investors and venture capitalist backers.” (Washington Post, 
03/07/2000) 
o “After 10 years of hype and dashed hopes, after more than 4,000 
patients with more than a dozen diseases were treated unsuccessfully 
in hundreds of studies, gene therapy has finally worked.” (New York 
Times, 04/30/2000) 
o “The revolution in human gene therapy, so long ballyhooed and 
debated, began today in earnest as a Government panel approved 
 109  
experiments with two therapies designed to treat human disease by 
inserting new genes into cells.” (New York Times, 08/01/1990) 
o “Researchers are striving to devise gene therapies to better treat 
inherited diseases like hemophilia, cystic fibrosis, dwarfism and 
immune deficiencies, as well as chronic adult ailments like cancer and 
heart disease…they had until recently sneered at the notion of human 
gene therapy as gee-whiz hyperbole.”  (New York Times, 04/14/1992) 
o “Indeed, after much hype and few results, gene therapy is finally 
making major strides” (Time, 11/08/1999) 
 
Another form of promise-related imagery is that which refers to confidence or 
doubt that promises made about gene therapy will be realized. Images of confidence or 
absence of doubt suggest that expectations have been very reasonable, whereas images of 
doubt of course question expectations. Although opposite in their assessments about 
expectations, both confidence and doubt-related imagery affirm the importance of 
acknowledging expectations within the discourse about gene therapy. (Notably, although 
it also appeared in article narratives, “confident” or “confidence” in particular gene 
therapy treatments more often occurred within quotes from researchers or clinicians.) 
o “On the immediate horizon, experts are confident that gene-therapy 
techniques will be used not only to cure classical genetic disorders but 
also to harness the body's natural defenses to combat killers such as 
cancer, heart disease and AIDS.” (Los Angeles Times,  10/20/1991) 
o “Scientists say that the discouraging results of the two studies show 
that it is time to rethink the methods they are using for gene 
therapy...But, they emphasize, they remain confident that gene therapy 
will eventually transform medicine.” (New York Times, 09/28/1995) 
o “’This is a vote of confidence for gene therapy in cardiovascular 
disease,’ said Jonathan L. Halperin, director of clinical cardiology at 
Mount Sinai Medical Center in New York.” (Wall Street Journal, 
08/29/2000) 
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o “This finding removes all doubt that gene therapy is the avenue of 
choice for treating Duchenne muscular dystrophy," (Los Angeles 
Times, 08/19/1993) 
o “…he said that 'all of these issues are solvable' and that he had 'no 
doubt' that gene therapy for hemophilia could be made to work.” (New 
York Times, 05/28/2004) 
o “'I have no doubt if we did this [gene therapy] in a patient today it 
would correct the abnormalities of the lung.'' (USA Today, 01/10/1992) 
 
Doubt-related imagery is less common but still occurs regularly. Terms like 
“doubt” or “uncertainty” typically refer to concern that either the promises of gene 
therapy will not be realized or that treatments are not or will not be adequately safe or 
effective. 
o “He doubts that the technology will leap ahead with anything like the 
ease predicted by the visionaries.” (Los Angeles Times, 04/09/2000) 
o “Gene Experiment in Doubt” (New York Times, 02/11/2000) 
o “Fresh doubts are cast on a troubled gene-therapy treatment even as 
the French hint at new advances” (Time, 02/14/2000) 
o “Benefits of Gene-Based Heart Therapy in Doubt” (Wall Street 
Journal, 03/13/2000) 
o “Watching and Waiting Infant to Finally Go Home, but Success of 
Gene Therapy Uncertain” (Los Angeles Times, 07/11/1993) 
o “Numerous uncertainties remain about whether the [gene therapy] 
drugs can be safe and effective.” (New York Times, 09/14/2004) 
 
 
 
 
2. Hopeful subtype 
 
Hope takes expectation one step further by adding the element of also wishing 
that an expected outcome will take place. Given the possibility that better understanding 
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the genetic bases for disease might lead to a genetics-oriented way of treating disease (so 
strongly encouraged by discoveries made by the Human Genome Project and other 
genetics research programs), it is unsurprising that gene therapy quickly became the 
object of many hopes for novel treatments and cures. Hopeful imagery is extremely 
widespread in the sample (as will be discussed further in the findings for Research 
Question #3). It is mentioned in reference to possible treatments for a broad range of 
conditions, from inherited diseases like cystic fibrosis and sickle cell anemia, to 
noninherited diseases like cancer and AIDS, to conditions such as hair loss and color 
blindness.  It is the focus of many headlines, the refrain of many researchers, the virtual 
capital of many companies, and the central narrative of many patients. Hope is portrayed 
as being based on animal studies, human clinical trials, expert opinion, and patient 
research (and often no more than the author’s judgment).  The preponderance of hopeful 
images in the media coverage of gene therapy causes the field to be strongly tied to high 
expectations. As seen in the discussion of the promise-related subtype, many media 
accounts not only address the hope that expectations will be realized, but they also 
acknowledge that many hopes have not yet been realized, and even that some realized 
hopes have resulted in painful unexpected consequences. A brief illustration of the 
hopeful imagery found in the sample, focusing on the areas of treatment hopes, cure 
hopes, and false hopes, demonstrates some of the ways in which expectations and wishes 
converge in the public discourse surrounding gene therapy. 
As noted, hopes that gene therapy might be a viable treatment for a wide variety 
of ailments are prevalent within the sample. This illustrates the range of research and 
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clinical trials being conducted within the field, and, by extension, the diversity of 
scientific, academic, corporate, and patient actors that could have an interest in the field’s 
development.  
o “Targeted Genetics hopes the gene will help the body make a protein 
that would ease arthritis pain.” (Los Angeles Times, 09/16/2007) 
o “Gene Therapy Offers Hope for Cystic Fibrosis” (Los Angeles Times, 
09/21/1990) 
o “Genes Are Hope as Alternative to Heart Bypasses” (New York Times, 
01/20/1998) 
o  “Her hope is that her discovery will lead to better forms of prevention 
and treatment, perhaps gene therapy, for hair loss.” (New York Times, 
01/30/1998) 
o “Now scientists are hopeful that gene therapy may help late-onset 
[Tay-Sachs] patients.” (ABC News, 05/13/2011)  
o “’The study by Bennett and co-workers will further boost gene therapy 
trials and provide hope for patients with inherited blindness and other 
genetic disorders,’" (Reuters, 10/25/2009) 
o “Two studies published on Thursday offer new hope for Parkinson's 
disease.” (Reuters, 06/22/2007) 
o “Gene Therapy Method May Offer Hope In Treating Anemia With 
Protein EPO” (Wall Street Journal, 11/10/1993) 
o “A single injection of a novel gene-therapy treatment appears to have 
cured diabetes in rats and mice, according to Canadian and South 
Korean researchers, who hope the approach eventually will work in 
human diabetes patients.” (Wall Street Journal, 11/24/2000) 
 
Imagery that addresses hopes for a cure refers to a similarly diverse group of 
diseases and conveys the wishes of an equally wide range of potentially interested parties. 
However, this imagery takes hope to a much deeper level, connecting to dreams of 
complete eradication of a disease as opposed to simply lessening its effects or addressing 
its symptoms. In this way, hopes for a cure are much more emotionally charged while 
also much more challenging to realize. Imagery that holds up gene therapy as a potential 
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cure often expresses a sense of desperation, an image of gene therapy as the “only” or 
“last” hope for patients with a particular disease.  
o “…a gene therapy expert…infused the genetically altered blood into 
Andrew. If, as doctors hope, the stem cells give rise to other cells that 
manufacture the correct enzyme, Andrew will be cured.” (Los Angeles 
Times, 07/11/1993) 
o “Researchers had hoped to cure him by injecting him with a modified 
virus carrying a gene that could replace the medications and special 
diet that had been controlling his condition.” (Los Angeles Times, 
02/10/2005) 
o “Since colorblindness is a genetic problem, he said, the best long-term 
hope for a cure is gene therapy.” (New York Times, 02/08/2000)  
o “Any hope for a cure [for ALD], Goldstein said, rests with gene 
therapy.” (New York Times, 11/24/1996) 
o “This new direction in Alzheimer's therapy could hold hope for some 
of the 4 million Americans with the progressive neurological illness, 
for which there is no cure and only limited medications.” (Los Angeles 
Times, 04/16/2001) 
 
Images of false or unrealized hopes are also very common, especially in the later 
years of the gene therapy field. As decades passed since the first clinical trial took place 
in 1990, the failure of gene therapy to live up to expectations started to be acknowledged 
with increased frequency in media accounts. Hopes that were once part of optimistic 
narratives are recast as false hopes in light of gene therapy’s slow progress. Further, gene 
therapy researchers and companies are sometimes charged with - or are quoted as trying 
to avoid – overselling their projects, to the detriment of patient care and research into 
alternative treatment methods. 
o “Despite high hopes for gene therapy, scientists have struggled to 
realize its potential.” (USA Today, 04/28/2008) 
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o “’People were hoping that gene therapy would progress a lot quicker 
than it has,'” (USA Today, 08/02/1990) 
o “Gene-therapy techniques have led to much hope over the last 20 
years, and about as much disappointment.” (Wall Street Journal, 
04/28/2008) 
o “So it has gone for gene therapy, the great hope of the genetic 
revolution …gene therapy would fix what was actually broken. IF 
ONLY.” (Wall Street Journal, 02/18/2005) 
o “[Gene therapy] has been a source of both hope and heartache for 
scientists…after more than a decade of human studies, gene therapy 
has proven to be stubborn, elusive and at times catastrophically 
disappointing.” (USA Today, 02/24/2003) 
o “For those who had invested their hopes in the therapy, the 
disappointment was devastating.” (New Yorker, 05/04/2009) 
o “Researchers also said they were concerned that with the enormous 
publicity surrounding Dr. Rosenberg's experiment, desperate patients 
would have false hopes that a cure was just around the corner.” (New 
York Times, 10/09/1991) 
o “’We don't want to raise false hopes. This is an experimental treatment 
in the early stages of development and this is the first attempt to use it 
for cancer,'” (USA Today, 01/30/1991) 
o “Experts and the researchers themselves, however, cautioned patients 
against investing too much hope in the findings because Parkinson's 
studies are notorious for showing placebo effects.” (Los Angeles 
Times, 10/18/2006) 
o “… most of the (Duchenne) research attention and financing focused 
on gene therapy…’There was great hope at the time,’ recalled Mr. 
Winheld… 'We always thought “cure.”’ But…researchers are now 
looking elsewhere for an answer.” (New York Times, 02/20/2008) 
 
 
Conflictive images and metaphors 
 The final type of imagery is the conflictive type, which represents gene therapy 
through two main subtypes – combative and sports-related. The imagery that falls within 
these categories primarily represents gene therapy in two ways. The first way – gene 
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therapy as fighting against disease – follows from the preceding three imagery types.  If 
genes are the essence of life and health, the development of gene therapy is resultantly 
necessary and inevitable, and expectations for gene therapy are therefore high, then gene 
therapy should naturally be considered the best weapon against disease. The second way 
– gene therapy as a sporting event – focuses more on the challenges that gene therapy 
meets on the road to treating disease.  
 
1. Combative subtype 
 The combative subtype includes militaristic and other imagery depicting violent 
conflict. The broad range of combative images and the frequency with which they occur 
in the sample suggest that this subtype is particularly important to consider. While part of 
a larger metaphorical frame of “war on disease” that occurs commonly in public 
discourse, combative gene therapy metaphors also highlight the field’s perceived unique 
ability to address disease in light of the assumption of genetic causation that has become 
increasingly common in recent decades. Through their emphasis on conflict, these 
metaphors also reinforce the notion of “bad genes” affecting health outcomes and support 
the role of gene therapy as a way of counteracting such genes. In this way, combative 
imagery draws upon and strengthens essentialist and fatalistic gene therapy narratives, 
even as it suggests that gene therapy may have the power to reverse genetic destinies.  
The most commonly used combative metaphors are “attack,” “fight,” “battle,” 
and other proximately synonymous terms. Such terms are used frequently to describe 
gene therapy’s presumed ability to treat or cure disease. They imply that unhealthy or 
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defective genetic material is something to be conquered or destroyed and invest gene 
therapy with the ability to do so. The violent nature of these terms also lends a sense of 
gravity and urgency to the gene therapy discourse.  
o “The experiment involved removing a patient's own cancer cells, 
modifying them with an immune system gene and then inserting them 
back into the patient to try to stimulate the immune system to attack the 
cancer.” (Los Angeles Times, 02/12/2000) 
o  “Researchers believe human gene therapy may also prove valuable in the 
battle against cystic fibrosis, familial cholesterol disorders, metabolic 
deficiencies of the liver and other genetic disorders.” (New York Times, 
03/08/1990) 
o “The key is a gene that produces a protein that combats tumors.” (Time, 
08/13/1990) 
o “…[gene therapy] involves inserting genes into a patient's cells to 
compensate for an inherited genetic defect or to enable the body to fight a 
disease on its own, without taking medicine.” (Wall Street Journal, 
09/01/2006) 
 
This type of imagery is not only prevalent within articles but is also often found in 
headlines, which demonstrates combative metaphors’ strong presence in gene therapy 
public discourse.  
 
o “Scientists are Newly Optimistic that Gene Therapy Will Help Fight the 
Most Serious Diseases.” (Los Angeles Times, 08/28/2006) 
o “Cancer Team to Expand Genetic-Therapy Testing; In One Patient, 
Altered Cells Attack Tumor.” (Washington Post, 03/31/1990) 
o “Genetic Attacks On AIDS Readied” (New York Times, 05/31/1994) 
o “A way to help healthy genes fight disease” (USA Today, 07/09/1993) 
o “Battler for gene therapy.” (Time, 01/17/1994) 
o “AIDS Battle Advances on 2 Fronts; Gene Therapy Or Experimental 
Vaccine that 'Hijack' the Immune System may be the Next Step in Fighting 
HIV” (Los Angeles Times, 12/30/2002) 
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Another very common combative metaphor is “killing.” This or other similarly 
dramatic and anthropomorphic terms are often used to describe both the effect of diseases 
on the patient or patient’s body and the way in which gene therapy might potentially treat 
disease. The use of “killing” not only adds emotional weight to gene therapy discussions 
by conjuring images of brutal and intentional violence, but it also emphasizes disease’s 
power to destroy life and gene therapy’s (presumed or anticipated) power to destroy 
disease. Endowed with such powers, both disease and gene therapy seem worthy of 
significant attention from science and the media.  Further, for gene therapy to “kill” 
disease suggests that it can completely eradicate – in other words, cure – disease, not just 
treat it.  
o “Even in its mild form, the disease often kills people by the time they 
reach 35.” (New York Times, 08/04/1998) 
o “ALS kills motor neuron cells that connect the spinal cord to the body's 
muscles, causing paralysis and death when breathing becomes 
impossible.” (Wall Street Journal, 08/08/2003) 
o “The same characteristics that make the AIDS virus such a cunning and 
effective killer may make it ideal as a medical tool for gene therapy, new 
research indicates.” (Washington Post, 04/12/1996) 
o “Once taken up, the genes force the cell to produce proteins that can kill 
the cancer.” (Reuters, 03/11/2009) 
o “Because the goal is to insert genes that will kill the cancerous cells, the 
vehicle's limited period of effectiveness is not an issue” (New York Times, 
02/23/1999) 
o “The most widely discussed and attempted is the use of "suicide genes" 
which, correctly triggered, will kill the cell they sit in.” (The Economist, 
02/25/1995) 
o “Nanotech Gene Therapy Kills Ovarian Cancer in Mice” (Fox News, 
07/31/2009) 
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The “killing” image is also used quite often in discussions of one of the landmark 
events in the history of gene therapy – the 1999 death of 18 year old clinical trial 
participant Jesse Gelsinger. In this case, the gene therapy treatment that led to his death is 
identified as the (direct or indirect) “killer.” This emotionally charged term portrays gene 
therapy as a dangerous and even deadly endeavor. 
o “But these viruses can produce an immune reaction such as the one that 
killed 18-year-old Jesse Gelsinger.” (Los Angeles Times, 12/13/1999) 
o “The scientist who ran a gene therapy study that killed an 18-year-old 
patient at the University of Pennsylvania will no longer conduct 
experiments on people, and the prestigious gene therapy institute he 
founded is being scaled back, university officials announced today.” (New 
York Times, 05/25/2000) 
o "I trusted a system that needlessly killed my son [Jesse], and I'm working 
to make it aware of the problems we uncovered," he says.” (Wall Street 
Journal, 04/11/2002) 
 
Imagery that invokes “revolution” and related terms is often used to describe the 
field of gene therapy and its potential efficacy as a treatment for a variety of conditions. 
This metaphor suggests that gene therapy has the power to bring about drastic change that 
may overthrow previously established ways of addressing disease. 
o “Even the acceptance of that notion, of addressing genetic flaws through 
gene-to-gene combat, is considered a biotech revolution.” (Los Angeles 
Times, 05/29/1991) 
o “Human genetic engineering--the fourth medical revolution--will 
profoundly change the practice of medicine over the next 30 to 40 years.” 
(Newsweek, 01/01/2000) 
o “Gene therapy -- the revolutionary concept that disease can be treated with 
the body's own genetic material -- is alive and well, and not just in San 
Diego.” (New York Times, 06/01/1995)  
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Although the “revolution” metaphor usually conveys a hopeful attitude toward gene 
therapy, it is also sometimes used in discussions of the field’s failure to live up to 
expectations.  
o “In the 1990s, gene therapy was considered the next revolution in 
medicine. But a pair of high-profile deaths in clinical trials tainted the 
field.” (Los Angeles Times, 09/01/2006) 
o “Even Dr. Anderson has tempered his enthusiasm. ‘We were naive to 
think we could revolutionize medicine in 10 years,’ says the researcher, 
who now doubts that major gene-therapy drugs will reach the market 
before 2004 or 2005.” (Wall Street Journal, 10/27/1999) 
 
Various terms for weapons are frequently used to describe the field of gene 
therapy and applications of gene therapy technologies. Among the more common 
weapons-related images and metaphors are “gun,” “armed/disarmed,” “arsenal,” 
“trigger,” “bomb,” and “missile.” These terms further develop the notion of gene therapy 
as empowered to fight disease and highlight specific methods for defending the body 
against the effects of “bad” genes.  
o "What we have done today is add gene therapy to vaccines, antibiotics and 
radiation in the medical arsenal. Medicine has been waiting thousands of 
years for this." (Los Angeles Times, 07/31/1990) 
o “In this case, the defective p53 was the trigger. The gene bomb sat quietly 
unless it encountered this protein. The warhead was a gene that produced 
a bacterial enzyme called purine nucleoside phosphorylase.” (New York 
Times, 04/24/1996) 
o “[Gene] Therapy turns patients' cells into cancer smart bombs” 
(CNN.com, 08/31/2006) 
o "’We have an enemy, hair follicle disease, and Dr. Hoffman has invented a 
gun with which to fight that enemy…He has demonstrated that the gun 
works by firing blanks at the hair follicles. What remains for us to do is to 
develop the ammunition that will make the gun useful in the fight against 
hair loss.’” (New York Times, 07/11/1995) 
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o “The technique is no miracle cure, but the experiment adds a promising 
new weapon to the arsenal of genetic medicine.” (Time, 12/13/1993) 
o “The vaccine is constructed like a missile with multiple warheads. The 
vehicle is another virus, called an adenovirus, armed with genes from the 
different types of HIV.” (Wall Street Journal, 07/29/2004) 
 
As is true of the revolution metaphor, weapons-related imagery primarily occurs 
within contexts that present gene therapy in a positive light. Nonetheless, it is also 
sometimes employed in discussions of the technology’s slow or uncertain progress, 
particularly when using the metaphor of gene therapy as a “magic bullet.” In these cases, 
the weapon metaphor points to dramatic expectations for gene therapy while 
acknowledging that dramatic results have not yet been achieved.  
o “After the rise of genetic engineering in the late '70s, gene therapy had 
been touted as a magic bullet that would quickly fix an array of 
debilitating and often fatal inherited ills. It was nowhere near that simple.” 
(Los Angeles Times, 08/28/2006) 
o "’There is no such thing as a magic bullet to cause all cancers to go away,’ 
says M.D. Anderson's Dr. Clayman. ‘All cancer treatment is incremental, 
and so is gene therapy.’"   (Wall Street Journal, 05/04/2000) 
o The industry was supposed to be awash by now in magical biological 
bullets curing everything from baldness to cancer. But development has 
proved tougher than expected, and strategic blunders have made things 
worse. (Wall Street Journal, 05/20/1994) 
 
Setbacks experienced by the gene therapy field (especially in terms of damage 
done to clinical trial participants and regulatory censures or limitations) are often 
conveyed with the violent phrase “blow to the field.” This vivid image suggests that these 
setbacks may have dramatic or devastating effects upon the field’s future success.   
o “The [restrictive FDA] decision represents a serious blow to the field of 
gene therapy, which had begun to bask in the glow of its first successes 
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when it became clear last year that recent cases of leukemia in two 
toddlers were caused by the gene treatments they had received as infants.” 
(Washington Post, 03/01/2003) 
o “When 18-year-old Jesse Gelsinger died this past fall after an infusion of 
genetically altered cells, the burgeoning field of gene therapy suffered a 
blow from which it still is reeling.” (USA Today, 02/02/2000) 
o “The government has suspended a Seattle company's gene-therapy study 
and is reviewing the safety of 28 others around the country after learning 
that a patient died Tuesday…It marks the third blow since 1999 to the 
field of gene therapy, as scientists struggle to determine if the viruses they 
use to deliver new genes may themselves cause serious trouble.” (Wall 
Street Journal, 07/27/2007) 
 
The research space in which gene therapy studies and clinical trials are conducted 
is often referred to as a “front” or the “front lines” within a stated or implied “war.” Such 
metaphors reveal hopes that gene therapy can effectively fight diseases like cancer, while 
at the same time implying that conquering these diseases may necessitate multiple 
strategies and attempts, just as wars are fought over time on multiple fronts.  
o “Taking Control --- The Genetic Front Lines: At the Salk Institute, the 
promise of gene therapy has never seemed brighter; But the risks have 
never been more obvious” (Wall Street Journal, 12/09/2003) 
o “But the success with two patients, who are cancer-free more than a year 
and a half after their treatment, was enough to demonstrate the possibility 
of a new front in the war against cancer.” (Los Angeles Times, 
09/01/2006) 
 
Relatedly, those working at these gene therapy “front lines” are referred to as 
“veterans” and the “vanguard,” which further reinforces an image of gene therapy as one 
component of long and multifaceted wars against disease.  
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o “The work was led by Steven Rosenberg of the National Cancer Institute, 
a veteran of both gene therapy and cancer research.” (Wall Street 
Journal, 09/01/2006) 
o “Kenneth Culver, M.D., and Richard Mulligan, Ph.D., both work at the 
vanguard of human gene therapy, the grand new scientific enterprise to 
treat patients afflicted with genetic diseases by inserting foreign genes into 
their cells.” (New York Times, 04/04/1990) 
 
Combative language is also used to describe how gene therapy is delivered to 
cells – typically by a virus or other similar agents. These delivery mechanisms are often 
referred to as “invaders” or “Trojan horses.” The use of these metaphors reinforces the 
idea of genes as being inherently “good” or “bad”; the “good” genes must boldly march 
into the cells and destroy the “bad” genes.  
o “To accomplish that, they had to figure out how to deliver the therapeutic 
genes to cells. The leading method today uses viruses, which naturally 
invade cells.” (Los Angeles Times, 08/27/2004) 
o “Some reasoned that one way to get genes into a cell nucleus would be by 
mimicking the methods used by nature's own best invader, the virus.” 
(New York Times, 03/31/1991) 
o “The virus could thus be an effective "Trojan horse" that would sneak the 
gene into the cells in the same fashion that, according to legend, Greek 
warriors were sneaked into the ancient city of Troy in a large wooden 
horse” (Los Angeles Times, 01/10/1992) 
o “While researchers have talked for years about using gene therapy to cure 
cancer and other ills, they are confounded by one serious drawback: how 
do you get the killer genes into the cells you want to eliminate? One 
strategy is to use viruses as Trojan horses to carry them in.” (New York 
Times, 04/24/1996) 
 
The combative metaphors “enemy” or “foe” are also used to refer either to 
diseases and conditions or to perceived challenges to the future of human gene therapy. 
 123  
Such terms legitimize gene therapy and its continued development by demonizing the 
diseases it targets and the limitations it faces.  
o “One team found that gene therapy can marshal the body's own defenses 
to strike at the hidden foe [AIDS].” (Los Angeles Times, 07/02/1998) 
o "We have an enemy, hair follicle disease, and Dr. Hoffman has invented a 
gun with which to fight that enemy," (New York Times, 07/11/1995) 
o "This has been a spectacularly successful endeavor up to this point," said 
Dr. Savio Woo, former president of the American Society of Gene 
Therapy. "This [serious side effect] is a new enemy that we have 
discovered. We know that there is a theoretical possibility, but it has never 
been seen before." (New York Times, 10/04/2002) 
 
“Enlistment” and “recruitment” are combative terms which describe patients’ 
participation in clinical trials or biological entities’ function within the application of 
gene therapy technology. This language supports the image of disease treatment as a 
“war,” one in which afflicted patients can be persuaded to “fight” for the benefit of their 
own health and the health of others. Viruses and proteins can also “serve” in this war. 
Again, this imagery positions gene therapy as a strategy or approach in ongoing warfare 
against disease.  
o “Thus, large numbers of patients must be sampled to winnow the 
statistical connections that will implicate the genes responsible. To date, 
more than 4,500 people have enlisted.” (Wall Street Journal, 11/06/2000) 
o “Jesse Gelsinger, 18, enlisted in a gene-therapy trial to treat an inherited 
liver disorder.” (USA Today, 02/27/2001) 
o “Some members said Ms. Mohr might not have been given enough time to 
consider whether to enroll in the trial. And they said the fact that she was 
recruited by her rheumatologist might have led her to believe she would 
benefit from the trial, even though its main purpose was to gather 
information.” (New York Times, 09/18/2007) 
o “Researchers are subverting some of nature's most potent viruses--the 
infectious agents responsible for HIV, the common cold and herpes--to 
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enlist them in defense of the ailing human brain” (Los Angeles Times, 
11/20/1996) 
o “The MECP2 gene plays a central role in this silencing process. Its job is 
to recognize chemical tags called methyl groups that get added to DNA at 
what are called CpG sites, and to recruit proteins that silence or switch off 
the genes at these regions.” (New York Times, 02/20/2007) 
 
2. Sports-related subtype 
 
Imagery within this subtype compares the development and application of gene 
therapy to various sporting events and competitions. In doing so, it represents gene 
therapy as in conflict with both the conditions it means to treat and also the institutions 
which regulate its practice. These conflicts are illustrated by metaphors that highlight 
challenges faced in gene therapy research and treatment programs and victories 
experienced along the way. Further, by positioning gene therapy within metaphorical 
events that have distinct endings, such as “races” with “finish lines” or “games” with 
“winners” and “losers,” sports-related metaphors contribute to a narrative of gene therapy 
as moving forward toward anticipated eventual success.    
One of the most common sporting-related metaphors within the sample is 
“hurdle,” which frequently references challenges to the development of gene therapy 
technologies or the field in general. Technical problems or government 
regulations/limitations are the primary “hurdles” discussed within gene therapy discourse. 
This imagery implies that gene therapy is competing in a “race” to find treatments or 
cures for disease. Although they acknowledge that obstacles may arise, “race” and 
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“hurdle” metaphors also support the fatalistic notion that gene therapy will keep 
progressing and eventually reach a “finish line.”  
o  “Scientists at the University of Michigan in Ann Arbor recently vaulted 
over the biggest hurdle to gene therapy experiments, winning permission 
from two important government panels that monitor attempts to 
manipulate human genes” (New York Times, 10/29/1991) 
o “Hurdles: Genes work only a couple of weeks, and immune reactions are 
caused by viruses that carry genes or the genes themselves. Experts predict 
such problems are beatable.” (USA Today, 11/10/1993) 
o “Medical researchers cleared the last big scientific hurdle to gene-based 
treatment of major diseases by implanting a nonhuman gene into patients 
in a clinical trial.” (Wall Street Journal, 08/30/1990) 
o “The gene therapy plan also needs the approval of the director of the 
National Institutes of Health and the FDA, but Anderson said that the NIH 
advisory panel was the largest hurdle.” (Los Angeles Times, 07/31/1990) 
o "We have some hurdles down the road…but it's remarkable how fast this 
field is moving. I think we're going to cure this disease." (Washington 
Post, 01/10/1992) 
 
The term “obstacle” is used with similar frequency and reference within the 
sample. Like “hurdle,” it recognizes the challenges faced by gene therapy while at the 
same time connoting that gene therapy will continue to move forward once it addresses or 
works around those challenges.  
o “’Often in gene therapy, the obstacle is getting the gene where you want it 
to go,’ Huie said.” (Los Angeles Times, 06/30/1995) 
o “Gene therapy still faces some obstacles. Serious side effects in other 
studies have heightened concerns over the technology, which has yet to 
prove commercially successful.” (Wall Street Journal, 08/08/2003) 
o “…after the Jesse Gelsinger death, ‘the FDA said you have to come to a 
higher standard’ in conducting clinical trials, including much greater 
documentation of all aspects of the trials. The new obstacles…have been a 
deterrent to conducting these trials in academia.” (Wall Street Journal,  
12/09/2003) 
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o ”…the Food and Drug Administration yesterday approved a highly 
experimental treatment for advanced cancer. The decision swept away the 
final obstacle to the radical new therapy, an attempt to treat patients by 
infusing them with genetically engineered blood cells custom-designed to 
target and destroy tumors.” (New York Times, 11/14/1990) 
 
In addition to being implied by “hurdle” and “obstacle” metaphors, the “race” 
metaphor is also often explicitly used. Typically, it refers to the speed with which 
patients, researchers, and corporate interests feel it is necessary to move forward with 
gene therapy research and clinical trials. For patients, speed is important because of the 
progression of disease (and consequent potential death); for scientists, helping patients is 
one motivation for speed, but desires to achieve professional success or create marketable 
products are also at play. 
o “One cystic fibrosis patient, Eric Kast, of Norman, Okla., told 
senators…‘My battle with C.F. is a race…Don't let me lose that race 
when the finish line might be just around the corner.’” (New York Times, 
02/03/2000) 
o “Has Gene Therapy Stalled? Scientists May Have Pushed Too Far Too 
Fast in a Race for Breakthroughs” (Time, 10/09/1995) 
o “[The father of Jesse Gelsinger] attacked the influence of money from 
biotech companies in the race to making gene therapy work.” (New York 
Times, 02/03/2000) 
o “The Race to Cash In On the Genetic Code” (New York Times, 
08/29/1999) 
o  “…several companies are in a race to determine whether gene therapy 
and related techniques can be used to promote the development of new 
blood vessels in the heart.” (Wall Street Journal, 10/18/1999) 
o “Now that a delivery vehicle exists, Dr. Hoffman predicts a race to find 
the best genes.” (The Economist, 08/05/1995) 
o “Gene therapy for blocked arteries will be tested on humans in a high-
stakes corporate and academic race to develop the revolutionary 
technique.” (Wall Street Journal, 01/06/1998) 
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o “In the race to develop treatments aimed directly at the patient's genetic 
code, commercial and competitive impulses have been key in development 
(much as in the race to decode the genome itself).” (Wall Street Journal,  
03/14/2001) 
 
The term “leap,” a physical activity which often occurs within races or other 
sporting events, is used often to represent forward progress that has occurred (or is 
predicted to or hoped to occur) in gene therapy development. The dynamic and dramatic 
nature of this term imbues the events it describes with a sense of great importance. 
o “…the research represents a leap toward gene therapy to prevent heart 
attacks and strokes,” (Los Angeles Times, 01/16/1990) 
o “Gene therapy for human disease took a leap from the theoretical realms 
of the laboratory toward the real world of practicing medicine today…” 
(New York Times, 03/08/1990) 
o “…researchers are working to perfect a great leap in medical technology, 
one they hope will enable doctors and scientists not only to cure lethal 
diseases, but to prevent them.” (New York Times, 10/06/1997) 
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Chapter 5  
Findings – Subtype Co-occurrences and Narratives 
 
 
Finding 2 
(Research Question 2: What sorts of narratives are formed through the use of these 
images and metaphors?) 
Some image/metaphor subtypes frequently co-occur in the media accounts sampled. 
These co-occurrences help to clarify and explain the larger narratives that emerge 
from the data. 
 
Common image/metaphor subtype co-occurrences 
1. Good genes vs. bad genes and natural world-related 
 
Images that label genes as “good” or “bad” frequently co-occur with natural 
world-related imagery. These types share an emphasis upon the essential or inherent 
qualities of genes, health/disease, and gene therapy treatment.  Metaphors borrowed from 
the animal world, such as “defanged,” are used to describe the viral vectors used to 
deliver “good” or “healthy” genes into the body, replacing “bad” genes: 
o “The good copy of the RPE65 gene was inserted into a defanged version 
of a human adenovirus.” (Los Angeles Times, 10/29/2009) 
o “In trying to cure cystic fibrosis, researchers inserted a healthy copy of the 
defective gene that causes the respiratory illness into a defanged common 
cold virus.” 
Plant-based metaphors are also used to elaborate on the inherent “goodness” or “badness” 
of genes. Metaphorical use of terms like “ripe,” “fruit,” and “harvest” connect gene 
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therapy to organic, natural processes, and, when paired with “good gene” or “bad gene” 
images, reinforce the notion that genes possess essential qualities.   
o “Three children whose immune systems were not functioning because of a 
defective gene… have been restored to normal, healthy lives… The 
immune deficiency tackled…was deemed a particularly ripe target for 
gene therapy.” (New York Times, 04/30/2000) 
o  “[R]esearchers began studies in humans of a new form of therapy for 
Duchenne muscular dystrophy based on the recent discovery of the 
defective gene that causes that disorder. These results and others still in the 
laboratory stage suggest that intensive efforts over the last decade to 
understand genetic diseases are beginning to bear rich fruit in therapeutic 
applications.” (Los Angeles Times, 09/21/1990) 
o “The success of the venture assures that the embryonic field of human 
gene therapy, the effort to treat disease by replacing bad genes with good 
ones, will continue its momentum…’This paper is the first fruit of a long 
and involved process…One hopes there will be a large harvest to come.’” 
(New York Times, 08/30/1990) 
 
 
2. Good genes vs. bad genes and promise-related/hopeful 
 
“Good gene” or “bad gene” metaphors also commonly co-occur with images 
emphasizing promises of or hopes for gene therapy technology. These types of imagery 
are logically connected, since if genes can be “good” or “bad,” it is reasonable to assume 
that a technology that intends to replace bad genes with good ones would hold great 
promise. Emphasis on this connection is evident within the sample, wherein good vs. bad 
genes imagery is used to demonstrate why gene therapy technology is viewed as 
promising and worthy of high hopes:   
o “In gene therapy, a field so new it was a mere notion 20 years ago, 
scientists are still attempting to translate the promise of ideas to actual 
medications that can treat patients with deadly diseases. With gene 
 130  
therapy, scientists hope to one day edit the body's genetic code, stifling 
harmful genes and promoting useful ones.” (Los Angeles Times, 
05/23/1992) 
o “’It is counted among the most promising of all areas of medical research 
because, if it works as a general matter, there are few human diseases or 
disorders that could not use the therapy.’ In principle, the treatment uses 
healthy genes to counteract the effects of diseased ones.” (New York 
Times, 02/08/2000) 
o “Gene therapy is seen as one of the most promising fields of research in 
which scientists try to replace defective or missing genes that cause 
disease with healthy ones that treat or cure the disease.” (USA Today, 
03/08/2000) 
In passages like these, good vs. bad genes and promise-related/hopeful images reinforce 
each other, linking the purportedly inherent qualities of genes to hopes that gene therapy 
can control them. This relationship also contributes to themes of essentialism and high 
expectation within the larger gene therapy news media discourse. 
 
3. Mechanical and natural world-related 
 
Mechanical and natural world-related imagery co-occur quite frequently within 
the sample. In some accounts, they are used to convey similar messages about gene 
therapy; namely, that because genes are essentially and inherently responsible for disease, 
gene therapy technology is naturally appropriate for treating disease. In other cases, 
mechanical and natural world-related metaphors are set in opposition to one another. The 
mechanical metaphors emphasize the technical soundness of the technology, while the 
natural world-related metaphors highlight how challenging it has been to successfully use 
it to treat or cure disease.  
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o “Even in the midst of this work, however, researchers have been plagued 
by the nagging fear of too much success. What if the new genes worked 
too well, and could not be turned off?” (New York Times, 09/03/1996) 
o “Dark clouds have blown over the field in the past…But the ideal solution 
is to perfectly fix a genetic error without introducing any extra DNA, like 
the deft replacement of a spent battery in a car. (Los Angeles Times, 
11/12/2002) 
Images like these support an essentialist notion that disease is best treated by fixing the 
body’s broken parts (i.e., genes). They also imply that eventual success in the field is 
likely, provided periodic challenges can be overcome.   
 
4. Mechanical and combative 
 
 Co-occurrence of mechanical and combative imagery is also frequently present 
within the discourse studied. The “fixing” or “switching off” of diseased genes depicted 
in mechanical metaphors is often analogous to “attacking,” “disarming,” and similar 
combative metaphors. 
o “RNAi could…disarm an invading virus by knocking out its 
genes…RNAi, he said, ‘turns off the leak at the faucet.’” (New York 
Times, 09/14/2004) 
o “Gene therapy aims to attack disease at the most basic level 
…Researchers around the world are racing to insert new copies of missing 
or defective genes -- or to switch off the activity of harmful genes.” (Wall 
Street Journal, 12/02/1994) 
o “[S]cientists can develop ways to effectively and cheaply use human genes 
as medical science's ultimate fix-it kits…Even the acceptance of that 
notion, of addressing genetic flaws through gene-to-gene combat, is 
considered a biotech revolution.” (Los Angeles Times, 05/29/1991) 
Mechanical and combative images and metaphors promote a vision of the gene as 
something to be controlled or conquered and invest gene therapy with the power to do so. 
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This power is fortified through the use of dramatic, action-oriented metaphorical 
language. 
 
 
5. Mechanical and transportation-related 
  
  The mechanical and transportation-related subtypes co-occur often within the 
sample. Both subtypes include metaphors and images that relate human gene therapy to 
control or direction of the body. Further, they tend to focus on familiar objects and their 
parts and functions, thereby contributing to an objectified image of gene therapy 
technology and the conditions and patients it is intended to treat. In many cases, 
mechanical and transportation-related images overlap via the use of vehicle metaphors 
(such as gene therapy’s function as “changing a broken gasket on a car” or gene therapy 
delivery systems as “taxis” or “shuttles”). Metaphorical use of “landmark” or “milestone” 
also often co-occurred with mechanical imagery. For example, this passage uses the 
mechanically-oriented term “electric” within close proximity to the identification of a 
gene therapy “turning point” or “milestone”:  
The room was electric with excitement as the procedure, scheduled to take 
two hours, got under way. Dr. Kenneth Walsh, a molecular biologist who 
supervised the preparation of the DNA for the experiment, said he saw the 
moment as a turning point. "Every now and then you reach a milestone 
where things tomorrow are not going to be the same as today.” (New York 
Times, 12/13/1994) 
 
This type of reporting about gene therapy portrays the technology as both forward-
moving and emotionally charged, as a technology with an exciting future. At the same 
time, co-occurring transportation-related and mechanical metaphors are not exclusively 
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used to convey positive images of gene therapy. Some accounts focused on the 
challenges of “repairing” broken genes and also identified “roadblocks” to the 
technology’s successful application.  
 
 
6. Transportation-related and promise-related/hopeful 
 
 The co-occurrence of transportation-related and promise-related/hopeful imagery 
is also commonplace within the sampled media accounts. Transportation metaphors that 
emphasize forward motion or inevitability toward a given end (namely, the eventual 
success of gene therapy in treating disease) can frequently be found in the same articles 
that tout the promise of the technology or highlight hopeful perspectives. Metaphors such 
as “landmark,” “steps,” and “paving the way” suggest that gene therapy is a viable, if not 
inevitable, approach to creating disease. That the technology holds great promise and 
should inspire hope is highly compatible with this type of imagery. Transportation-related 
language is also sometimes used to emphasize the strength of the hope that has been 
placed in the technology: 
“Fulfilling hopes that had gathered locomotive force in the past several 
months, a 23-year-old man this weekend became the first patient to 
receive human gene therapy against cystic fibrosis…” (New York Times, 
04/20/1993) 
 
The repeated use of such imagery contributes to overarching themes of forward 
motion within gene therapy development, inevitability of the technology’s 
eventual success, and high expectations for the field.  
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7. Transportation-related and combative 
 
Transportation-related imagery is also often present in the same media accounts 
as combative imagery. Both of these imagery types are action-oriented, describing gene 
therapy in terms of movement toward the goal of disease treatment or eradication. 
Combative metaphors like “battling,” “attacking,” and “fighting” often co-occurred with 
vehicle and road metaphors: 
o “The technique…paves the way for a new approach to fighting 
cancer by harnessing - and boosting - the body's own immune 
system.” (Los Angeles Times, 09/01/2006) 
o “We're hoping this direct attack on the genetic structure can alter 
the course of the disease…But that's down the road.” (USA Today, 
08/12/1996) 
Such metaphors both invest gene therapy with the power to act decisively against 
disease and also suggest a level of inevitability to the forward movement of the 
technology. Vehicle metaphors in combination with images of weaponry or war 
convey a similar message: 
o “Adenovirus is a fine vehicle; it inserts new genes into many kinds 
of human cell, and the genes produce protein. But only for eight 
weeks or so. That is how long it takes for the body's immune 
system to identify and root out every Trojan horse cell…” (New 
York Times, 02/23/1999) 
o “But that delivery vehicle contains some genes of its own that 
trigger immune responses in the patient.” (USA Today, 
06/10/1999) 
o “These crippled viruses are about to be enlisted in humankind's 
war against brain cancer, inherited diseases, heart attacks and a 
host of other life-threatening and vexing ailments…[Scientists] 
hope to use the virus[es] to ferry disease-fighting genes into 
regions of the human body generally inaccessible to modern 
medicines.” (Wall Street Journal, 01/18/1994) 
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8. Transportation-related and natural world-related 
 
 Transportation-related images often also co-occur with natural world-related 
metaphors. Together, such images strongly emphasize a presumed forward movement 
and the inevitable or meant-to-be nature of gene therapy as a method of treating disease. 
o "’It is definitely the wave of the future.’ But, he added: ‘It's a little bit like 
the first car or the first airplane. There is a long way to go before it 
becomes standard therapy.’” (New York Times, 08/09/1994) 
o “For scientists, and possibly for all humanity, a watershed event is about 
to take place…[R]esearchers at the National Institutes of Health are ready 
to take the big step: within the next two months they will perform the first 
authorized gene transplants into humans.” (Time, 02/13/1989) 
Natural world-related images in and of themselves (especially those that evoke visions of 
sweeping motion or powerful natural forces) contribute greatly to a fatalistic or 
deterministic portrayal of human gene therapy; when paired with transportation-related 
images, they do so with even greater intensity. 
 
 
9. Transportation-related and sports-related 
 
Another frequently co-occurring pair consists of the transportation-related and 
sports-related types. These types commonly overlap by way of the metaphor of a “race,” 
which is used to describe a sense of urgency (attributed to scientists and commercial 
entities alike) for gene therapy to achieve clinical success. The “race” metaphor not only 
highlights the forward motion and pace of gene therapy development, but it also suggests 
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that a positive, victorious outcome will eventually be realized (even if obstacles or 
setbacks are experienced along the way).  
o “While some teams race to harness useful genes, others are working to 
handcuff harmful ones.” (Newsweek, 04/10/2000) 
o “Gene Therapy Race is just Barely Out of the Starting Blocks” (Los 
Angeles Times, 02/12/2001) 
o  “Researchers around the world are racing to insert new copies of missing 
or defective genes -- or to switch off the activity of harmful genes.” (Wall 
Street Journal, 12/02/1994) 
Sports and transportation-related images also often co-occur through the use of delivery 
vehicle and target/hurdle/obstacle metaphors. These co-occurrences demonstrate the 
acknowledgment of challenges to gene therapy development within the discourse. At the 
same time, they imply (like the “race” metaphor) the deterministic notion that gene 
therapy researchers will one day achieve success, once they perfect their delivery 
vehicles and learn how to overcome obstacles. 
o “Scientists now think they can surmount some of the obstacles 
surrounding gene therapy. They've created specially modified viruses that 
can shuttle genes to the proper place in the body…researchers have 
created customized gene carriers that home in on different parts of the 
body.” (Los Angeles Times, 04/24/2006) 
o “A treatment of great promise, gene therapy, has long been stalled by the 
lack of suitable vehicles to get genes into human cells and maintain them 
in working order. But that obstacle could dissolve if a strange new 
biological invention works as well as its makers hope.” (New York Times, 
04/01/1997) 
 
 
 
10. Natural world-related and numinous 
 
Natural world-related and numinous images also co-occur frequently in the 
sample. These images emphasize the essential qualities of genes and gene therapy. Both 
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also often include dramatic or emotionally charged language, which contribute to the 
elevation of gene therapy beyond the mundane and into a more sacred space. Such 
elevation does not mean that natural world-related and numinous images are only used in 
presenting gene therapy in a positive light.  Co-occurrences of these images are also 
present in discussions of gene therapy challenges and setbacks.  
o “After 10 years of research on more than 4,000 subjects, gene therapy 
researchers may finally have reached their Holy Grail - curing a patient 
with a genetic disease… The achievement was good news for gene 
therapy researchers, who have been laboring under the shadow of the 
treatment-related death of 18-year-old Jesse Gelsinger.” (Los Angeles 
Times, 04/28/2000) 
o “For years, gene therapy was heralded as a technology that would soon 
yield blockbuster drug innovations...Reaping the fruits of such 
technological advances is taking much longer than executives in 
biotechnology and pharmaceuticals once suggested. As a result, the 
industries are suffering a drought of new products.” (New York Times, 
03/03/2005) 
Regardless of the tone of the message in which they are included, these types of images 
invest gene therapy with mystical, elemental significance. 
 
 
11. Natural world-related and pioneering 
 
Co-occurrences of natural world-related and pioneering images are common as 
well, which is unsurprising since pioneering is, linguistically, so strongly linked to nature 
(often in terms of conquering it). In some cases in which the two types occur together, 
they reference gene therapy’s forward movement and imply eventual success for the 
field: 
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o “The experimental hemophilia treatments represent a new wave of gene-
therapy approaches being developed for a number of 
diseases…Researchers are applying lessons learned from pioneering, 
largely unsuccessful gene-therapy trials that took place earlier this 
decade.” (Los Angeles Times, 06/28/1999) 
o “[I]t was a breakthrough to show that genes could be added to the body -- 
and in the wake of that pioneering experiment, more than 450 gene 
therapy tests were launched, involving 4,000 volunteers.” (Los Angeles 
Times, 08/28/2006) 
In doing so, this pair provides another example of imagery taking a deterministic turn 
within the discourse sampled. 
 
 
12. Natural world-related and promise-related/hopeful 
 
Natural world-related images also share media space with images of promise and 
hope. In general, natural world-related images are used to describe (often with drama or 
intensity) the (usually high) level of promise gene therapy is perceived to hold. In other 
cases, this is moderated by acknowledgments of hopes that are too high or promises not 
yet met.  
o “For the first time, researchers have used gene therapy to increase light 
sensitivity and improve vision in patients who were virtually blind, a 
finding that offers new hope to hundreds of thousands of patients…’This 
has changed the landscape of hope for patients.’” (Los Angeles Times, 
04/28/2008) 
o “Study lifts cloud over promising genetic therapy.” (Reuters, 09/26/2007) 
o “In those days, the idea that diseases could be treated, or even cured, by 
infusing patients with healthy DNA was the bright light of medicine, 
offering hope to patients and the promise of profits to investors. But the 
light has dimmed considerably.” (New York Times, 12/12/1999) 
o “The Gelsinger case has called much needed attention to the dark side of 
gene therapy, which - no less than other experimental treatments - has the 
power to harm as well as help…’ "I realize it holds so much promise for 
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so many people. But we cannot allow what happened to Jesse to happen 
again.’” (Time, 02/14/2000) 
The metaphorical use of terms like “cloud,” “darkness,” and light, in conjunction with 
images of hope and promise, elevate the discussion of gene therapy beyond its technical 
details and capabilities to some extent. 
 
 
13. Natural world-related and sports-related 
 
Natural world-related imagery also co-occurs often with sports-related imagery. 
When appearing together, these types often share an emphasis on gene therapy’s ability 
to control genes and conquer disease. Genes and the body are portrayed as difficult to 
subdue, challenges to gene therapy’s development are described with metaphors like 
“hurdle” or “plague,” and the technology’s successes (potential or realized) are 
characterized as victories or moments of “light” or “air.”   
o “Though there are reasons to be optimistic that this new technology will 
lead to powerful and nontoxic new treatments, there are many obstacles to 
overcome... Eventually, gene therapy may be used to express microRNAs 
throughout a patient's life, but gene therapy has been plagued by 
difficulties.” (Newsweek, 06/10/2005) 
o “Nevertheless, experts who cited the new results and previous work in 
animals said the finding held out a real ray of hope…’It is encouraging to 
see that there are some real possibilities here, but there are a lot of hurdles 
ahead.’” (New York Times, 06/03/1990) 
o “[Scientists] called it ‘a breath of fresh air’ given current criticism of gene 
therapy. But they stressed that many hurdles must be cleared before any 
gene-therapy strategies become available to patients.” (Wall Street 
Journal, 08/29/2000) 
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Through images like these, themes of forward-movement, power, and presumed eventual 
success within human gene therapy are conveyed. 
 
 
Finding 3 
 
(Research Question 2: What sorts of narratives are formed through the use of these 
images and metaphors?) 
 
 The types and subtypes illustrated in Finding 1 and the themes that emerge 
from their co-occurrences contribute to four primary narratives within the media 
discourse surrounding human gene therapy. The narratives are, again, as follows: 
 
1. Essentialist 
2. Fatalistic 
3. Expectant 
4. Conflictive 
These four narrative categories represent the principal ways in which the media content 
in the sample tends to discuss gene therapy. The images and metaphors (and their types 
and subtypes) detailed in Chapter 4 and the subtype co-occurrences discussed above both 
construct and are constructed by these narratives. They are, in a sense, stories about the 
field and technology, and the many varied images and metaphors discussed previously 
are the language with which these stories are told.  Like Goffman’s frame and Gamson 
and Modigliani’s package, each narrative expresses a way of thinking and talking about 
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gene therapy, as well as a way of interpreting its (past, present, and future) applications.  
Further, each narrative not only conveys predominant meanings and perceptions of the 
technology, but it also possesses the power to shape them.  Articulating these narratives, 
therefore, helps to paint a clearer and more vivid portrait of the technology than the 
preceding detailed discussion of imagery can provide on its own. Within this sample, the 
narratives that have emerged (perhaps more than most frames or packages) have dramatic 
storylines, full of magic, tragedy, symbolism, and prognostication. This is true not only 
because of the life and death issues with which gene therapy is intertwined, but also 
because of the extensive use of metaphor within the media content studied. The narratives 
are, admittedly, presented below in a sometimes theatrical way and often include 
metaphors borrowed from or suggestive of the imagery in the sample. They are a 
deliberate attempt to portray the often dramatic sensibilities that come to the forefront 
when closely examining the sample.  When summarized and distilled, the media imagery 
of human gene therapy tells an intense story. 
 
 Essentialist narrative 
 The essentialist narrative tells the story of genes as the essence of life, health, and 
identity. The individual’s genetic make-up determines his/her propensity to contract a 
wide variety of inherited and noninherited diseases and plays a significant role in 
determining health status. In this narrative, health and disease are located at the level of 
the gene, and, consequently, so is medical care. Gene therapy, therefore, becomes the 
health intervention of choice, since it alone can speak directly to genetics-based 
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conditions. Because it defines and controls health and disease, the gene is suffused with 
numinous and magical powers. It is our most crucial biological component and also holds 
within it the blueprint or script to our future. It also can be inherently good or inherently 
bad – good genes should be cherished and preserved, and bad genes should be repaired or 
replaced. Because the gene is so fundamentally important, gene therapy, too, is highly 
valuable, almost sacred. Its technology is worthy of praise and adoration, and it may be 
the miracle cure for many diseases, from inherited genetic disorders to scourges like 
cancer and AIDS. Although it may be tempting to misuse gene therapy, the field’s 
potential to save humanity from suffering and disease is too powerful to ignore. Overall, 
the essentialist narrative tells the story of gene therapy as a sacred technology that is or 
will be able to fix defective genes and restore human health.   
 
 Fatalistic narrative 
 In the fatalistic narrative, inevitability and forward motion are the rule. The 
genetic make-up with which each individual is endowed at birth helps to determine health 
outcomes. If left alone, defective genetic endowments can lead to a wide variety of 
diseases.  However, gene therapy, in its ability to modify, repair, or replace defective 
genes, may be able to reverse humans’ genetic destinies. In fact, gene therapy has a 
certain inevitability of its own. It is part of a natural progression of scientific and 
technical knowledge; we’ve cracked the genetic code; now it’s time to figure out how to 
fix the bugs. The gene therapy field is moving forward, getting ever closer to developing 
effective medical treatments. It certainly has met (and will likely continue to meet) many 
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roadblocks along the way, yet it journeys onward, edging ever closer to eventual success. 
The pioneering researchers working within the field have made many groundbreaking 
discoveries, each bringing the field one step closer to conquering disease. The main 
theme of the fatalistic story, therefore, is that of gene therapy as a natural scientific and 
technological response to genetically-based disease, one that is continually moving 
forward toward its destined end – a diverse array of effective medical treatments.  
 
 Expectant narrative 
 The expectant narrative tells a story of great hope in the promises of gene therapy 
technology. In this story, gene therapy has the potential to treat myriad disorders and 
conditions, and it seems only a matter of time until that potential is met. Sadly, however, 
a number of tragic events (including death and disease purportedly caused by gene 
therapy) have occurred, threatening the very future of the field.  Despite being clinically 
applied in humans for over two decades, few of gene therapy’s many promises have been 
realized. Could all of these promises be nothing but hype? Doubt and uncertainty seem 
difficult to avoid when so little progress has been made. Nonetheless, the expectant story 
remains, at its heart, one of hope. With more genetic bases for so many diseases being 
found every day, how can gene therapy not be a viable treatment, if not cure? Some warn 
about the dangers of too much hope – such cures may not be as close as has been wished 
for or expected. Still, hope endures, ever buoyed by announcements of new 
breakthroughs and new potential applications. Thus the expectant narrative is a story of 
high hopes and renewing promise, while also a story of failure and misfortune.  
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 Conflictive narrative 
 In the conflictive narrative, the story takes place in two dramatic settings – the 
battlefield and the sporting venue. In each, gene therapy is portrayed as the (real or 
potential) conquering hero. On the battlefield, the enemies are disease and defective 
genes. Using a variety of weapons and strategies, gene therapy strives to at least disable 
and ideally kill the enemy. Admittedly, some collateral damage has occurred during this 
effort, and the field has been dealt a number of blows over the years. However, gene 
therapy soldiers on and continues to enlist support (in terms of researcher interest, 
funding, and clinical trial participation). In the sports-related setting, gene therapy is in a 
race against the clock, seemingly unable (but always trying) to keep pace with patient 
needs, scientific aspirations, and commercial expectations. Technical and regulatory 
hurdles abound, but the technology’s advocates seem determined to push forward toward 
the finish line. The conflictive narrative uses a great deal of vivid imagery to tell the story 
of gene therapy’s varied, numerous, and continuing attempts to defeat disease.  
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Chapter 6 
Findings – Tone and Landmark Moments 
 
Finding 4 
(Research Question 3: How can the tone of the media discourse about human gene 
therapy be characterized?) 
As previously stated, tone (in the context of this study) refers to a quality that 
suggests a set of prevailing attitudes toward an entity or phenomenon. Three predominant 
tones were identified within the human gene therapy discourse studied: 
1. Optimistic  
2. Disappointed  
3. Cautionary 
These tones occur frequently throughout all sources sampled. The optimistic tone is 
predominant, but not to the exclusion of the two other tones. The significant presence of 
tone that is not purely positive suggests that gene therapy media coverage may not be 
overwhelmed by “hype” or “overselling” of the technology and field (contrary to 
numerous scholarly assertions [Young and Mautner, 2001; Stockdale, 1999; Nelkin, 
1996; Orkin and Motulsky, 1995]).  To be sure, positive characterizations occur very 
frequently, and the primary narratives identified within the sample include a great deal of 
optimistic imagery. However, the media coverage studied presents relatively balanced 
reporting about the technology. While many accounts herald the wonders of gene 
therapy, many others noted its lack of success (and many accounts did both). In fact, it is 
often difficult to discern a primary tone within many of the accounts, since they either 
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attend to both the “promise and pitfalls” of the technology or remain tonally neutral. The 
three types of tone will be examined in greater detail (using articles’ headlines as concise 
and generally accurate representations of their tone). Consideration of tone helps to 
supplement the highly distilled data presented through images, metaphors, and narratives, 
because it speaks instead to the general orientation of the media accounts studied.    
 
 Optimistic tone 
 Media content that takes an optimistic tone depicts human gene therapy as a field 
and technology with vast potential.  It recounts encouraging developments within the 
field and suggests that major breakthroughs have occurred or are imminent. It praises the 
advanced techniques of gene therapy and often identifies the field as the best hope for 
treating or curing a variety of diseases. The contexts that feature this tone range from the 
earliest stages of exploratory research to reporting of long-term clinical trial results. This 
tone has been prevalent since 1989 and remains so in 2011.  A brief look at some of the 
headlines of articles that take an optimistic tone illustrates these points: 
- Amazing' New Gene Therapy Destroys Leukemia In 3 Patients (Huffington Post, 
08/10/2011) 
 
- Targeted Gene Therapy May Offer Hope Against Melanoma (ABCNews.com, 
08/26/2010) 
 
- Gene Therapy Aids Vision for 3 with Rare Blindness (CNN.com, 11/20/2008) 
 
- Scientists Discover Gene Therapy for Depression (Fox News, 12/29/2006) 
 
- Gene Therapy Appears to Relieve Parkinson's Symptoms (USA 
Today, 12/20/2005) 
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- Gene-Therapy Tests Show Positive Results, GenVec Says (Washington 
Post, 11/21/2002) 
 
- *Gene Therapy* May Make Radiotherapy More Effective (The Economist, 
07/20/2002) 
 
- At Long Last, Gene Therapy (New York Times, 04/30/2000) 
 
- Kids Could Benefit from Gene Therapy (USA Today, 07/26/1990) 
 
- New Era of Gene Therapy Begins; Experiment Opens the Door to Treating a 
Wide Range of Diseases (Washington Post, 05/30/1989) 
 
Disappointed tone 
 The disappointed tone is typically conveyed through discussion about gene 
therapy’s failure to live up to expectations or slow progress in developing viable 
treatments or cures. Poor clinical trial results or detrimental side effects are also part of 
this tone. Most accounts that take a disappointed tone state or imply that hopes or 
expectations for gene therapy have been high. Given such high expectations, anything but 
clear success could be interpreted as a letdown. However, the disappointed tone occurs 
much less often than the optimistic tone, despite very few instances of success in the field 
since its 1989 inception. (It should be noted that references to disappointment do occur 
quite frequently; however, these references are more likely to be located within accounts 
that take a generally optimistic tone or have no strong element of tone.) 
- Mom's Death Casts Pall on Gene Therapy Study; Young Woman's Rapid Decline 
is a Mystery; Federal Officials are Investigating. She Fell Ill One Day After an 
Experimental Injection (Los Angeles Times, 09/16/2007)  
 
- Gene Therapy's Slow Path (USA Today, 04/05/2005) 
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- Why Gene Therapy Still Hasn't Produced Major Breakthroughs (Wall Street 
Journal, 02/18/2005) 
 
- Benefits of Gene-Based Heart Therapy in Doubt (Wall Street Journal, 
03/13/2000) 
 
- A Promising Experiment Ends in Tragedy (U.S. News & World 
Report, 10/11/1999) 
 
- Gene Therapy 'Oversold' By Researchers, Journalists; NIH Advisers Cite Nearly 
Uniform Failure (Washington Post, 12/08/1995) 
 
 
Cautionary tone 
The cautionary tone suggests that gene therapy in general or certain applications 
of gene therapy in particular are dangerous, too risky, or may have concerning 
unintended consequences. It tends to occur within media accounts that discuss halted 
clinical trials, the discovery of negative side effects, or the airing of ethical hesitations. 
As is true for the disappointed tone, moments of cautionary tone also sometimes occur 
within coverage that has an overall optimistic tone. This seems to happen less frequently, 
however, than is true for the disappointed tone. 
- FDA Halts Study After Death (Wall Street Journal, 07/27/2007) 
- F.D.A. Halts 27 Gene Therapy Trials After Illness (New York Times, 01/15/2003) 
- 2 Gene Therapy Studies Halted; AIDS, Hepatitis Virus Contamination of 
Engineered Cells Feared (Washington Post, 03/09/2000) 
 
- Study Finds Risks to Patients in Drug Trials (New York Times, 05/30/1998)  
- Ethicists Wary Over New Gene Technique's Consequences (New York Times, 
11/22/1994) 
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- Ethical Pitfalls Await World of Gene Therapy (USA Today, 05/22/1991) 
 
Finding 5 
(Research Question 4: How, if at all, do the images/metaphors/narratives/tones change 
over time?) 
 
The images, metaphors, narratives, and tones identified within the sample did not 
appear to change meaningfully over time. In general, they appeared with relative 
consistency throughout the entire date range sampled (and across types of sources [i.e., 
newspapers, magazines, and online news sources]). Given the very limited success and 
many failures experienced by the human gene therapy field in the decades following its 
first clinical trial in 1990, it seems reasonable to imagine that as the years progressed, the 
tones would have reflected growing frustration and disappointment with the field. Such a 
supposition is not supported by the data. Further, time has not observably affected the 
larger stories being told about gene therapy; the narratives and corresponding images and 
metaphors have not shifted much, despite how strongly hope, expectation, and forward 
motion figure into them. 
 Few accounts with primarily disappointed or cautionary tones can be found in 
recent years (2007 to the present), but since far fewer accounts about gene therapy have 
appeared in major news publications in general in that time period, it is inappropriate to 
assign too much meaning to this change.  Since 2007, most gene therapy media accounts 
are hopeful or optimistic and focus on reports of “promising research” in a variety of 
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areas of medical application (e.g., “'Amazing' New Gene Therapy Destroys Leukemia In 
3 Patients,” Huffington Post, 08/10/2011; “Gene-Therapy Trial Offers Parkinson's 
Patients New Hope,” ABCNews.com, 03/17/2011; “Scientists Look to Cure HIV With 
Gene Therapy,” Fox News, 02/28/2011; “Study points to possible gene therapy for 
depression,” Reuters, 10/20/2010).  
The other type of media coverage that appears commonly in recent years is 
theoretical imaginings about the possibilities of gene therapy technology (for medicine, 
but also for other areas, such as “gene doping,” which would entail athletes using gene 
therapy techniques for performance enhancement). These accounts often have 
sensationalistic titles like “Gene doping: Genetically Modified Olympians?” (The 
Economist, 08/02/2008), “Glow-In-The- Dark Cats Could Help Fight Against Aids,” 
(Huffington Post, 09/12/2011), or “What Will Human Beings Become?” (U.S. News and 
World Report, 08/04/2008). Both of these types of articles would have seemed quite at 
home in 1989.  
Those patterns and changes that do exist seem to be less related to the passage of 
time (i.e., the more years that gene therapy has failed to realize its original promise) and 
more related to major events that have taken place within the field, as is discussed in 
Finding 6 below.  
 
Finding 6 
 
(Research Question 5: How, if at all, do these elements change in relationship to 
publicized successes or failures in the application of human gene therapy?) 
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 Although a significant change in the imagery, narratives, and tone of the gene 
therapy discourse studied over time was not observed, some changes did seem to occur in 
relationship to publicized successes and failures within the field. Several of the six 
landmark moments identified in Chapter 3 did seem to contribute to some extent to the 
relative emphasis or de-emphasis of certain ways of talking about gene therapy. While 
these moments did not lead to the complete silencing of alternate voices, they did seem to 
(at least temporarily) affect the focus and content of the discourse. Changes were not 
dramatic but do suggest that the discourse was sometimes responsive to landmarks within 
the technology’s development (and did not present an entirely static portrayal of the gene 
therapy field, regardless of what took place within it). By looking at trends within the 
sample in the three month periods preceding and following these noteworthy events, 
several types of change were identified.  
 Moment 1 (September 14, 1990 – the first instance of a clinical trial 
participant in the United States being treated for a genetic disease by human 
gene therapy.) 
 Moment 2 (September 17, 1999 – the death of clinical trial participant Jesse 
Gelsinger.) 
 Moment 3 (April 27, 2000 – the announcement of success in treating SCID.) 
 Moment 4 (January 15, 2003 – the announcement that several pediatric SCID 
clinical trial participants developed leukemia as a gene therapy side effect.) 
 Moment 5 (July 24, 2007 – the death of clinical trial participant Jolee Mohr.) 
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 Moment 6 (May 7, 2009 – Targeted Genetics, one of the leading human gene 
therapy companies, reveals it is near bankruptcy.)  
Moments after which there was a change in imagery, narratives, or tone: 2, 3, 
4, 5 
Moments after which there was no noticeable change – 1, 6 
 
Moment 1 – No significant changes seemed to occur in the imagery/narratives/tone after 
reports of the first clinical trial participant in the United States being treated for a genetic 
disease by human gene therapy. Since the first instance of gene transfer in 1989, the 
promises of gene therapy were being covered quite frequently within the mainstream 
media sampled, and this optimistic, expectant imagery continued after the first patient 
was treated. Roughly the same amount of cautionary tone seemed present before and after 
this moment as well (based mostly on ethical and social concerns about both gene therapy 
in particular and genetics technologies in general).   
 
Moment 2 – This moment represents the first known death of a gene therapy clinical trial 
participant – an 18-year-old volunteer named Jesse Gelsinger. In the months (and years) 
preceding his death, reporting about gene therapy in the mainstream media had slowed. 
When Gelsinger’s death was announced, however, most of the major news outlets 
sampled published stories (with varying promptness), many of them fairly lengthy and 
quite detailed. Interviews with scientists (both those involved directly with the clinical 
trial and those with general expertise in gene therapy) and with Jesse’s grieving father 
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were often quoted. The tone varies in these accounts, although most stories take at least a 
partial cautionary tone. Many articles reference the FDA’s decision to “halt” or 
“suspend” gene therapy trials until the circumstances surrounding Gelsinger’s death were 
better understood. Comparing his death to the transportation/forward progress-related 
term “setback” is very common, sometimes with intensifying modifiers (e.g., “severe 
setback” [New York Times, 09/29/1999]). Other dramatic images are used to describe the 
tragedy’s presumed impact on the field, such as “perilous time for gene therapy” (New 
York Times, 11/28/1999) and “the whole gene-therapy field is ‘in shock’” (Wall Street 
Journal, 10/11/99). The combative image of “killing” also appears frequently, with the 
gene therapy technology or the clinical trial as the perpetrator and Gelsinger as the 
victim: “[Gelsinger] became the first person killed by gene therapy” (New York Times, 
12/11/1999); “[He] was killed by the procedure” (USA Today, 12/02/1999).   
 Despite the prevalence of cautionary tone and vivid negative imagery, many 
accounts at least reference some optimistic or expectant imagery, suggesting that “not all 
the headlines have been gloomy” (New York Times, 12/12/1999) or maintaining that the 
field is still “promising” (Time, 10/11/99). This type of imagery lends to a construction of 
Gelsinger’s death as an isolated incident rather than an indictment of the gene therapy 
field as a whole. The potential influence of this construction upon media coverage seems 
supported by the fact that even in the three months immediately following Gelsinger’s 
death, new reports of other possible applications of gene therapy were published. 
(“Experimental Gene Therapy Vaccine Gets Response in some Prostate Cancer Cases” 
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[Los Angeles Times, 10/21/1999]; “A Boost for Bypass; Therapy Aims to Improve 
Survival” [Washington Post, 10/12/1999]) 
 
Moment 3 - This moment refers to the announcement that several young patients with the 
genetic disorder severe combined immunodeficiency (SCID), also known popularly as 
“bubble boy disease,” had apparently been cured by treatments they received as 
participants in a gene therapy clinical trial. This finding resulted in a noticeable increase 
in coverage of human gene therapy in the mainstream media sources sampled. Within this 
coverage, optimistic tone and positive imagery (often of the essentialist, fatalistic, or 
conflictive types) became more common than they had been in preceding months 
(especially in light of the fact that the death of Jesse Gelsinger was still being discussed 
in many gene therapy-related stories in early 2000). Headlines such as “Success in Gene 
Therapy, at Last” (New York Times, 04/30/2000) suggested that finally the optimism and 
expectation that had been persisting for years may have been proven worthwhile. 
Accounts noted that gene therapy scientists “may finally have reached their Holy Grail” 
(Los Angeles Times, 04/28/2000) and “score[d] a gene-therapy triumph” (Time, 
05/08/2000). The success in treating SCID was identified as a “medical miracle,” a “very 
important milestone” and a “major step” (New York Times, 04/30/2000; Wall Street 
Journal, 04/28/2000; Los Angeles Times, 04/28/2000). As demonstrated by such imagery, 
a tone of optimism did appear to become more common. Nonetheless, many accounts did 
emphasize that results were preliminary or included statements from scientists that 
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suggested these results should not be interpreted as a sign that many more gene therapy 
successes were imminent. 
 
Moment 4 – This moment occurred in when news outlets reported that several pediatric 
SCID clinical trial participants had developed a serious leukemia-like disease as a gene 
therapy side effect. Although gene therapy was being covered much less by the 
mainstream press than had been true in late 1999 and early 2000, this event did seem to 
increase the level of coverage. Most reports had a predominantly cautionary tone, 
focusing (as was the case for Moment 2) on how other gene therapy trials were being 
“halted” or “suspended” in reaction to the reported side effect. Headlines such as “A 
Treatment Gone Wrong” (U.S. News and World Report, 01/27/2003) and “Gene Therapy 
Debacle Casts Pall on Field” (Washington Post, 02/28/2003) demonstrate that accounts 
with a disappointed tone also appeared frequently. This disappointment – seemingly 
expressed more often than was the case after Gelsinger’s death – may have reflected a 
growing (public and/or media) acknowledgment that gene therapy was both creating a 
mounting toll of troubling unintended consequences and also failing to advance as 
quickly as expected. Indeed, this disappointment may have been even more acutely felt in 
light of the fact that the leukemia side effect was experienced by patients with the one 
disease gene therapy had hitherto proven useful in treating – SCID. As expressed in a 
New York Times “Quotation of the Day,” “The exciting thing was that it was working. 
The horrible thing is that a shadow has been cast over that success” (01/15/2003). 
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Many metaphors identifying the patients’ leukemia as an obstacle to the 
development of the field were used (e.g., “setback,” “shadow cast,” “bump in the road,” 
“blow to the field”). However, there was still a strong element of (and no apparent 
reduction in, compared to the preceding months) expectant imagery. Images included 
assurances that “Gene Therapy Has Vast Potential Despite Setbacks,” and that the “Push 
[is still] on with Human Trials” (Los Angeles Times, 02/18/2003). The prevalence of this 
imagery was greater in this case than with the death of Jesse Gelsinger (Moment 2); this 
may be because the patients in this case were still alive (and suggested in some accounts 
to be responding favorably to chemotherapy).  
 
Moment 5 – This moment refers to the death of gene therapy clinical trial participant 
Jolee Mohr. Like the other two aforementioned moments that relate to tragic unintended 
consequences of gene therapy, Mohr’s death resulted in an increase of articles with a 
cautionary tone. Headlines such as “Mom's Death Casts Pall on Gene Therapy Study; 
Young Woman's Rapid Decline is a Mystery” (Los Angeles Times, 09/16/2007) and 
“Death in Gene Therapy Treatment Is Still Unexplained” (New York Times, 09/18/2007) 
typify the way in which this incident was covered in the press. However, it is worth 
noting that Mohr’s death was not even reported by the majority of the sources sampled. 
Further, far fewer media accounts about gene therapy in general were being published 
around this time (as mentioned in reference to Finding 4). Therefore, while this moment 
did bring about more cautionary reporting about gene therapy, its impact may not have 
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been as greatly felt as that of previous moments, simply because it (and gene therapy as a 
field) was rarely “making the news” in 2007.  
 
Moment 6 – Not only did this moment not bring about noticeable change in the imagery, 
narratives, or tones of gene therapy media coverage, but it did not even appear in the 
news media sampled. Although the fact that one of the consistently most influential gene 
therapy companies was in financial distress came to my attention in my study of the gene 
therapy field, it was apparently not considered newsworthy by the mainstream media 
sources I chose to examine. This may in part relate to the overall decrease in coverage 
about human gene therapy (again, see Finding 4). It also may suggest that when a highly 
anticipated medical technology fails to achieve real success over time, it is less 
interesting to the news media (and perhaps to the scientists who inform that media) to 
report on its incremental achievements, whether positive or negative. Only the more 
theoretical, expectant, or hopeful stories, similar to those that were common in the 
earliest days of human gene therapy, may seem worth covering.  
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Chapter 7 
 
Analysis and Interpretation of Findings 
 
 
Introduction 
 
The purpose of this study was to explore how human gene therapy has been 
presented in the mainstream media over the past 20 years. The study aimed to use the 
insights and approaches of the sociology of technology to better understand the “public 
face” of human gene therapy. Without attempting to ascertain the intentions of either the 
sources or disseminators of media coverage about gene therapy, I intended to summarize 
and analyze the various human gene therapy narratives that have emerged. 
I examined media coverage of human gene therapy from 1989 to 2011, focusing 
on 15 mainstream U.S. newspapers, news magazines, and online news sites. By 
conducting a qualitative content analysis that employs a constant comparative method 
and uses the computer-assisted qualitative data analysis software HyperRESEARCH, I 
coded and analyzed images and metaphors about human gene therapy while continually 
redefining and updating my coding categories throughout the data collection and analysis 
process. I also identified four thematic narratives about the technology. Patterns and 
changes over time – especially in relationship to six well-publicized moments within the 
field’s history – were assessed.  
My study was based on the following five research questions: 
1. What types of images and metaphors are used to represent human gene 
therapy? 
2. What sorts of narratives are formed through the use of these images and 
metaphors? 
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3. How can the tone of the media discourse about human gene therapy be 
characterized? 
4. How, if at all, do the images/metaphors/narratives/tones change over time? 
5. How, if at all, do these elements change in relationship to publicized 
successes or failures in the application of human gene therapy? 
The results of the investigation of these questions are presented in Chapters 4 
through 6. I identified four main types of images and metaphors found within the sample: 
essentialist, fatalistic, expectant, and conflictive. Each of these types was composed of a 
number of subtypes, each of which more specifically describes the identified images and 
metaphors. Co-occurrences of these sub-types were examined. The main types also 
represent the four primary narratives that emerged from the data. Three primary tones – 
optimistic, disappointed, and cautionary – were most prevalent with the sampled media 
accounts. No significant changes in the images, metaphors, narratives, and tones were 
identified over time. However, some changes were noted in relation to four of the six 
landmark moments that occurred within the field’s history.   
This chapter presents my analysis and interpretation of these findings. It is 
organized according to the following three analytic categories, which correspond to the 
research questions as noted. 
- Analytic Category 1 –  Predominant images, metaphors, and narratives about 
human gene therapy (Research Questions 1 and 2) 
- Analytic Category 2 – Predominant tone of human gene therapy discourse 
(Research Question 3) 
- Analytic Category 3 –  Changes and patterns in human gene therapy discourse 
(Research Questions 4 and 5) 
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Analytic Category 1: Predominant images, metaphors, and narratives about human 
gene therapy  
 
Essentialist images, metaphors, and narrative 
 
Essentialist images and metaphors were some of the most widely used and vividly 
expressed, and the essentialist narrative was present to some degree in many of the media 
accounts studied. The central theme of this type is that human gene therapy is deeply 
relevant to the essence of human life, in that it not only involves the elemental, sacred 
gene but also may have the capability of modifying the gene. Within this narrative, the 
gene is invested with great significance as the location of the human essence or “soul.” It 
contains the “code,” “script,” or “blueprint” to our medical destiny, is the location and 
point of origin of disease, and is the most important component part of our bodily 
“machinery.” As such, the gene is a crucial determinant of the human body, self, and 
identity. With all this being true of the gene, genetics technologies are therefore 
profoundly important and may have great influence upon all levels of human experience.  
This essentialist theme is commonplace within media portrayals of genetics, so 
the identification of this narrative within my sample is unsurprising.  Many previous 
studies have noted the prevalence of essentialism, referring to it variously as “genetic 
essentialism,” “genetic determinism,” and “molecular vision,” among other 
characterizations. (Nelkin and Lindee, 1995; Conrad, 1999; Anker and Nelkin, 2004). 
Most recently, one of the most popular labels to apply to this theme is geneticization, 
which offers genetics as an explanatory force for most everything – including disease. 
The findings about human gene therapy media coverage discovered herein support the 
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notion that essentialist or geneticized representations of genetics technologies are 
enduringly present within the public discourse. 
 
1. Numinous 
Among the most prevalent of the essentialist images found within the sample are 
those that suggest the numinous (i.e., spiritual, religious, divine, magical, or 
otherworldly). Such imagery has often been found within sociological studies of genetics 
technologies and seems likely to continue to appear (Anderson, 2002; Liakopoulos, 2002; 
Nelkin and Lindee, 1995). Since its inception, genetics has been bound up with sacred 
thoughts and imagery. From the earliest days of genetics discovery, an image of genetic 
material as having qualities that surpass human understanding or evoke the divine has 
proliferated. As artist Salvador Dali famously stated, “And now the announcement of 
Watson and Crick about DNA. This was for me the real proof of the existence of God” 
(Crick, 1967, p. 1). The symbolism of genetic science has long been elevated to a level of 
sanctity typically reserved for religious icons, and scientists have been anointed as more 
than just experts, but as the keepers of divine wisdom: “’The double helix has replaced 
the cross in the biological analphabet’… DNA spelled God, and the scientists’ knowledge 
of DNA was a mark of their divinity” (Noble, 1997, p. 181). Genes, in their apparent 
possession of the secrets of life, quickly were assigned the status of magical, mysterious, 
and holy – all the more so because they are so out of reach of everyone but the most 
educated and distinguished experts. This distinction is very important to understanding 
why the gene has been set apart and exalted to such a great extent; the further something 
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is removed from the (physical and intellectual) grasp of the average individual, the more 
it is driven into the realm of the sacred or supernatural.  
In light of all of this about the gene, it is no wonder that gene therapy has been 
elevated to the sacred level. Gene therapy is a way of altering God’s handiwork, of 
performing magic on the mystical, of transcending the limitations of genetics. Within the 
rhetorical world of gene as essence, soul, and pathway to God, gene therapy is no less 
than the possibility of salvation. As with the gene, the separation of gene therapy 
technology from the capabilities of the typical individual further removes it from the 
earthly realm. As Clarke writes, “Any sufficiently advanced technology is 
indistinguishable from magic” (1973, p. 21). Gene therapy is surrounded by a particularly 
strong aura of magic because, as Pfohl writes, “genetics technologies [are] capable of 
desubstantializing human biology, replacing the finiteness of the flesh with infinitely 
interchangeable communicative codes” (2006). This endless changeability, occurring at a 
level beyond the reach of all but the smallest group of specialized scientific and technical 
experts, makes it difficult to conceive of gene therapy as anything but supernatural.  
The origins of gene therapy’s strong association with the numinous go back much 
further than the history of genetics technologies. Technology in general has been closely 
linked to religious thought and impulses for centuries. In current discourse, religion and 
technology are typically portrayed at odds with one another. Religion upholds tradition 
and reflects God’s plan for the world, whereas technology promotes constant change and 
illustrates the ingenuity of man. This may not, however, be an entirely accurate or 
complete portrait of how the two interrelate. Per Pfohl, “From debates about the ethics of 
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stem cell research to divergent understandings of the nature of creation, contemporary 
culture is replete with numerous instances of conflict between religion and technology. 
Yet, over the longer course of history, this is far from the case” (2006). A case can be 
made that technology and its historical development are actually deeply rooted in 
religious ideas and practices. Noble notes that “the striking acceleration and 
intensification of technological development in post-Carolingian Europe emanated from 
contemplative monasticism,” and that “Bacon defined the Western project of modern 
technology, and his bold vision was ‘framed with reference to the millennial expectation 
of man’s dominion over nature’” (1997, pp. 13, 48-9). Stahl (1999) also suggests that 
religious utopian visions motivated many of the earliest proponents and developers of 
technological advancements. A dedication to the ideals of religion, as well as practices of 
contemplative thought, helped to inspire the invention of means by which man could get 
closer to God and maintain and enforce his dominion over God’s creation.  
Therefore, it is not surprising that gene therapy is bound up with numinous 
imagery. In its potential to manipulate sacred genes, it is heralded as an answer to 
prayers, a Holy Grail, and a magical cure and is surrounded by a “miracle technology 
aura” (Stockdale, 1999, p. 582). Further, it can be perceived of as a means both of 
accessing the divine and of fulfilling man’s divine responsibility to rule over creation. 
Through the application of gene therapy, scientists are consorting with gods and angels; 
through the eradication of disease via genetic manipulation, they are casting out the 
demons of sickness. Gene therapy’s practitioners are portrayed as akin to the monastics 
and utopian zealots of technology’s early years. They are, per Noble, “driven also by 
 164  
distant dreams, spiritual yearnings for supernatural redemption” (1997, p. 3). Noble goes 
on to assert that (for early gene therapy pioneers, at least) there was a deep sense of 
mission, calling, and divine power: 
Thus, in their own professional personas and anointed activities, no less 
than in the holy alphabet of DNA itself, genetic engineers labored in the 
presence of God. They imagined that, with their new insights into the 
mechanisms of life, they had come closer than ever before to share in 
divine knowledge, and with their new technical capabilities for 
manipulating the basic material of life, they had in a sense become God’s 
companions in creation. (p. 192) 
 
Further, as Sidler (2006) suggests, it is even possible that associating genetics 
technologies with religious imagery could help to engender public support, even from 
those sectors where doubt and hesitancy about technological change can be the most 
ingrained: “scientists have actually seized upon an image of DNA as the essential, 
immortal, and magical force within humans as a way both to empower their research with 
grand meaning and to reconcile it with the religious community, which has strong 
reservations about genetic research” (p. 65). 
Implicit in images of gene therapy as a divine calling to control creation is that the 
technology is being used as form of social control, an exercise of expert power over the 
bodies of the (powerless and inexpert) public.  This suggests that at its heart, gene 
therapy is not really about meeting the pressing human need of healing or curing the sick, 
but rather about those who control technology gaining ever more dominion over society. 
This notion must be addressed and will be discussed in more depth in the next section. 
However, it is worth noting that the numinous foundations and associations of technology 
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may have contributed to constructing human gene therapy as  a field that is as much (or 
more) concerned about achieving divinity as it is about meeting earthly  goals: 
On a deeper cultural level, these technologies have not met basic human 
needs because, at bottom, they have never really been about meeting them. 
They have been aimed rather at the loftier goal of transcending such 
mortal concerns altogether. In such an ideological context, inspired more 
by prophets than by profits, the needs neither of mortals nor of the earth 
they inhabit are of any enduring consequence. (Noble, 1997, pp. 206-7)  
 
Overall, the numinous images and metaphors found within this sample seem to 
both reflect and reinforce long-standing linkages between the otherworldly and 
technology in general and genetics technology and religious imaginings in particular. 
These linkages have most likely contributed to the initial and continuing support for the 
gene therapy field through their emphases on the sanctity of the gene and the possible 
omnipotence of gene therapy as a medical intervention. However, careful consideration 
of this imagery also provides a possible site for questioning the development of the 
technology. By examining the value and meaning of the supernatural qualities ascribed to 
genes and gene therapy, it may be possible to arrive at a more refined and accurate 
understanding of how gene therapy could (or should) fit into the universe of medical care.   
 
 
2. Good gene vs. bad gene 
 The good gene vs. bad gene characterization is fundamental to the essentialist 
narrative about human gene therapy. If genes are the essence and location of health, they 
must possess some inherent quality that drives or directs health outcomes. They must 
either be “good,” leading to healthy outcomes, or “bad,” leading to the expression of 
disease. The good genes should be promoted and preserved, and the bad genes should be 
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repaired or replaced. This provides a compelling rationalization for supporting the 
advancement of gene therapy as the most effective way of accessing and fixing the bad 
genes.  
 The good gene vs. bad gene image is underpinned by a tendency within discourse 
to personify the gene. It has become common to endow the gene with agentic qualities, 
suggesting it can perform and act as a human would. Per Liakopoulus, “The gene 
person…is a new image unique to biotechnology. So far as we know, there was never 
before a systematic attempt to personify any part of living tissue in humans or other 
living organisms” (2002, p. 24). This personification lends further authority to the gene in 
regard to determining health outcomes. Further, when the gene takes on its personified 
form, the good gene vs. bad gene image is even easier to understand and seemingly more 
relevant. Just as (particularly in light of currently predominant moral sensibilities) a 
“good” person tends to do good things and a “bad” person does bad things, so do the 
good and bad genes act out their destinies.  
 The good vs. bad/personified gene image is also vitally necessary for legitimizing 
the authority of scientific experts over health and disease. When likened to a person, the 
gene takes on a life of its own. If left to its own devices, the gene will then, presumably, 
do whatever bad or good thing it is programmed to do, and its human carriers are 
powerless to stop it. Only the rarified expert and his/her advanced technologies can 
subdue or control the gene. Therefore, while investing the gene with inherent qualities 
empowers it to affect health outcomes, it also provides a basis for the gene (and hence the 
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individual who carries the gene) to be controlled. Human gene therapy, again, emerges as 
the means to exercise this control, and thus seems incredibly powerful.   
 
 
3. Mechanical/computers/text 
 As is true of numinous images and metaphors, images of the 
mechanical/computer/text variety were found very widely and with great frequency 
within the sample. These forms of essentialist imagery perhaps best display the 
phenomenon of geneticization that so many cite as a predominant media frame for 
genetics technologies. Mechanical metaphors compare the elements of gene therapy to 
parts and functions, reinforcing a notion of the gene as the physical component in which 
disease is located. In mechanical imagery, genes are defective or broken, and gene 
therapy is the way to fix them; genes can be turned on and off, and gene therapy controls 
the switch. Computer and text/language metaphors portray genes as the individual’s 
operating system, code, or book of life; gene therapy’s job is to fix the bugs or correct the 
typos. This sort of imagery typifies and perpetuates a geneticized picture of the body and 
health. It supports the notion that a “genetic body” now often prevails in media discourse. 
(Martin, 1999) For the genetic body, causes of and treatments for disease are located 
within the genes; genes are, ultimately, the primary physical determinants of health.  
These images have been commonly and repeatedly identified within news media 
accounts and in popular media. (Melendro-Oliver, 2004; Nelkin, 2001a; Kirby, 2000; 
Nelkin and Lindee, 1995; Hubbard, 1993) Others argue that essentialist or geneticized 
media coverage has not become more prominent in recent decades or has not been proven 
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to influence public opinion about genetics technologies (although they do not deny the 
presence of geneticized imagery or narratives). (Kerr, 2004; Condit, 1999; Hedgecoe, 
1998) The findings of my study indicate that, at least in the case of human gene therapy, 
the geneticization frame – expressed through extensive essentialist images and metaphors 
– is indeed present in mainstream media discourse. It is by no means the only frame used 
in media accounts about gene therapy, but it is widespread and diversely applied. 
(Examining whether this has influenced public opinion about gene therapy would be 
valuable but is not done in this study.)    
 The reduction of health and illness to a function of the gene carries with it many 
potential implications. First, it privileges genetics-based approaches to treating disease. 
One way in which this can occur is through the aforementioned OGOD (one gene, one 
disease) assumption (Conrad, 1999), which involves labeling a gene as the gene 
responsible for a disease or condition (i.e., “the cancer gene,” “the baldness gene,” etc.). 
This assumption implies that if scientists can just figure out how to fix the gene, they can 
cure the disease, a relatively simple-sounding task. Of course, treating or curing most 
diseases involves many biological, environmental, social, and commercial factors. Even 
when a disease does have a uniquely genetic cause, devising and applying a gene-based 
therapy is complicated, challenging, and often ultimately unsuccessful. Imagery that 
supports an OGOD assumption does little to promote a better understanding of health and 
illness and could contribute to inaccurate public perceptions of what matters, what works, 
and what should be done about health care.  
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 Another way in which essentialist imagery can be seen to promote genetics-based health 
interventions (and, by extension, detract attention from alternative approaches) relates to Kay’s 
(1994) molecular vision concept.  This concept asserts that an overriding ideological and 
sociocultural dedication to technocratic principles has supported the development of a 
molecular vision, in which the smallest biological entities take on the biggest significance in 
directing biological processes. The smaller and more removed from physical experience the 
entity is, the more powerful the scientific expert becomes. The individual cannot access his/her 
genes; if disease is located within the genes, the individual then has no power over his/her 
disease and no ability to contribute to its treatment. Therefore, he/she becomes entirely 
dependent upon (and, Kay suggests, controllable by) the scientific/technological expertise-
based powers-that-be:  
A biology governed by faith in technology and in the ultimate power of 
upward causation is far more amenable to strategies of control than a 
science of downward causation, where elements cannot be fully 
understood apart from the whole...The molecular vision of life was an 
optimal match between technocratic visions of human engineering and 
representations of life grounded in technical intervention, a resonance 
between scientific imagination and social vision. (1994, pp. 17-8) 
 
To the extent that it deemphasizes the whole person as the object of disease 
treatment and focuses instead on the gene, essentialist imagery supports an 
approach to health care that invests most or all of its power in genetics experts 
and little to no power in those being treated.  
 Relatedly, essentialist images also may contribute to the (re)construction 
of illness. Insofar as it promotes the notion that health and illness originate from 
and reside within the gene, and thus invests experts with the power to treat 
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sickness, such imagery also gives those experts the power to decide who is sick. 
Illness is determined by the nature and status of the genes, not by the experience 
of the patient. The more patients subscribe or submit to this way of thinking, the 
more they may be come willing to let the experts decide when they are sick and 
(whether and) how they should treated. Per Frank (1997), this is accomplished in 
part via “narrative surrender,” whereby the patient accepts that he/she must 
subordinate his/her own thoughts, feelings, and experiences of illness to the 
medicalized, expert-oriented side of the story.  
Frank suggests that this fits into a larger “restitution narrative” about 
illness. Part of this narrative is the assumption that in a healthy person, the body 
and its parts are in good working order. If they stop working well, every effort 
should be made to return them to their original state. Technologies emerge as the 
natural means by which this can be achieved; as Frank writes, “Whatever is 
wrong with the body, these stories describe the imminent development of a high-
tech remedy that will cure it” (1997, p. 86). Imagery that privileges technology as 
the all-powerful solution makes alternate approaches seem useless.  
Amid talk of the advances in genetic screening and manipulation…amid 
all this restitution talk, the single certain fact of death has little place. The 
“gee whiz” news releases and medical self-congratulations are not wrong, 
but they betray a conspicuous lack of narrative balance: other stories are 
happening as well, and the restitution story crowds them out. (p. 87)  
 
Mechanical/computer/text essentialist imagery is certainly compatible with the 
“restitution narrative.” Through its characterization of malfunctioning genes as the 
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determinants of health outcomes and its support of gene therapy as the repair mechanism, 
such imagery promotes a definition of illness that devalues patient input.  
 In this way, essentialist imagery also detracts from the importance of 
illness meanings (Kleinman, 1988) as part of the medical encounter. How the 
patient feels about or experiences his/her illness is of little importance when 
treatment occurs at the level of the gene. In fact, illness, as the holistic lived 
experience suggested by Kleinman, is negated by essentialist imagery; biological, 
geneticized disease is all that matters. Another way of expressing this is that the 
privileging of the gene promotes the “reification of disease,” wherein disease 
becomes the legitimate unit of analysis and point of treatment, and through which 
“[t]he patient’s body,” illness stories, and experiences “become superfluous to the 
molecular physician” (Fuks, p. 59). The more powerful a technology like gene 
therapy is portrayed to be over a particular condition, the more that condition may 
be likely to be understood (and, consequently, treated and experienced) as a 
disease, not an illness. 
 Definitions and meanings of the body are also challenged by mechanical 
essentialist imagery. When genes take on the role of the essential, life-giving, 
health-defining body part, the importance of the body becomes reduced to the 
genetic level.  No longer is the whole body the object of the “medical gaze” 
(Foucault, 1973), but rather the gene becomes the object of the “molecular gaze” 
(Anker and Nelkin, 2004). Yet just because the gaze has shifted away from the 
body, this does not mean that any less social control is being exercised upon the 
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individual. In fact, the atomization of health and disease to the tiniest of biological 
entities in fact increases the necessity of the individual to rely up on the expert, 
reinforcing expert authority and power. Indeed, constructs such as Foucault’s 
(1978) bio-power assert that the more bodies can be subjugated, objectified, and 
reduced to their component parts, the more they can be coopted, manipulated, and 
controlled. The potential dangers of this do not lie only in the possibility of the 
individual being subjected to expert control (although a long tradition of 
sociological theory would suggest that this is sufficient danger in itself). A further 
risk is that without a sense of embodiment within the whole physical form, the 
individual may feel powerless or demotivated to direct (or even contribute to) the 
management of his/her personal health. Genes are invisible, require specialized 
knowledge to understand, and can be accessed and altered by only a select group 
of experts and their expensive and highly advanced technologies. If health resides 
within them, then self-directed health care, for most individuals, is out of reach. 
 Similarly, essentialist imagery and narratives (if culturally assimilated) could 
affect definitions and understandings of the self/identity. As sociologists have long noted, 
the construction of the self is grounded within culture, experience, and power relations. 
However often genetics may be portrayed as defining the “boundaries of personhood” or 
as being “the location of the true self” (Nelkin, pp. 41-2), few would argue that they 
solely determine an individual’s identity or his/her understanding of it. Still, essentialist 
images and narratives (particularly those that compare genetics to scripts, blueprints, etc.) 
have the potential to function as cultural inputs into the process of self formation. The 
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more internalized these images become, the more influence genes will be seen as having 
on determining human personhood. This leaves less room for self-determination, 
whereby the individual takes a consciously active role in the creation of his/her self. 
Confronted with genes as the determinant of self, the individual could find little point in 
trying to participate in self-development. Further, if one’s genes are determined via 
testing to be “bad” or “defective,” the self  can take on a primary definition as  
“potentially ill,” which becomes a lens through which life experience and identity issues 
become filtered.   A potential consequence of increasing passive acceptance of a gene-
determined self is that the individual may feel alienated from the self and perceive a lack 
of personal agency, which can engender a sense of powerlessness that extends far beyond 
the construction of the self.   
 Mechanical/computer/text-related essentialist imagery, therefore, carries 
with it powerful meanings. The extent to which these meanings become 
normalized and operationalized within the medical research and treatment system 
will help to determine how illness, body, and self are experienced by many future 
patient-individuals.    
 
Fatalistic images, metaphors, and narrative 
 
 
1. Transportation-related/pioneering 
 
Images and narratives that suggest inevitability or forward motion toward a given 
end occur quite commonly within the human gene therapy public discourse. Genetic 
fatalism is acknowledged and discussed in other genetic contexts (often in reference to 
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genes’ influence on traits and behaviors). Conrad (1999) defines it as a type of framing 
wherein “genetic associations to behaviours or conditions are deemed to be deterministic 
and unchangeable” (p. 237). Alper and Beckwith (1993) maintain that such framing is 
widespread, that “the belief that people bear no responsibility for aspects of their 
behavior that are genetically influenced can be correlated with a genetic fatalist 
perspective,” and that “beliefs in genetic fatalism, particularly as they relate to human 
behavior, have been used to inform and influence social policy” (pp. 512, 520).  
A similar assertion could be made in reference to genes as the cause of disease (as 
opposed to behavior); a fatalistic narrative that suggests that genetic propensities 
inevitably determine health removes the individual from the health equation and could 
greatly influence future health care policies and priorities. Images that emphasize the 
inevitability and forward motion of gene therapy technology could make a similar 
impact.  When gene therapy is described as moving along on a predetermined “path” or 
“route” to destined discoveries that are “just around the corner,” it is positioned as the 
natural response to the accumulation of scientific knowledge. Since the influence of 
genes has been discovered, gene therapy follows as the logically best approach to treating 
disease. Whether it has been proven to be effective is subordinated by its predetermined 
role; eventually it will work, so it is not necessary to be too concerned about the fact that 
it has not yet worked.  
Similarly, describing gene therapy as a “frontier” and its researchers as “pioneers” 
also provides assurance that the uncertainties associated with the technology will 
eventually be resolved. If gene therapy is like the “first car” or “first airplane,” it has 
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ahead of it a long history of discovery, invention, and success. Therefore, imagery that 
promotes a fatalistic narrative about human gene therapy, that suggests the technology is 
meant to and will continue to move forward toward a successful end, could prove very 
valuable for the field’s development.  
 
2. Natural world-related 
Images and metaphors referencing fatalistic elements of the natural world could 
have a similar effect. First, simply mentioning nature is a way of asserting that gene 
therapy is inevitable or meant to be. Per Hansen, “Appeals to nature or to natural qualities 
are...powerful because they invoke genuine, eternal and non-negotiable qualities. Of 
these, it is perhaps the ‘non-negotiable’ that is the most important in terms of exercising 
discursive or rhetorical power” (2006, p. 813). To compare gene therapy to natural forces 
or elements is to suggest that it has “non-negotiable” power and potential. Comparison of 
gene therapy to a “wave,” “flood,” “fire,” or “storm” proposes that it possesses a innate 
physical intensity that will propel it forward largely on its own. These images in 
particular convey a sense that the field could not be stopped even if society wanted to 
stop it; fires and weather-related phenomena carry with them the potential to advance in 
an uncontrollable fashion.   
Although such imagery usually appears in the sample as a positive portrayal of 
gene therapy, it could also be interpreted as suggesting that gene therapy is an 
unstoppable, dangerous force that could bring with it destructive consequences. This is 
consistent with Nesbit and Lewenstein’s (2002) “runaway” framing typology, which 
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typifies imagery that references “fatalism after the innovation; having adopted the new 
technology/products a price may well have to be paid in the future; no control any more 
after the event” (p. 372). Although in one sense this would seem to discourage support 
for the field, in another sense it reinforces the notion of gene therapy’s inherent, natural 
power and affirms that it will continue to move forward on its inevitable course.   
The likening of this inevitable course of gene therapy to evolution represents a 
further extension of the fatalistic narrative. Evolution, even more strongly than any 
singular natural force, suggests inevitable progress and destiny. It also includes a firm 
insistence that the (scientific and technological) progress that is made over time is not 
only unstoppable but also will bring with it improvement of the human condition. To 
suggest that gene therapy is “evolving” is to say that it is a natural progression of 
scientific knowledge and medical treatment, that its progress will continue, and that it is 
meant to be.  
The potential effect of the fatalistic narrative, then, becomes obvious. If images of 
gene therapy as an inevitably forward-moving force and a natural result of scientific 
progress take root culturally and socially, they could strongly encourage further 
ideological, political, financial, and public support for the field.  
 
Expectant images, metaphors, and narrative 
 
The expectant narrative and the images and metaphors it contains are very 
prevalent throughout the human gene therapy media discourse. From the time of the first 
human gene transfer (and even before) to the present moment, a sense of great 
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anticipation that gene therapy will soon be able to treat or cure a variety of diseases has 
endured. Doubts have surfaced along the way, especially in light of several publicized 
failures and no unequivocal success. Nonetheless, hope in the promise of gene therapy 
technology has maintained a strong presence in media coverage.  
Expectations are an important area of consideration when studying the 
development of any emerging medical technology. In general, modern society has a 
tendency to react positively to new technological possibilities; Noble maintains that it 
displays “extravagant anticipation of every new technical advance – however much each 
fails to deliver on its promise” (1997, p. 6). Technologies are often valued more for what 
they might be able to accomplish than for what they have been proven capable of 
accomplishing. Further, much sociological theory (from the work of classical theorists 
like Weber and Mead to that of current scholars [e.g., Borup et al., 2006]) supports the 
notion that expectations about technologies can affect their development. As Haraway 
writes, “tool and myth mutually constitute each other” (1991, p. 164). Because it is so 
predominant, apparently does not depend on whether a technology can deliver on its 
promises, and may affect technology development, technological expectation demands 
attention.  
According to recent empirical studies, expectations do play a significant role in 
the construction of new technologies. For example, Selin’s (2007) inquiry into 
expectations of nanotechnology found that “speculative claims are powerful 
constructions that create legitimacy in this emerging technological domain” (p. 196). 
Brown and Kraft (2006) suggest that “communities of promise” develop around 
 178  
expectations and then go on to reinforce them, which in turn promote technological 
development. In their study of pharmacogenetics, Hedgecoe and Martin (2003) found that 
expectations were “actively shaping the trajectory of this nascent technology and its 
potential socio-economic consequences” (2003, p. 327).  Studies such as these support 
the idea that expectations function as inputs into the process of constructing technologies.  
Because expectations help to construct technologies, it is valuable to consider 
how they are expressed – and potentially generated – by media discourse. As seen in 
Chapter 4, many instances of expectations for human gene therapy appear within the 
sample via discussions of “great promise,” “confidence” that it will succeed, and many 
“high hopes” for a cure. Also prevalent throughout the sample is an optimistic tone, 
which reflects a widespread sense that gene therapy will eventually work. Although 
concerns, doubt, disappointment over as-yet unmet promises, and accusations of hype all 
are also present (especially after major setbacks were reported), an expectant narrative 
remains strong through all years of the media discourse.  
This finding is important for a number of reasons. First, it confirms the suggestion 
of previous theoretical and empirical studies that human gene therapy, as a developing 
technology, is connected to a large body of expectations about its potential. Based on 
previous research that indicates that expectations are generative, performative, and 
contribute to the construction of technologies, these expectations may be shaping the 
development of human gene therapy. Although examining whether and to what extent 
this is true goes beyond the scope of this study, the data about expectations generated 
here could be valuably applied to future research into those issues. As touched upon in 
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Chapter 3, expectations are in a sense like self-fulfilling prophecies – it is possible that 
the many hopeful expectations about gene therapy are themselves contributing to the 
continuing support being experienced by the field. Further, it is possible that the support 
provided by these expectations is to some extent counterbalancing the enduring lack of 
success and repeated failures that might otherwise be reasonably anticipated to dampen 
enthusiasm for the field. In clarifying how expectations are presented within the public 
discourse, this study could prove a helpful resource for any scholar hoping to investigate 
the construction of human gene therapy.  
It is also important to consider possible reasons for the enduring hopeful 
expectations for human gene therapy. One possible explanation is tied to the essentialist 
and fatalistic narratives. For decades, and even more so after the achievements of the 
Human Genome Project, the role of genetics in determining health outcomes has been 
widely reported by the mainstream media and heavily assimilated into public discourse. 
Genes “for” countless disease, conditions, behaviors and traits have been “identified,” 
and the power of the genetic “code” and “blueprint” in (at least partially) determining 
humans’ health and fate has been continually emphasized, to the point of becoming 
largely “taken for granted” in popular understanding. With the gene being so essential to 
the determination of health, treatments and cures that address disease at the level of the 
gene seem incredibly appealing. Further, if science is advanced and powerful enough to 
decode the genome, it might seem like devising genetic therapies should not be that 
difficult. Indeed, it may be that in the early years of gene therapy, the scientists 
themselves may have held that same belief. Time has clearly illustrated how challenging 
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it has been to create and deliver effective gene therapies, and the media discourse has 
reported and reflected on these challenges. However, it is possible that hopeful 
expectation for the technology rose to such a high level that it would take many more 
years of stagnation and/or many more failures to reduce it significantly. Further, the 
enduring geneticization of disease (demonstrated, for instance, by the growing presence 
of genetic screening tools in health care practice) may make abandonment of high hopes 
for gene therapy too anomic for science/medicine, the media, government, and/or the 
public to accept. As long as optimistic expectations endure, then the harsh possibility that 
science may not soon (or ever) determine how to reverse or repair the genetic aspects of 
disease can be ignored.  
 
Conflictive images, metaphors, and narrative 
As demonstrated, conflictive images and metaphors portray gene therapy as 
engaged in a battle against disease. Combative imagery is especially prominent within the 
sample. Just as such imagery is common in media coverage of human gene therapy, it is 
very typical within other disease-related media discourses. As Fuks (2010) writes, 
“Medical discourse is replete with the language of war and such phrases as ‘the war on 
cancer,’ ‘magic bullets,’ ‘silver bullets,’ ‘the therapeutic armamentarium,’ ‘agents of 
disease,’ ‘the body’s defences,’ and ‘doctor’s orders’ are deeply engrained in our medical 
rhetoric” (p. 57). The use of such language is widespread throughout the public discourse 
and in reference to a wide range of inherited and noninherited diseases. Sometimes the 
“enemy” is disease itself, but oftentimes it is diseased or defective genes that are 
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identified as the necessary objects of attack. This is demonstrated by the way media 
accounts frequently portray cancer: “It is certainly the case that the combative metaphors 
that are readily used in political as well as medical talk about cancer are frequent. Thus 
genes can ‘target’, ‘attack’, ‘get you’ and generally threaten at will. Equally they can 
‘jump’, ‘miss’ and ‘hide’ in such a way that their effects become puzzling. Either way, 
humans are seemingly at the mercy of capricious DNA” (Prior, 2007, p. 996). Similarly, 
Miller et al. note that “the impact of genetics is akin to an ‘explosion’ or a ‘propelling’ 
force that is part of an ‘ongoing invasion of medicine’” (2006, p. 2378).  These 
characterizations lead naturally into depictions of gene therapy as a weapon and its 
practitioners as those who will fight the battle. As Petersen writes, “geneticists are 
portrayed as warriors or heroes, as constituting the vanguard of the ‘genetics revolution’ 
who are waging a war against disease or ‘rogue genes’” (2001, p. 1264). Not only are 
these scientists capable of fighting the battle; their unique position essentially requires 
them to engage in the fight: “War frames…provide a strong focus and a moral imperative 
to use the means available to ‘help’ the individuals in question” (Coveney et al., 2009, p. 
490). 
Through metaphors such as these and the many similar images found with my 
sample, the combative narrative serves to expand the effects of the essentialist narrative; 
since genes cause disease, they become the enemy. This provides a very compelling 
rationalization for the development of gene therapy, as it may be the only way to win the 
war. Combative imagery is very dramatic and undoubtedly adds a sense of urgency to the 
development of gene therapy as a disease treatment. Depending on the extent to which 
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such imagery becomes cemented in public discourse, it could encourage support of the 
gene therapy field. As Petersen asserts, “Military metaphors help convey the importance 
of the research for the development of new preventive techniques, drugs or therapies” 
(2001, p. 1264). Regardless of its future impact, it may bring with it several immediate 
consequences affecting patients’ illness experience and medical care. By identifying 
defective genes as the true enemy to health and gene therapy technology as the one 
effective weapon for fighting this enemy, combative imagery excludes the patient’s voice 
and experience from the health care narrative. Instead, the story is about the doctor/expert 
conquering the enemy, genetic disease; patient involvement or agency does not play an 
important part. Per Fuks, “The mindset engendered by this discourse of war renders the 
patient as a battlefield upon which the doctor-combatant defeats the arch-enemy, disease. 
The reified disease becomes the object of the physician’s attention, displacing the patient 
as the interlocutor in the doctor-patient relationship” (2010, p. 57).  
As was true of essentialist imagery, combative imagery also reinforces patients’ 
dependence on gene therapy experts. They control the weapon and are the only ones who 
know how to use it; without the experts, patients are helpless to fight against their 
diseased genes. This is compatible with Horst’s (2007) “assemblage of heroic action in 
which the individual patients can only hope to encounter an action hero, who might 
provide them with a last chance” (p. 165). Complete reliance upon a heroic expert totally 
removes the patient’s agency from the health care narrative. An added effect is that “non-
experts” – patients, ethicists, social scientists, government officials, the public, or anyone 
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outside of the gene therapy field – have little right to question the course or advancement 
of the gene therapy field. Per Dobson (1999),  
The use of anthropomorphic terms such as ‘rogue genes’ and ‘killer 
diseases’, which attribute malevolent intent to genes and diseases, 
reinforce the heroic image of genetic researchers, and bolsters their status 
as guardians of the public's health…There is little debate about the value 
of particular lines of genetic research, about whether research can deliver 
what is promised, and whether funds used for research would be better 
spent in other ways. (p. 16) 
 
It is possible that combative images of genetics and human gene therapy are even 
more salient in the present historical moment because of the ubiquity of images of actual 
war. News reports about the advanced technologies being employed in global warfare 
proliferate. By linking disease treatment to images of fighting, battles, and weaponry, it is 
possible that media discourse promotes “high-tech” gene therapy as the ultimate modern 
health care intervention. Conversely, it is possible that such strong combative imagery 
may turn off some of its consumers. As Larson writes, “Militaristic language could also 
prove ineffective because of the ‘boomerang effect’, whereby ‘extremely intense 
language or images used for purposes of persuasion can have an opposite effect on the 
receiver’” (2005, p. 497). The continuing wide use of militaristic imagery in media 
discourse about genetics, disease, and many other areas suggests, however, that it is not 
currently been judged as unappealing to the public.  
 Although the combative portion of the conflictive narrative seems to be dominant 
(both in terms of frequency of use and interpretive force), sports-related imagery is also 
an important part of the gene therapy discourse. Likely the most meaningful sports image 
is that of gene therapy being a “race” and its accompanying metaphors of “hurdle” and 
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“finish line.”  The story of gene therapy development as a race emphasizes that there is a 
set track upon which the field is racing. As it moves forward along that track, various 
hurdles will have to be cleared. While doing so is naturally difficult, it is just a part of the 
race and is therefore to be expected, not feared; ultimately, it will not hinder the field’s 
progress. Eventually the field will reach its finish line, namely the development of a wide 
range of effective disease treatments. This story – implicit even in many accounts that do 
not use sports metaphors – is a powerful one, and if it is believed, there is little reason to 
question the ongoing financial, intellectual, and public support for gene therapy 
technologies.  
 
 
Analytic Category 2 – Predominant tone of human gene therapy discourse 
 
As discussed in Chapter 6, the three main tones identified within the sample were 
as follows: 
 
1. Optimistic 
2. Disappointed 
3. Cautionary 
These tones occur with relative consistency throughout the sample. The optimistic tone is 
most common, yet accounts with disappointed and cautionary tones also appear 
frequently. The optimistic tone is associated with positive reports of incremental 
successes, hopeful discussions of potential applications, and predictions of the 
technology’s future impacts. The disappointed tone typically relates to the slow pace of 
advancement within the field or the failures or side effects of clinical trials, and the 
cautionary tone relates to suspended clinical trials, perceived risks, and ethical 
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misgivings. While these were the main tones identified, not all accounts were found to 
take a discernible tone, and some seemed to reflect more than one tone.  
 The finding that the optimistic tone was predominant is consistent with the 
common scholarly assertion that coverage of biotechnologies is overwhelmingly positive. 
(Petersen, 2006; Mountcastle-Shah, E. et al., 2003; Conrad, 2001) Per Bubela et al. 
(1999), “research has shown that positive results are more likely to be published, whereas 
studies that refute previously published research are less likely to gain attention” (p. 514). 
Others suggest that this may relate to journalists’ interest in reporting only the most 
“attention-grabbing” information, not necessarily the most scientifically significant. 
According to Relman (1982), “The press, the media in general, are much more interested 
in the story, the news, than in the facts” (p. 16). In addition to greater reporting of good 
results, studies have suggested that the positivity of media reports about biotechnology 
often rises to the level of “hype,” wherein the potential capabilities of technologies are 
largely overstated (based on available evidence). (Brown, 2003; Stockdale, 1999)  
Caulfield (2004) suggests that this type of reporting may be encouraged by scientists, 
their employers, and the media: “[B]ecause all three parties gain short-term benefits, 
researchers, research institutions and reporters can be viewed as inadvertent ‘complicit 
collaborators’ in the subtle hyping of science stories” (p. 338). Others studies assert that 
reporting about genetics technologies is not all just “genohype” and that media accounts 
often portray their capabilities and potential quite accurately. (Caulfield, 2004; Wilkes 
and Kravitz, 1992) Regardless of the relative levels of accuracy or hype within reporting, 
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however, that positive portrayals of genetics technologies are very common would be 
difficult to dispute. 
 Still, in human gene therapy coverage there is also a good deal of negatively 
oriented tone. The polarized nature of the tones is not surprising, given that previous 
studies have noted that science and technology reporting often portrays biotechnologies 
as being on the far ends of the value spectrum – they are either labeled as highly 
promising or disturbingly perilous, as sacred or profane. (Liakopoulos, 2002; Nelkin and 
Lindee, 1995) This is not to say that all accounts provide dramatic or polarized 
representations of gene therapy; as stated, many of the media accounts in the sample did 
not display a strong tone. However, in those where a tone was discernible, it often 
conveyed strong impressions about gene therapy in one direction or the other.  
As is true in regard to much of the imagery discussed earlier, dramatic tone may 
contribute to the shaping of public perception about human gene therapy.  Just like media 
content, it is a means by which journalists actively participate in the construction of the 
technology (whether they intend to or not). As Nelkin (1987) writes, 
Science writers, in effect, are brokers, framing social reality for their 
readers and shaping the public consciousness about science-related events. 
Their selection of news about science and technology sets the agenda for 
public policy. Their presentation of science news lays the foundation for 
personal attitudes and public actions. They are often our only source of 
information about the scientific and technical choices that significantly 
affect our work, our health, and our lives. (p. 161) 
 
What journalists report, of course, is also affected by the information that they 
receive from or is brought to them by the researchers and clinicians themselves. 
Sociological research suggests that scientists often actively control what is 
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reported about scientific and technological development through press releases, 
personal relationships with journalists, and other strategic ways of sharing (or not 
sharing) information about their research. (Nelkin, 1987) The extent to which the 
tone (and imagery/metaphors/narratives) of gene therapy media discourse is 
determined by the (intentional or unintentional) influence of gene therapy 
scientists could (and should) be the subject of its own study, but it is not within 
the scope of this one. Nonetheless, because of the relationships between media 
discourse and public understanding and opinion, is equally important to clarify the 
message that is being delivered, regardless of who is directing the delivery.  
This study’s findings about tone in gene therapy media coverage suggest that the 
coverage could affect public support for the technology and field. The preponderance of 
optimistic accounts (some of which may overstate the potential of the technology) may 
lead to greater hope and expectation; the disappointed and cautionary tones may 
encourage skepticism or concern about the field’s advancement. This matters, again, 
because public perception – through its influence upon policy, regulation, and funding – 
contributes to the shaping of the technology. The extent to which the development of 
gene therapy will respond to human health care needs is dependent upon these effects.  
 
 
Analytic Category 3 – Changes and patterns in human gene therapy discourse 
 
This study found that there was not significant change over time in the images, 
metaphors, narratives, and tone that were used in media coverage of human gene therapy. 
However, some changes did occur in relation to four of six landmark events within the 
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field’s history. In the case of three “failures” of gene therapy technology (wherein two 
clinical trial participants died and several others contracted a leukemia-like disease), an 
increase in disappointed and cautionary imagery and tone was noted, and in the case of 
one gene therapy “success” (the effective treatment of SCID in a clinical trial), hopeful 
and optimistic images seemed to increase.  
To some extent, it is surprising that the tone and imagery about human gene 
therapy have not changed significantly since 1989. The field, acclaimed as so promising 
in its early years, has realized very little success, which would suggest that perhaps a 
decrease in optimistic tone and hopeful imagery could have been expected. Without 
conducting in-depth study of the process of gene therapy media reporting and extensively 
interviewing those that produce it, it is not possible to make assertions about why the 
coverage of the issue is as it is. However, it is possible, based on what is known about the 
relationship between expectations and the construction of technologies, to make some 
conjectures about the possible sociocultural underpinnings of these coverage trends.  
The evidence compiled in this study reveals that expectations for gene therapy 
have remained high for over twenty years and that these expectations are to some extent 
uncorrelated to actual developments within the field. This may relate to an overriding 
cultural tendency to have “faith” in the power of technology. Noble suggests that for 
centuries Western society has trusted that a broad range of technologies will ultimately 
improve life, even in the absence of any evidence that those technologies were helping 
(and sometimes in the presence of evidence that showed they were hurting) mankind. Per 
Noble, this trust reveals “a deep-seated cultural compulsion….[which] can only be 
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understood by regarding it as one of those strange epidemics of insane excitement which 
have been known to affect whole populations at certain periods, especially of the middle 
ages. Rational explanation it has none” (1997, pp. 99-100). Although “insane excitement” 
is one possible explanation, widespread faith in the promises of gene therapy technology 
may seem more rational when the prominent narratives of the public discourse 
surrounding it (as illustrated in the findings of this study) are considered.  
As has been noted, images of genes as the “essence of life” and the “blueprint” or 
“code” which determine our health and personal destinies have become commonplace in 
public discourse. Coupled with a cultural tendency to think deterministically about 
technology, a public perception of genes as the location of health and disease and gene 
therapy as the obvious path to disease treatment seems reasonable. In fact, if genes truly 
do determine disease, gene therapy not only seems like a reasonable health care option; it 
may seem like the only reasonable health care option. Given the support for this potential 
mindset that has appeared for decades in the mainstream media, it becomes less 
surprising that hope for gene therapy as a viable disease treatment would endure. Further 
social psychological research would be necessary to determine whether faith in gene 
therapy serves as a protective or defense mechanism for individuals who believe that 
genetics determines disease (i.e., if genes cause disease, and gene therapy fixes genes, 
then without gene therapy there is no hope; society might need its faith in gene therapy to 
protect it from despair and panic over its doomed genetic fate). Nonetheless, the 
prevalence of essentialist and fatalistic narratives about genetics and gene therapy seems 
to provide some level of rational support for high faith in gene therapy.  
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The predominant gene therapy media narratives also make high expectations for 
gene therapy seem fairly reasonable. As discussed earlier in this chapter, the striking 
advances in genetic science that have occurred over recent decades have been highly 
publicized and frequently characterized as capable of changing and redefining life as we 
know it. If the powers of science are so vast as to be able to unlock the secrets of life 
hidden within the tiniest of human cells, how much harder can it be to figure out how to 
make gene therapy work? The long-term tendency of media coverage to emphasize the 
promise of genetics technologies may have in itself contributed to the resilience of that 
promise.     
At the same time, it is important to acknowledge that gene therapy media 
coverage does not originate out of nowhere and that its content is not purely a reflection 
of cultural trends and mindsets. Media accounts are created by actors and are shaped by 
the motivations and intentions of those actors. Certainly, gene therapy scientists and the 
research and commercial institutions with which they are affiliated stand to benefit from 
continued high hopes and expectations in the technology.  As discussed earlier, these 
actors’ frequent role in influencing media content has been acknowledged.  It is possible 
that the information-sharing choices of these actors have contributed to the relatively 
consistent optimistic tone that has characterized gene therapy media coverage since 1989. 
Similarly, if journalists perceive a benefit to telling a hopeful or expectant story about 
human gene therapy, their choices may also have influenced the type and character of 
information shared with the public.  
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These factors may also help to explain why coverage of gene therapy has 
decreased in recent years, and why what little coverage that does exist contains much 
hopeful, expectant imagery and often takes an optimistic tone. Journalists and their 
employers may judge that the only news worth reporting about gene therapy is “good 
news,” since the fact that the field has been largely unsuccessful for over two decades is 
no longer really “news” at all. Attention-getting headlines about novel and innovative 
uses for gene therapy or new reports of diseases which gene therapy may be able to treat 
or cure may be the only types of stories deemed worthwhile when a technological field 
seems especially slow-developing or stalled. At the same time, scientists and their 
employers may perceive little benefit in publicizing the results of their research unless 
they have something seemingly new or exciting to convey. Periodic sharing of positive or 
hopeful data and results might seem like a good way of promoting sustained support for 
the gene therapy field without drawing attention to its sluggish and obstacle-ridden 
developmental journey.     
The changes that did occur in relationship to four of the six landmark gene 
therapy moments does show, however, that the media coverage does in fact acknowledge 
at least some of the realities of the technology’s development (rather than only 
representing with predetermined narrative scripts). When serious unintended 
consequences of clinical trials (illness and death) occurred, they were reported, and the 
tone of media accounts sometimes changed. This helps to demonstrate that gene therapy 
media coverage is not all “hype,” but instead shows at least some level of balanced 
representation of the technology.  
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Chapter 8 
 
Conclusions and Recommendations 
 
 
 The purpose of this study was to explore how human gene therapy was presented 
in the mainstream media over the past 20 years. The study aimed to use the insights and 
approaches of the sociology of technology to better understand the “public face” of 
human gene therapy. The following conclusions discuss some of the most important 
discoveries about gene therapy and the media discourse that surrounds it that have 
emerged from this work. The discussion is followed by a number of recommendations for 
further consideration and future research.  
 
Conclusions 
 
1. The imagery/metaphors/narratives of human gene therapy media coverage 
indicate that geneticization and technological determinism do occur within 
current technological public discourse. 
In recent years, much sociological study of genetics-related technologies has 
occurred.  The concept of geneticization emerged from that work and soon took hold as a 
way of interpreting the public discourse surrounding various technologies. Some scholars 
have since argued that “[h]owever attractive and intuitively correct” geneticization might 
seem as a theoretical construct, many claims of its value “lack adequate grounding in 
empirical reality” (Hedgecoe, 1998). My study answers the call for more empirical 
investigations into the interpretive value of geneticization.  
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The images and metaphors that emerged through my analysis process do confirm 
the presence of a geneticized way of thinking about the body, health/disease/illness, and 
self/identity within the media discourse surrounding gene therapy. Essentialist and 
fatalistic imagery that portrays the gene as the location of disease and gene therapy as the 
inevitable scientific response define health and medicine in genetic terms. These genetic 
messages are reinforced repeatedly through many vivid metaphors.  
Technological determinism – however outdated it may seem to the sociologist – 
also appears to have a strong continuing presence in public discourse, as evidenced by the 
findings of my study. Images of human gene therapy as part of a natural progression of 
medical knowledge, as well as high levels of hope for and faith in technology in general 
and genetics technology in particular, are abundant in the media discourse.  
The prevalence and apparent influence of geneticization and technological 
determinism within human gene therapy  media accounts suggest that these concepts are 
not only still relevant to the sociology of technology, but also that they should be 
deliberately and carefully considered in future studies of genetics technologies.  
 
2. Human gene therapy is, to some extent, “hyped” in media accounts. 
As has been noted in other research into biotechnologies, evidence of a “hyped” 
(i.e., overly optimistic and oversold) portrayal of human gene therapy in the mainstream 
media was found in my study. The level of hope and expectation for human gene therapy 
demonstrated in the sampled media accounts seemed to far outweigh the levels of 
experienced and perhaps potential success of the technology.  Further, an optimistic tone 
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predominated throughout the decades since the field’s inception, despite little success and 
several major setbacks.   
The problem with hype in media discourse about medical technologies is that it 
can misrepresent the progress or capabilities of those technologies. This can lead to 
unrealistic expectations of treatment availability and can detract attention and support 
from alternative treatment approaches. Another very immediate and tangible possible 
effect relates to clinical trial participation; patients may elect to participate in gene 
therapy trials (or to not participate in other types of clinical trials) based on the stories 
they encounter about gene therapy in the media. To the extent that their perceptions of the 
benefit they might receive do not match the real potential benefit, this can be misleading 
and dangerous. This, among many other reasons, is why it is important for sociologists to 
identify hype in media discourse. 
 
3. Media portrayals are, to some extent, responsive to events occurring within the 
development of gene therapy.   
Despite the overselling of gene therapy that did seem to occur within the sampled 
accounts, there were also many accounts that told a more balanced, neutral, or sometimes 
negative story about human gene therapy technology. Further, the imagery, tone, and 
narratives did seem to be responsive to major events within the field’s development. 
When several tragedies occurred in clinical trials, they were (generally) well publicized 
and seemed to precipitate an increase in cautionary and disappointed imagery and tone.  
This suggests that the media coverage of human gene therapy is not purely hype. 
Reporting of the failures, challenges, and obstacles experienced by the field were fairly 
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prevalent, even in the context of accounts that took a primarily positive tone. However, it 
is also important to note that the coverage of human gene therapy in the most recent years 
of its history (post-2007) is largely optimistic and hopeful (even though the volume of 
accounts has decreased significantly).   
Clarifying patterns such as these is an important task for sociologists of 
technology. For the average individual seeking to learn about human gene therapy 
through the media at the present moment, the future would seem relatively bright. 
However, it seems likely that current reporting on the technology represents mostly 
positive results from a field that has been struggling for decades (and likely has at least as 
many negative results occurring now as it ever has). Sociologists of technology should 
endeavor to share information about trends in medical technology media coverage with a 
wide public audience to help the public contextualize what they learn through their media 
consumption.  
 
 
4. Images and metaphors most likely contribute to the construction of human gene 
therapy as a technological field. 
Finally, this study reinforces the already widespread sociological assumption that 
media images and metaphors about technologies matter. The evidence presented herein 
suggests that not only does media imagery portray a technology’s development, but it 
also may play a significant role in shaping that development. In the case of human gene 
therapy, it seems that the prevalence of essentialist, fatalistic, and expectant imagery may 
have helped to encourage support for the advancement of the field. Vivid metaphors from 
these imagery types – and perhaps especially from the conflictive type – repeatedly 
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promote the necessity and legitimacy of gene therapy as they are used and reused over 
many years. 
Because images and metaphors participate in the construction of medical 
technologies, it is important for sociologists to closely examine them. As an effort to do 
just that, this study will hopefully encourage similar in-depth explorations of the media 
discourses surrounding many other genetics-based medical technologies.   
 
 
Recommendations 
 
1. Institutionalized support for the sociology of technology in general and 
studies of the public discourse surrounding genetics technologies in particular 
needs to be encouraged.  
In light of enduringly high expectations for genetics technologies in society today, 
the sociology of technology has much to offer. Although the subfield has enjoyed less 
emphasis in academic contexts than many other subfields over its history, it seems 
important that institutions encourage the growth of sociology of technology and support 
the work of scholars who hope to make new discoveries within it. The high level of 
attention, hope, and resources that have been (and seemingly will continue to be) given to 
genetics technologies like human gene therapy suggests that the insights of sociology will 
be valuable for years to come. If human gene therapy and similar technologies are to have 
any hope of developing in ways that are attentive to the diverse and holistic needs of the 
people they are meant to help, then the sociology of technology must be actively involved 
in understanding those technologies and the discourses that represent and construct them.   
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2. Sociologists of technology should engage in public sociology in order to assist 
the public in navigating the discourse surrounding genetics technologies.  
 
While it is important for sociologists to build academic knowledge about human 
gene therapy and other genetics technologies, it is also important for them to share that 
knowledge with the public. Because media accounts about such technologies are filled 
with such vivid (and sometimes conflicting) imagery and do not always accurately reflect 
the status or potential of their development and application, it could be very valuable for 
sociologists to provide the public with information and tools that help them to navigate 
the media discourse.  Devising ways to share such information with the public and 
developing innovative, accessible, and powerful navigational media tools should become 
a priority of sociologists of technology. 
 
3. More research into the role of metaphor in the construction of technologies is 
needed. 
Although some effort (including that of this study) has been made within the 
sociology of technology to increase understanding of the role of metaphors in the 
construction of genetics technologies like gene therapy, more such effort is needed. 
While it seems indubitable that metaphor does play a significant role, understanding of 
the nature of this role needs to be clarified and expanded. To that end, further study of the 
contours of metaphors within media discourses needs to be done.  
 
4. Specific to gene therapy, more study of the inputs into the production of media 
accounts is warranted.  
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While it is hoped and believed that the findings of this study are valuable in 
themselves, it is important for further examination of the production of the human gene 
therapy media accounts studied to be conducted. While studying the media discourse 
does provide many insights into the ways in which that discourse may contribute to the 
construction of the technology, a better understanding of who is shaping that media 
discourse and how they are doing so would further sociology’s ability to contribute 
positively to knowledge building (and, ideally, advocacy) in regard to the human gene 
therapy field.  
 
5. Images/metaphors/narratives/tone in new media accounts of human gene 
therapy and other genetics technologies should be studied. 
Finally, future studies of the human gene therapy discourse and other similar 
genetics technology discourses should include new and nontraditional sources of media 
in their analyses. However standardized they are as source of sociological data, 
newspapers and magazines are no longer the primary sources of news and information for 
many media consumers. The public now learns about science and technology from a wide 
array of sources, to include social media, online news aggregators, talk radio, and late-
night satirical television programming, among many others. Sociologists of technology 
need to move toward including these in their studies, which will require devising new 
strategies of data collection and analysis. Qualitative researchers can use computer-
assisted data analysis software to aid that process, as it often has features that support a 
variety of types and formats of source data. Additional tools will most likely have to be 
developed to most effectively study some of the newest media sources. Whatever tools 
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and methods researchers choose to use, it seems important for new and emerging media 
to be increasingly incorporated into future studies of genetics technologies and their 
media discourses.  
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Appendix A 
 
Findings Roadmap 
 
 
Finding 1 
 
Four types of images and metaphors commonly occur within the sample: 
 
1. Essentialist 
2. Fatalistic 
3. Expectant 
4. Conflictive 
Within each of these types, a number of subtypes were identified, as outlined below: 
  
1. Essentialist  
a. Numinous 
b. Good genes vs. bad genes 
c. Mechanical 
d. Computer-related 
e. Text/Language-related 
2. Fatalistic 
a. Transportation-related 
b. Pioneering 
c. Natural world-related  
3. Expectant 
a. Promise-related 
b. Hopeful 
4. Conflictive 
a. Combative 
b. Sports-related 
 
 
Finding 2 
 
Some image/metaphor subtypes frequently co-occur in the media accounts sampled. 
These co-occurrences help to clarify and explain the larger narratives that emerge from 
the data.  
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- Good genes vs. bad genes and natural world-related 
- Good genes vs. bad genes and promise-related/hopeful 
- Mechanical and natural world-related 
- Mechanical and combative 
- Mechanical and transportation-related 
- Transportation-related and promise-related/hopeful 
- Transportation-related and combative 
- Transportation-related and natural world-related 
- Transportation-related and sports-related 
- Natural world-related and numinous 
- Natural world-related and pioneering 
- Natural world-related and promise-related/hopeful 
- Natural world-related and sports-related 
 
 
Finding 3 
 
The image types listed in Finding 1 correspond to the primary narratives occurring within 
the media discourse surrounding human gene therapy.  
 
1. Essentialist – the story of gene therapy as a sacred technology that may fix 
defective genes and restore human health.   
2. Fatalistic – the story of the inevitability and forward motion of gene therapy. 
3. Expectant narrative – the story of hope in the promises of gene therapy. 
4. Conflictive narrative – the story of gene therapy struggling to defeat disease. 
 
 
Finding 4 
 
Three predominant tones were identified within the human gene therapy discourse 
studied: 
 
4. Optimistic – the sense that gene therapy will work eventually. (This tone is 
predominant, but not to the exclusion of opposing tones.) 
5. Disappointed – frustration over gene therapy’s failure to live up to expectations. 
6. Cautionary – concern that gene therapy may be too risky or dangerous. 
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Finding 5 
 
The images, metaphors, narratives, and tones identified within the sample did not change 
meaningfully over time. Despite the very limited success and many failures experienced 
by the human gene therapy field in the decades following its first clinical trial in 1990, 
the imagery, narratives, and tones stayed relatively consistent over time. There was, 
however, much less coverage of human gene therapy in the mainstream media after 2007.  
 
 
 
Finding 6 
 
Some changes in imagery, narrative, and tone did occur in relationship to publicized 
successes and failures within the human gene therapy field. The announcement of success 
in treating SCID seemed to precipitate an increase in optimistic tone and positive 
imagery. The death of clinical trial participant Jesse Gelsinger, the announcement that 
several pediatric SCID clinical trial participants developed leukemia as a gene therapy 
side effect, and the death of clinical trial participant Jolee Mohr related to an increase in 
cautionary tone.  
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Appendix B 
 
Human Gene Therapy Image and Metaphor Types, Subtypes, and Common Codes 
  
Essentialist 
 
Numinous 
Hailing/praising/heralding 
Miracle 
Faith 
Holy Grail 
Prayer/blessing 
Saints 
Monsters/dragons 
Magic 
Temptation 
Salvation 
Proselytizer/evangelist 
Soul 
 
 
Good genes vs. bad genes 
Bad/defective/faulty/ 
aberrant genes 
Good/healthy/functioning/
working genes 
 
Mechanical  
Fixing/repairing genes 
Switches turning genes on 
and off 
Tinkering 
Blueprint 
Machine parts (brakes, 
conveyor belts, batteries) 
 
Computer-related 
Code 
Bugs 
Programming 
Operating system 
Software 
 
Text/language-related 
Writing 
Spelling 
Word processing 
Book 
Typos 
Alphabet 
 
Fatalistic 
 
Transportation-related 
Delivery vehicle (van, ferry, 
taxi, shuttle, freighter) 
Road/avenue/route 
Paving the way 
Steps/step forward 
Milestones/landmarks 
On the verge/brink 
Around the corner 
Green light 
 
Pioneering 
Pioneer/pioneering 
Frontier 
Kitty Hawk/first car or 
airplane 
 
Natural world-related 
Waves 
Cascades 
Groundbreaking 
Fire/ignition/rekindling 
Light/darkness 
Evolution 
Animals 
Defanged 
Taming/shepherding 
Weather 
Cloud 
Flood 
Storm 
Flurry 
Heat 
Plants 
Harvest 
Fruit/fruition 
Roots 
Ripening 
Weeding 
 
Expectant 
 
Promise-related 
Promise/promising 
Matter of time 
Broken/unmet promises 
Hype 
Confidence/doubt 
 
Hopeful 
Hope 
Hope for a cure 
False/unrealized hopes 
 
Conflictive 
 
Combative 
Attack/fight/battle 
Killing 
Revolution 
Weapons 
Gun 
Armed/disarmed 
Arsenal 
Trigger 
Bomb 
Missile 
Magic bullet 
Blow to the field 
Front/front lines 
Veterans/vanguard 
Invaders/Trojan horse 
Enemy/foe 
Enlistment/recruitment 
 
Sports-related 
Hurdle 
Obstacle 
Race 
Leap 
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Appendix C 
Media Accounts Quoted 
 
ABCNews.com 
08/26/2010. “Targeted Gene Therapy May Offer Hope Against Melanoma.” Hutchison, 
Courtney.  
03/17/2011. “Gene-Therapy Trial Offers Parkinson's Patients New Hope.” Moisse, Katie. 
05/13/2011. “Tay-Sachs, a Killer in Children, Also Strikes Adults.” James, Susan 
Donaldson. 
 
CNN.com 
11/18/2005. “This Week in the Medical Journals.” Peck, Peggy. 
04/10/2006. “The code of life.” Bay, Michael and Matt Ford. 
08/31/2006. “Therapy Turns Patients' Cells into Cancer Smart Bombs.” Feig, Christy.  
11/20/2008. “Gene Therapy Aids Vision for 3 with Rare Blindness.” Author unlisted. 
 
The Economist 
09/05/1992. “Stemming Disease.” Author unlisted. 
02/25/1995. “Riding the Tiger. (Medical Applications of Genetic Research) (A Survey of 
Biotechnology and Genetics).” Author unlisted. 
08/05/1995. “Baldness: Slap it on heads.” Author unlisted.  
07/20/2002. “Radioing for Help: Gene therapy may make radiotherapy more effective.” 
Author unlisted. 
08/02/2008. “Gene Doping: Genetically Modified Olympians?” Author unlisted. 
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Fox News 
12/29/2006. “Scientists Discover Gene Therapy for Depression.” Lloyd, Robin.  
07/31/2009. “Nanotech Gene Therapy Kills Ovarian Cancer in Mice.” Steenhuysen, Julie. 
02/28/2011. “Scientists Look to Cure HIV with Gene Therapy.” Author unlisted. 
 
Huffington Post 
11/21/2007. “Hurdles Remain After Stem Cell Advance.” Ritter, Malcolm. 
08/10/2011. “‘Amazing’ New Gene Therapy Destroys Leukemia in 3 Patients.” Nano, 
Stephanie. 
09/12/2011. “Glow-In-The- Dark Cats Could Help Fight Against Aids.” Chan, Amanda. 
12/10/2011. “New Method Boosts Blood-Clotting for Hemophiliacs.” Stobbe, Mike. 
 
Los Angeles Times 
01/16/1990. "Gene Therapy Provides Internal Band-Aid Medicine: Researchers Say the 
Technique is a Step toward Reducing Risk of Heart Attacks and Strokes.” 
Roach, Linda M.  
03/08/1990. “Gene Transfer for Human Illness Gets OK.” Cimons, Marlene. 
03/23/1990. “Biotech Firm Takes the Simple Route to Gene Therapy Success.” Roach, 
Linda M.  
07/31/1990. “Gene Therapy Trials OKd by Health Panel.” United Press International. 
08/30/1990. “Inserting Lab-Made Genes into Humans Proved Safe Health: Modified cells 
could deliver cancer-fighting matter to tumors or fix inherited defects, 
researchers say.” Cimons, Marlene. 
09/21/1990. “Gene Therapy Offers Hope for Cystic Fibrosis.” Maugh, Thomas H., II. 
11/08/1990. “Gene Therapy's Promising, but at a Price.” Schrage, Michael.  
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04/19/1991. “Defused Virus Studied in Gene Therapy Medicine: Test, which produced 
human protein in rats, shows promise in treating cystic fibrosis and 
inherited emphysema.” Maugh, Thomas H., II. 
05/29/1991. “Meet the Mr. Greengenes of Biotech Gene Therapy: UCSD's Theodore 
Friedmann makes no apologies for scientists tinkering with what he calls 
nature's ‘mistakes.’  Series: Frontiers of Science: Inside San Diego's 
Thriving Biotech Industry.” Gorman, Tom.  
10/20/1990. “One Last Chance: Ovarian Cancer is Killing Diane Hinton. Conventional 
treatments have failed. Now her life depends on an experimental therapy 
that would Block the action of a deadly gene.” Marsa, Linda.  
01/10/1992. “Cystic Fibrosis Cure Seen in Gene Therapy.” Maugh, Thomas H., II. 
05/23/1997. “S.D. Scientists Hold High Hopes for New Gene Therapy Method.” 
Zamichow, Nora.  
09/29/1992. “Study Reveals Public's Ignorance about Genetic Therapy, Testing.” 
Zamichow, Nora. 
12/05/1992. “Genentech's Next Big Bet: New Cystic Fibrosis Drug Biotechnology: 
DNase could become a leader in treating symptoms of the congenital 
disease.” Associated Press. 
01/15/1993. “‘Compassionate Approvals’ for Unproven Gene Therapies OKd.” Times 
Wire and Staff Reports. 
05/18/1993. “2nd Infant Gets Gene Therapy for Immune System Disorder.” Associated 
Press. 
07/11/1993. “Watching and Waiting; Infant to finally go home, but success of gene 
therapy uncertain.” Stolberg, Sheryl.  
08/19/1993. “Gains Made Against Muscular Dystrophy.”  Maugh, Thomas H., II. 
06/30/1995. “Researchers Call Gene Therapy a Possible Baldness Cure Medicine: Team 
reports successfully putting a gene into a mouse follicle. But key to hair 
growth remains elusive.” Monmaney, Terence.  
03/03/1996. “The Dots Are Almost Connected....Then What? Mapping the Human 
Genetic Code; They’ve almost cracked the human genetic code. That’s the 
good news. What happens after that is the harder part.” Garrett, Laurie. 
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11/20/1996. “Altered Viruses Offer Hope in Treating Brain Maladies; Researchers use 
HIV, cold or herpes agents to restore health to diseased cells in lab 
experiments.” Hotz, Robert Lee. 
04/27/1997. “Biotech: the Revolution Is Already Underway; Dolly the cloned sheep 
made headlines. But she is just one of many living inventions - created by 
the new world of biology - that are pushing the frontiers of science and 
society.” Hotz, Robert Lee and Thomas H. Maugh, II. 
04/30/1997. “The Big C, from A to Z; in their new book, a doctor and his colleagues 
explain cancer specifics with warmth and plain words. And they offer 
information about treatment options.” Levine, Bettijane. 
06/28/1998. “Researchers Push Limits of Humanity; Cyborgs: ‘Wearable’ computers, 
digital implants and DNA engineering could change forever what it means 
to be mortal. Enthusiasts put their faith in technology, not religion, to find 
eternal life.” Allbritton, Chris.  
07/02/1998. “Tracing AIDS to Its Last Hiding Place: Scientists are trying to find ways to 
attack the virus in lymph nodes, tonsils and gastrointestinal system.” 
Maugh, Thomas H., II. 
07/02/1998. “A Sense of Control: Technique for rare disorder offers hope for others who 
lose brain functions because of various diseases.” Maugh, Thomas H., II. 
01/01/1999. “Scientists Report Advance in Gene Therapy.” Newsday. 
06/28/1999. “Closing in on an Answer for Hemophiliacs; Gene Therapy: Three 
experimental treatments are encouraging researchers to believe a cure is 
near for the inherited disorder.” Okie, Susan. 
07/25/1999. “Developments in Genetic Engineering Continue at a Blistering Pace. Some 
cheer researchers on; others would slam on the brakes.” Jacobs, Paul. 
10/21/1999. “Experimental Gene Therapy Vaccine Gets Response in some Prostate 
Cancer Cases.” Maugh, Thomas H., II 
12/09/1999. “U.S. Wants More Sunlight on Researchers: Agencies urge full reporting on 
federally funded medical experiments that end in fatality or cause serious 
side-effects. Teen's death brings scrutiny.” Cimons, Marlene. 
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12/13/1999. “Saddled With Setbacks, Gene Therapy Finally Looking Up.” Maugh, 
Thomas H., II. 
12/26/1999. “Era of Genes and Dilemmas; As atomic science did in the 20th century, 
21st century genetic science will raise wrenching social questions.” Author 
unlisted. 
02/05/2000. “Put Light on Gene Therapy; the secrecy around new and risky procedures 
must be eliminated for the sake of patients and science.” Author unlisted. 
02/12/2000. “FDA Investigates Possible Gene Therapy Contamination.” Cimons, 
Marlene. 
04/09/2000. “Science Aims for Designer Babies: Researchers say parents soon will be 
able to pick their children's genes. The process, called germline engineering, 
is showing promise in lab animals. But critics warn of unintended 
consequences.” Haney, Daniel Q. 
04/17/2000. “A Thriving Pioneer of Gene Tests; Girl who was first to receive 
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